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Abstract 
 
This thesis reports four studies which have been designed to promote the greater 
involvement of primary care in the treatment of epilepsy.  The primary aim is to 
study whether programs of high capacity, low interventional care for people with 
epilepsy are feasible and effective in primary care, within specific programs.  
 
The secondary aims explore the uptake and utility of such programs with 
preliminary examination on national trends in mortality and hospitalisation for 
people with epilepsy during the time of the study.      
 
1.) The first study called the Primary Care Clinical Effectiveness program 2 
[PRICCE-2] determined the extent to which primary care in East Kent was 
able to be produce an epilepsy register, ascertain the number of people who 
were seizure free and  identify people at risk from retinal damage from 
vigabatrin. Also GPs were required to ensure that women were prescribed 
appropriate contraception and that pregnant women were offered folic acid. 
The program also studied trends in unplanned visits to hospital which 
occurred during the program. 
 
The PRICCE-2 project demonstrated GPs are willing to participate [89% of eligible 
practices in 2001] and could identify people who were seizure free [71.25% by the 
end of the program.] The identification of people on Vigabatrin was also successful 
identifying 21 people, [20 were expected,] but the ability to support women with 
epilepsy was less successful. The number of emergency admissions to the local three 
hospitals for epilepsy was seen to rise steadily, however diagnostic indexing was 
fairly poor at this stage.   
 
2.) The second study called the Quality and Outcome Framework, determined 
the extent to which primary care was able to produce an epilepsy register, 
record seizure frequency, perform a basic epilepsy medication review and 
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determine people who were seizure free. Later on in the study, GPs were 
required to ensure that women were prescribed appropriate contraceptive 
medication and offered prenatal advice. The program also studied trends in 
mortality from epilepsy and trends in unplanned visits to hospital for 
epilepsy.  
 
The study revealed GPs were able to identify people with epilepsy [initially 86.8% 
rising to 99.8% by 2011], review their medication [95.3% in 2011] and identify 
people who were seizure free [73.9% in 2011] however they have found it harder to 
support women with epilepsy with high exception reporting used for this group 
[36.7% in 2011/12]. The unplanned hospital admissions steadily rose during this 
time, whilst the mortality for epilepsy began to decline [ R 2 = 0.6118] however 
whether this was a casual or causal link could not be determined. 
 
3.) The third study determined if primary care could proactively identify social 
consequences of active epilepsy including the recording of driving status and 
social factors affected by epilepsy. It also identified and offered women with 
epilepsy folic acid, pre conception advice and ensured they were prescribed 
appropriate contraceptive. In addition it required GPs to identify people with 
epilepsy under hospital care.  
 
The study revealed that GPs were able to identify social consequences of epilepsy 
and identify people under hospital care but once again they found it difficult to 
support women with epilepsy related issues. The restructuring of PCTs at this time 
resulted in a loss of data. 
 
4.) The final study determined the extent to which pharmacists can be trained to 
proactively support people with epilepsy in a Medicines Use Review [MUR] 
format. Pharmacists grasp of epilepsy before and after training and 
customer’s knowledge and readiness to approach their pharmacist for support 
were assessed before and after the consultation. In addition pharmacists were 
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taught how to recognise red flag symptoms and directly refer at risk patients 
to specialist epilepsy services. 
 
The pharmacists readily absorbed the epilepsy training and their customers reported 
benefit in improved knowledge about epilepsy and also indicated that in future they 
would seek support for epilepsy from their pharmacist. The direct referral process 
for epilepsy was not successful however and would need refining in the future. 
 
  
The overall aim to study whether high capacity, low interventional care for epilepsy 
is both feasible and effective has I believe, been demonstrated in these studies to be 
possible.    Pro-active care for epilepsy is possible in general practice, with GPs 
being able to provide high capacity epilepsy care. The influence on admission rates 
and mortality for epilepsy is less clear and requires further study.  
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Author’s contribution 
 
The author has been the lead GP for Epilepsy in East Kent for the past 15 years and 
during this time has been aware of the potential for primary care to contribute further 
to the delivery of epilepsy care. The concept of proactive support offered to 
everybody with epilepsy rather than specialist care to a proportion of this group, has 
been the author’s goal throughout this work1. This grassroots care is seen as being 
complementary rather than competing to specialist epilepsy services. It is this 
overarching objective which unites the four studies and this thesis examines various 
aspects of the contribution of primary care (see pp 26 for aims).  
 
Study One; Primary Care Clinical Effectiveness program PRICCE-2  
The author designed the epilepsy component of the PRICCE-2 study,[see page 74] 
set the quality standards, offered clinical support to both the practices and the audit 
team on epilepsy. There was also training to support the program on epilepsy which 
the author delivered at the local postgraduate centre. The PRICCE-2 program 
followed on from a pilot simply referred to as PRICCE from which the author was 
able to take many lessons learnt from this and introduced them into the PRICCE 2. 
The main one being the replacement of ‘idiopathic epilepsy,’ with ‘all cases of 
epilepsy,’ and hence broaden the scope of the program.  
 
Study Two; Quality and Outcomes Framework 
The regional pilot went on become a substantial part of the national Quality and 
Outcomes Framework2 [Q.O.F.] The section relating to epilepsy utilised components 
of PRICCE and the author was credited with having an input into this national 
program.[ see page on page 199]. It received a major redraft in 2007 [see page 207] 
the author was one of the eleven experts invited to contribute to that also.3 This 
group advised on the new standards which were introduced then. 
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Study Three; Locally Enhanced Service for Epilepsy 
The author then designed a Locally Enhanced Service (L.E.S.) for Epilepsy [see 
page 100] for East Kent Coastal PCG which was designed to explore whether 
regular GPs could be supported to take on higher levels of care for people with 
epilepsy. The concept, standards, training and oversight of the analysis were 
developed by the author. Mrs Sheila Pitt, Eastern and Coastal Kent Lead 
Commissioner for Long Term Conditions provided commissioning oversight for the 
project. 
 
Study Four; Targeted Medicines Use Review for epilepsy 
The final project the author designed explored whether it was possible to train 
community pharmacists to deliver support to people with epilepsy and also whether 
they could effectively identify people at high risk due to their epilepsy and refer 
them to specialist care. The pilot design and the subsequent project commissioning 
was discussed and negotiated between the author and local health authorities and 
pharmacy commissioners. [See page 111] The final training was given by myself 
with support from Mrs Trudy Thomas from Medway School of Pharmacy (Head of 
Postgraduate training) and clinical support during the project to the pharmacists was 
delivered also by the author. The referrals to the community epilepsy clinic were 
triaged by the author.  
 
Data collection for studies One, Two and Three was organised by the health 
authority and the data for study Four was collected by the author with advice on the 
Medicines Use Review format by Medway School of Pharmacy.   
 
The author carried out the analysis of the third and fourth studies, the further 
analysis of the first two studies and undertook the writing up of these studies. 
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Glossary of Abbreviations; 
 
 
 
East Kent MAAG : East Kent Medical Audit Advisory Group 
 
GMS : General Medical Services 
 
G.P: General Practitioner 
 
GPwSI Epilepsy: GP with a Special Interest in Epilepsy 
 
HES: Hospital Episode Statistics 
 
LES : Locally Enhanced Service   
 
PCT: Primary Care Trust 
 
PDP: Personal Development Plan   
 
P.R.I.C.C.E, 1 and 2: Primary Care Clinical Effectiveness Program 1(pilot) and 2 
 
Q.O.F : Quality and Outcomes Framework 
 
QMAS: Quality Management and Analysis System 
 
I.L.A.E: International League Against Epilepsy 
 
JCPTGP: Joint Committee on Postgraduate Training for General Practice 
 
M.U.R: Medicines Use Review 
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Overall Aim 
 
The aim of this thesis is to study whether programs of high capacity, low 
interventional care for people with epilepsy are feasible and effective in primary 
care, within specific programs.  
 
The secondary aims explore the uptake and utility of such programs with 
preliminary examination on national trends in mortality and hospitalisation for 
people with epilepsy during the time of the study.  Four separate studies were carried 
out to assess this and these are listed below.
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AIMS 
1. Study One; Primary Care Clinical Effectiveness program 2 [PRICCE-2] 
 
1.1. Determine the extent to which participating primary care practices in 
East Kent are able to be involved in basic proactive care for epilepsy 
using a disease register following the PRICCE-2 programme 
 
1.2. Determine the extent to which participating primary care practices in 
East Kent are able to identify potential problems which can arise as a 
consequence of suffering from epilepsy. The problems examined were: 
 
1.2.1. Identify people who are seizure free 
1.2.2. Ensure the people who are taking vigabatrin have their visual fields 
measured 
1.2.3. Identify women who are pregnant and also have epilepsy 
1.2.4. Ensure women and children of childbearing age are taking folic 
acid 
1.2.5. Ensure that women who are taking contraception medication are 
prescribed appropriate contraceptive medication 
 
1.3. A preliminary examination of local trends in hospitalisation. 
 
1.3.1. Trends in unplanned visits to hospital for acute problems arising 
from epilepsy  
 
2. Study Two; Quality Outcomes framework 
 
2.1. Determine the extent to which  primary care practices in England are 
willing to be involved in basic proactive care for epilepsy using a disease 
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register  following the QOF programme. The study examined the 
following aspects of care: 
 
2.1.1. Produce a register for people with epilepsy who are receiving 
treatment for epilepsy and are over 16 years old 
2.1.2. Record the seizure frequency for people over 16 years old 
2.1.3. Perform an epilepsy medication review for people over 16 years old 
2.1.4. Identifying people on drug treatment for epilepsy who are seizure 
free over 16 years old 
 
In 2006 the program was reviewed (see p 91 ] and the minimum age was raised to 
18years old as it was proposed that the care for younger patients is generally undertaken 
outside of primary care. 
 
2.1.5. Produce a register for people with epilepsy who are receiving 
treatment for epilepsy and over 18 years old 
2.1.6. Record the seizure frequency for people over 18 years old 
2.1.7. Perform an epilepsy medication review for people over 18 years old 
2.1.8. Identifying people on drug treatment for epilepsy who are seizure 
free over 18years old 
 
2.2. Determine if proactive care in England for epilepsy can successfully 
become more detailed within the Quality Outcomes Framework. 
 
2.2.1. Ensure that women who are taking contraception medication are 
prescribed appropriate contraceptive medication 
2.2.2. Offer prenatal advice for women with epilepsy 
  
2.3. A preliminary examination of national trends in mortality and 
hospitalisation during the Quality Outcomes Framework programme. 
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2.3.1. Preliminary examination of mortality from epilepsy in England 
2.3.2. Preliminary examination of unplanned visits to hospital for acute 
problems arising from epilepsy  
 
3. Study Three; Locally Enhanced Service for Epilepsy for East Kent 
 
The results from the Eastern and Coastal primary Care Trust were obtained as 
well as detailed results from two large practices in the PCT area. Two data sets 
were used to assess the following areas: 
 
3.1. To determine if primary care can proactively identify social 
consequences of active epilepsy 
 
3.1.1. Record driving status 
3.1.2. Record social factors affected by epilepsy 
 
3.2. Identify the number of women and children of child bearing age who 
have epilepsy 
 
3.2.1. Offer women and children of childbearing age folic acid 
3.2.2. Offer women and children of child bearing age pre conception 
advice 
3.2.3. Ensure that women who are taking contraception medication are 
prescribed appropriate contraceptive medication 
 
3.3. Identify people with epilepsy under hospital care  
 
 
 
 29 
4.  Study 4; Targeted medicines use review for epilepsy 
 
4.1. To determine the extent to which community pharmacists can be 
trained to proactively support people with epilepsy 
 
4.1.1. To be able to answer an anticonvulsant query from a patient with 
confidence 
4.1.2. To become familiar with epilepsy classification and explain them to 
customers 
4.1.3. To be able to advise a customer with epilepsy when they could re-
apply for their driving licence 
4.1.4. Feel confident in being able to assess how well a patient was taking 
their anti convulsant medication 
 
4.2. Determine if the advice given by the community pharmacists during a 
Medicines Use Review was of benefit to the customers. The MUR is an 
appointment between the pharmacist and the patient whereby a patient 
is invited to focus on their medication and is an opportunity to identify 
any problems associated with their tablets or of the illness for which 
they are taking them.   
 
4.2.1. improving their understanding of the underlying causes of epilepsy 
4.2.2. Understanding how to lessen the risk of having a seizure 
4.2.3. Determine if the customer was more likely to approach their 
pharmacist for advice about their epilepsy in the future 
 
4.3. Determine if community pharmacists can recognise red flag symptoms 
to allow direct referral to specialist epilepsy services 
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INTRODUCTION 
This thesis describes the evolution of clinical programs which were designed to 
promote the greater involvement of primary care in the treatment of epilepsy. The 
hypothesis underlying these studies is that high capacity and low impact programs of 
care in general practice is possible to achieve within specific programs of care.  
 
 
Definition of Epilepsy 
Epilepsy for this thesis is defined using the ILAE definition 2005  
 
“Epilepsy is the name of a brain disorder characterized predominantly by 
recurrent and unpredictable interruptions of normal brain function, called 
epileptic seizures. Epilepsy is not a singular disease entity but a variety of 
disorders reflecting underlying brain dysfunction that may result from many 
different causes.4” 
 
Over the past few decades the classification of epilepsy has evolved and  changes 
have be made to incorporate the many new discoveries in the aetiology and 
understanding of epilepsy over that period. Indeed the classification structure can be 
considered as being in a permanent state of flux5 of which a full synopsis of the 
classification of seizures can be found in more detail ILAE website6. For the 
specialist it is important to allow dialogue between colleagues to be accurate and the 
newer classification also helps to keep the diagnostic and treatment rationale in step 
with current advances.  
 
For the non-specialist in general practice however this has increased the sense of 
being “out of date,” with epilepsy as even the basic grasp of nomenclature and 
epilepsy classification can be faltering. This is arguably one of many factors to bring 
about a diminishing clinical confidence of front line primary care clinicians to treat 
epilepsy, with the decision to make even simple changes becoming hesitant7. The 
natural progression of this move to specialisation is to see the routine care of people 
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with epilepsy resting solely on the shoulders of epilepsy specialists. As epilepsy is a 
common neurological condition this may place unnecessary strain on the epilepsy 
specialist clinics and also see the care of people with epilepsy who also suffer from 
multi- morbidities such as cerebrovascular disease, becoming fragmented. 
 
History of Epilepsy care in England 
There have been several reports conducted to examine the care of people with 
epilepsy over the past fifty years and it is rather disheartening to see that many of the 
recommendations have not been adopted. Also the development of services has not 
improved as much as one would have hoped. 
  
 Key amongst these reports are: 
 
 “Welfare of Handicapped persons: the special needs of epileptics and 
spastics.” London: Ministry of Health, 19538.   
 “Medical care of epileptics: Report of the sub-committee of the Central 
Health Services Council.” Central Health Services Council, Ministry of 
Health, Lord Henry Cohen, London: HMSO, 19569   
 “Report of a joint sub-committee of the standing medical advisory committee 
and the advisory committee on the health and welfare of handicapped 
persons” Reid JJA, Department of Health and Social Security,., London 
196910.   
 “Report of the working group on services for people with epilepsy”: a report 
to the Department of Health and Social Security, the Department of 
Education and Science and the Welsh Office. Winterton PMC, London: 
HMSO, 198611.    
 . “Services for patients with epilepsy: a report of a CSAG Committee” 
London: Department of Health,  Kitson A, Shorvon S, Clinical Standards 
Advisory Group, 200012 
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 “The National Sentinel Clinical Audit of Epilepsy-Related Death: Epilepsy – 
death in the shadows”.  Hanna N J, et al. London 200213 
 
These reports in varying degrees report that care for epilepsy tends to be fragmented 
and poorly co-ordinated. The need to organise care in a more co-ordinated manner 
with seamless care between primary and secondary care has been mentioned 
repeatedly being a key message in the Reid report and highlighted again in 1983 by 
Goodridge14 and Shorvon.  
 
The Clinical Standards Advisory Group report nearly 20 years later in 2000 further 
highlighted this need and offered the suggestion which encouraged the participation 
of primary care to take a lead role in the community and advised that a lead GP is set 
up in a practice who has trained in epilepsy to a greater degree than his peer group 
and oversees the care of people with epilepsy for that practice. It was this suggestion 
which influenced the author to explore this suggested solution further and developed 
a system whereby there is a network of General Practitioners with a Special Interest 
in Epilepsy (GPwSI in Epilepsy.) Also within this report is the suggestion for more 
structured care for people with epilepsy and this has formed the basis for the main 
aim of this thesis. 
 
The national sentinel audit into epilepsy related deaths provided powerful evidence 
for the need for change to improve services for people with epilepsy. The stark facts 
relating to morbidity from poorly controlled epilepsy produced a persuasive 
argument to in seeing the commissioning of intermediate care of epilepsy becoming 
commissioned and the structured primary care program of care financed locally. 
 
 
Insufficient capacity of clinicians’ actively managing people with epilepsy 
 
The lack of capacity to actively manage epilepsy is a problem which seems likely to 
increase unfortunately as with an ever aging population, the numbers of people with 
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epilepsy is set to increase. The changing demography of epilepsy has resulted in the 
greatest prevalence now being seen in later life, with the number of people who 
develop dementia also increasing, as more people in the UK are reaching older 
age15. Individuals who have been diagnosed with Alzheimer’s disease are more at 
risk of developing epilepsy.16 The development of epilepsy can be a challenge to 
detect in this group making a wider awareness of epilepsy an important priority both 
in Primary Care as well as within specialist services17. 
 
To help redress this balance the author wishes to explore the extent to which 
programs of care can safely be introduced for epilepsy and also see if primary care 
can become increasingly involved in the long term management of people with 
epilepsy. This does not remove the need for epilepsy specialists; rather it identifies 
people in need of optimisation of epilepsy care which includes many who will need 
the input of an epilepsy specialist. The recurrent theme which runs through this 
thesis is for high capacity care which is seamless and can offer optimisation of 
treatment to all people with epilepsy and ensuring those with complex needs are the 
ones seen by specialist clinics. 
 
 
Primary Care emerging as a specialism 
Primary Care entered a new era in the 1990’s with General Practice becoming a 
positive career option for newly qualified doctors18. This process has its roots in the 
formation of the Joint Committee for Postgraduate Training in General Practice 
[JCPGT] in 1975 with representatives from the General Medical Council and the 
Royal College of GPs plus representatives from universities. In 1979 it became a 
requirement to complete a year in general practice as a trainee to achieve 
certification and in 1982 it was necessary to complete two years of approved 
hospital posts and a trainee year satisfactorily to be accepted by the committee as a 
GP . Initially this merely was a certificate that the appropriate time had been 
completed but by 1990 this was further defined as reaching an acceptable standard. 
This process was further tightened in 1996 when a process of summative assessment 
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for GP was introduced with a standard of medical competency being introduced and 
the identification of poorly performing GPs with formative and final summative 
assessment being undertaken.  
 
These changes were instrumental in lifting the prevailing professional view of 
general practice from frequently being a final career route for budding physicians 
and surgeons who had not quite made the grade in a hospital career. General 
practices was now for doctors who set out with an intent to follow a career path in 
family medicine19. The JCPTGP was a unique body that brought together not only 
the then divided tribes of general practice (it was a joint committee between the 
Royal College of General Practitioners [RCGP] and the General Practitioners 
Committee [GPC]), but also had representation from GP education directors, 
postgraduate deans, specialists, doctors in training, the Departments of Health and, 
latterly, the laity. 
 
The role of Primary Care in the management of Long Term Conditions 
As the skills increased in primary care in East Kent, so did the desire to treat people 
with long term conditions proactively rather than merely reacting to acute episodes. 
There was a realisation amongst family doctors in East Kent in the mid 1990’s that 
opportunities were being missed to preventing illness and that a good deal of 
primary care was organised to treat and respond to be reactive rather than have 
resources devoted to the pro-active care of people with long term conditions. To 
tackle this problem, medical managers had at their disposal several levers to help 
influence care in general practice; 
 Computerisation 
 Incentivisation 
 Education 
 Support of audit team 
 Peer pressure 
 Verification process 
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Computerisation of Primary Care 
 
General practice has progressively become computerized and is rapidly heading 
towards becoming paperless20. This has led to the production of computerised 
disease registers which include registers identifying epilepsy. The registers contain 
basic diagnosis, medication and demographic data. With these key components 
present, it has become feasible to conduct targeted review of people with epilepsy, 
utilising audit to identify people at risk. By the regular review of people with 
epilepsy a process has also begun to reduce unplanned access to emergency medical 
services and identify people in need of optimisation of their epilepsy care.   
 
Even though there are multiple software packages for GPs to use, they all retained 
the capability of performing disease specific searches of their practice database and 
initially this capability varied a good deal between the software however within time 
each one developed to allow it to be used for this purpose more readily. PCTs saw 
the advantages this gave to improved patient care and indeed monitoring of the 
quality of care in each GP’s surgery.   
 
 
Incentivisation 
Financial incentives offered to improve the quality of care can be met with 
disapproval by many outside of medicine. It would at first glance seem hard to 
understand why somebody needs to have a financial incentive to perform to a higher 
level when they are already employed within a professional vocation.21 The role of 
financial reward given to achieve targets however is effective in commissioning very 
specific tasks, such as those described in this thesis. Also the response to them 
appears to be disproportionate to the value offered. Incentivisation is an integral part 
of the commissioning of these epilepsy services. With development of the new GP 
contract in April 2004 for General Medical Services for practices in England, 
Scotland, Wales and Northern Ireland22, practices are financially incentivised for 
delivering measurable levels of quality in patient care, via the evidence-based 
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Quality and Outcomes Framework (QOF). Between 10–15 per cent of the new 
money tied to the contract is available to reward practices for providing higher 
quality services The initial plan was to pay for this program using money taken out 
of the GPs global sum which they could earn back by taking part in the QOF 
program. 
  
At that time morale and indeed GP numbers were assessed as being to be too low 
and the department of health had intended from the outset to increase spending on 
GP’s services23 and proposed to increase spending from £4.9 billion in 2002-03 to 
£6.9 billion in 2005-06.  The uptake and achievement of the QOF program resulted 
in a 9.4 per cent higher than expected overall spend on Primary Care. This was as a 
result of a significant underestimate of how readily practices would take up QOF 
and indeed how well they would do in achieving the targets which were optional. 
This supports related work that acknowledges that incentivisation can have a marked 
effect on behaviour.24 
 
The financial incentives appear to be particularly good tool for improving process 
driven measures and the benefit in some studies has tended to wear off over time25 
however they remain a powerful tool to help direct primary care activity. 
 
 
Education 
In 2003 the year before the launch of the QOF program PCTs were encouraged to 
develop new approaches to GP education, changes in the training and education 
strategies.26 These were advised by the Modernisation Agency as needing to be cost 
effective and help to deliver the Quality and Outcomes framework. They suggested 
that education and training should include management skills such as the 
management of change, audit skills, basic medical skills for all staff members such 
as basic life support. Also the introduction of critical event discussions was to be 
introduced and more peer review was encouraged between members of the primary 
health care teams and secondary care colleagues. The clinical sections of the QOF 
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framework in 2004 contained a clinical introduction offering brief medical update on 
the areas covered and also revision of the evidence based care recommended at the 
time. 
 
The new GP contract in 2004 altered the way that GPs organised their post graduate 
education with  the old system of payments from a set of terms and conditions 
commonly referred to as ‘red book,’ ceased and GP’s post graduate educational 
allowance payments were abolished. The new GMS contract offered payment which 
was effectively taken out of their income from the global sum allocated to the 
practice and were able to earn it back by offering evidence of their successful annual 
appraisal supported by personal development plans.   
 
Up to this point GPs had to earn points from attending meetings and courses to 
trigger a PGEA payment to an individual GP however under the new contract 
following a meeting with a designated appraiser , GP would have their PDP  ‘signed 
off,’ This process on completion would satisfy their annual postgraduate educational 
requirement. The consequence of self-directed learning can be that GPs tend to 
spend time studying their interests and omit areas that were of less clinical interest. 
It would be the role of the appraiser to high-light these areas of need and form a 
learning plan to include them. The role of ‘GP refresher,’ courses started to shrink 
from this time on and opportunities to offer education for epilepsy by the traditional 
tutorial or lecture method reduced. More creative ways have had to be developed 
such as tutorials on epilepsy via the internet and the author has worked with the 
British Medical Journal to produce a series of these on epilepsy. There is evidence 
that epilepsy care guidelines can be taught and delivered at lower cost that other long 
term conditions and the value of medical education in epilepsy can easily be 
justified. 27 
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Support of the Audit team 
One of the benefits of working as part of the larger project was having the support of 
the East Kent audit team and the author worked with them in PRICCE II to make the 
standards more clearly defined and measurable. This involved explaining to the 
group the basic risk factors for epilepsy and also describing areas of epilepsy care 
such as on-going seizures, contraception, hazards of unmonitored vigabatrin use etc. 
which were amenable to audit. The audit team also provided basic training to the 
practices in setting up disease specific searches of their data base and help in data 
management.  
 
 
Peer pressure 
The phenomenon of peer pressure is a potent factor in directing clinician’s choices 
for medical treatment, in one study it was stated by 29% to be an important factor in 
the selection of statin for a patient28. It can also be used a tool by medical managers 
to influence clinicians positively and help to improve quality of care for people with 
epilepsy using healthy competition and indeed can be a useful way to educate 
colleagues. The pooled knowledge in most large practices would likely be sufficient 
for most simple routine problems encountered and if one clinician trains in an area 
they are well placed to share this knowledge with their colleagues.29 To an even 
greater extent than PRICCE the practice achievement at QOF become a matter of 
pride between practices and it was not long before practices would describe 
themselves where applicable as ‘high achievers of QOF.’ As time has gone by this 
has turned somewhat to be something of a stick rather than a carrot and the 
department of health now freely publish each practice’s achievement of QOF as an 
open indicator to the general public on how well the practice is seen to be delivering 
these services. 
 
With the introduction of QOF GPs have become more used to peer review and the 
process of open questioning of their decisions, something previously that they had  
discomfort with30, they are now having to become more accustomed to. 
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Verification Process   
For all of these programs of care the health authority collect data at the end of the 
year using a standardized collection form, with a health authority team visiting all 
practices at the half-year and year-end. During these visits the QOF team perform 
random checks on the quality of the data which helps to deter reporter bias and also 
the team use prevalence and quality data from neighbouring practices to help to 
assess practice achievement.  Having a basis of self-reporting of achievement, 
incentive driven medical care holds the potential for being influenced by reporter 
bias. Outcomes reported by the investigator may be influenced as a result of being 
directly linked to subsequent financial income.  
 
From an audit perspective this method of self-reporting is far from satisfactory 
however in a pragmatic sense the aim was to drive up the quality of care for epilepsy 
and not primarily as a program of  audit and this still remains a weak point in this 
project. 
 
The advantages and disadvantages using process measures to assess quality of 
care. 
 
 
The measurement of process of care is relatively easy to gather and provides 
commissioners with useful information to further develop services for patients. 
There are however both positive and negative aspects to consider before using them 
as a marker of quality of care. On the positive side they help to provide useful 
feedback to clinicians on processes they did or did not follow which had the 
potential to affect patient outcomes. Also following a protocol for patients tends to 
be safer and has offers less risk of GPs deviating from the standard treatment 
pathway for that patient. In addition to this, process measures can be collected 
quickly and easily in contrast to outcome measures which can take a long while to 
become apparent. 
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However there must be a strong relationship between the process and the outcome 
measure. This may be obtained from previously published  
evidence but can be problematic when used in a practice which treats patients who 
are generally in poorer health and even though they may receive excellent care they 
invariably have poorer outcomes. Also there may be complex process to outcome 
linkages which draw on confounding factors to provide the final outcome. In 
addition to this while process factors may be meaningful to both clinicians and 
commissioners they have less direct relevance to patients. The process also usually 
only captures a specified part of the care provision for the patient and does not 
include the wider care for that particular disease. 
 
Overall however process measures are a useful tool to monitor the quality of care 
from providers and are generally accepted by care providers. They can be collected 
unobtrusively via electronic records and the results provide a useful guide to the 
quality of care delivered by the service provider. In comparison to this, outcomes 
have many confounding factors which may be outside the control of the care 
provider and may unfairly be attributed to a poor level of care.31 
 
 
 
 
Defining and classifying clinical indicators for quality improvement. 
 
The assessing of quality of patient care has become increasingly important to both 
clinicians and commissioners of care and more latterly to the service users who are 
able to compare these factors via performance lists placed in the public domain. 
Indicators have been developed in several ways and can include the following 
 
1. As measures that assess a particular health care process or outcome. 
2. As quantitative measures that can be used to monitor the quality of important 
governance, management, clinical, and support functions that affect patient 
outcomes. 
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3. As measurement tools, screens, or flags that are used as guides to monitor, 
evaluate, and improve the quality of patient care, clinical support services, 
and organizational function that affect patient outcomes32  
 
 
Indicators are based on standards of care which are usually evidence-based and 
many of which have been put forward by the National Institute for Health and Care 
Excellence [NICE]. This is a body who are accountable and supported by the 
department for Health and provides national guidance and advice to improve health 
and social care. When evidence is lacking, clinical standards can be set either 
nationally or locally by an expert panel of health professionals in a consensus 
process based on their experience. The indicators are then used to judge how well 
clinicians, organizations, and planners have achieved the improvement in care and 
the processes by which patient care is provided. 
 
Taking evidence gained from clinical trials and systematic reviews to individual 
patients in primary care can however be challenging. The use of performance 
indicators by themselves as a method to improve the effectiveness of health care in 
primary care are unlikely to be a sensitive enough tool to be of use.  However, the 
use of evidence based indicators linked to interventions that improve health 
outcomes, offers a better instrument to use to assess quality33.   
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Examples of measuring process redesign on other disease areas to improvement 
care. 
 
Diabetes:   
In a qualitative review of 41 studies on the management of diabetes in a mix of 
general practice, community care and outpatient clinics the reviewers sought to 
examine the role of different interventions including process change on the 
outcomes of care for people with diabetes. The studies observed changes in 
outcomes which varied between trials but which included at least one of the 
following parameters; urinary albumin excretion, attendance of patients, blood 
pressure , compliance, creatinine, glycaemic control, health maintenance 
organization, health survey, hospitalizations, macro-vascular complications, micro-
vascular complications and quality of life. The aim was to determine the 
effectiveness of the different interventions targeted at health care professionals 
and/or the structure of care, in order for the reviewers assess whether the re-
organising the structure of care had been shown to have a measurable impact to 
improve the management of diabetes. The reviewers concluded that interventions 
which involve a multi system change involving clinicians and support staff to 
facilitate the structured, regular review of patients in addition to patient education 
were effective in improving patient outcomes.34  
 
The reviewers identified measures to study the impact of process change on diabetic 
outcomes in 30 of these studies and found that process changes resulted in improved 
outcomes in 18 studies with a further 7 studies reporting a positive trend. Only 5 
studies failed to report any improvement in the outcomes for patients with diabetes 
as a result of process change. 
 
Inflammatory Bowel Disease;  
Another example of the impact of process redesign was undertaken in Sweden where 
service delivery was re-focused resulting in the delivery of care at the right level, at 
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the right time, by creating a trustful and long-term relationship with the patient. As 
part of this service redesign a specialist nurse and her assistant staffed the outpatient 
clinic full time on weekdays. In addition the nurse could offer patients who 
contacted the clinic an acute visit at the outpatient clinic within two days. For those 
with no acute symptoms yearly check-ups were offered as either a telephone call or a 
traditional visit to the clinic. 
 
The findings of the study revealed a reduction in the number of hospital admissions 
for inflammatory bowel disease and also an increase in the patient supported self-
care. The quality of life and haemoglobin levels of these patients were not affected 
and the system as a whole appeared better for patients as commissioners alike with 
waiting times reduced considerably. These changes were brought about by service 
process redesign. 
 
. 
 
Primary Care research methodologies 
It has been suggested that primary care utilises an eclectic range of research 
methodologies with a large reliance on qualitative research35 Statistical methods 
such as meta-analysis have been developed to summarize and to resolve 
inconsistencies in study findings—where information is available in an appropriate 
form however qualitative research requires other methods for interpretation. 
Consensus methods provide another means of synthesizing information, but are able 
to use a wider range of information than is common in statistical methods, and 
where published information is inadequate or non-existent these methods provide a 
means of harnessing the insights of appropriate experts to enable decisions to be 
made. Two consensus methods commonly adopted in medical, nursing, and health 
services research are the Delphi process and the nominal group technique   
 
The Delphi technique consists in a round of relevant individuals who provide their 
opinions on specific matters. These opinions are then grouped together under a 
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limited number of headings and then re circulated to the members of the group. 
Following this process the members of the group re rank their agreement with each 
statement in the questionnaire. These rankings are then summarized once more and 
re circulated to the group for a final ranking of their agreement with the responses. 
Finally the re-rankings are summarized and assessed for a degree of consensus- if an 
acceptable degree of consensus is reached then the process may cease. If not a third 
round is undertaken. This technique is utilized by NICE to prepare lists of proposed 
quality statements from their expert topic advisory groups. 
 
The nominal group technique uses a highly structured meeting to gather information 
from relevant experts usually in two rounds of the group rate, discuss, and then re-
rate a series of items or questions. The process starts with participants writing down 
their views which are then passed on to a facilitator often using a flip chart. Similar 
suggestions are then grouped together and group discussion is used to clarify the 
ideas. Each participant then ranks each idea and the results are re-presented. The 
overall ranking is then discussed and re-ranked and the results tabulated and fed 
back to the participants.36 
 
Consensus development conferences are another qualitative form of group 
consensus in which, a small selected group people are presented with items from 
individuals or organisations who are not part of the group and the selected group 
discusses this evidence and produces a consensus statement. During this process the 
group use specific methods such as majority voting to obtain aggregate judgements 
on the information. 37  
 
A process which utilised the views developed from developed by expert panels using 
a systematic process to combine evidence with expert opinions has been successfully 
field tested in terms of reliability, validity, and acceptability of review criteria for 
angina, asthma and type 2 diabetes.38   
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Another research methodology used in Primary care and is utilised in this thesis is 
that of Action Research. There are several definitions of Action Research, however 
the following definition described by  Hampshire39 encompasses several of these 
and is the one I have followed in this project.  She describes it as  
 
“ i) Focusing on change and improvement; ii) involving practitioners in the 
research process; iii) being educational for those involved; iv) looking at 
questions that arise from practice; v) being a cyclical process of collecting, 
feeding back and reflecting on data; and vi) being a process which generates 
knowledge. ” 
 
It is a step-by-step process, which is monitored by the researcher using a variety of 
mechanisms such as questionnaires, diaries, interviews, and case studies. The 
feedback from these methods can then be used to develop modifications and 
adjustments as necessary with the eventual outcome of improving the ongoing 
process which is under review.   
 
The practical, problem solving nature of Action Research makes this methodology 
appears to be well suited to practitioner-researchers who have identified a problem 
and seek if possible to improve practice.40 It is utilises a family of research 
methodologies, which pursue action [or change] and research [or understanding] at 
the same time using a cyclic process, which alternates between action and critical 
reflection. It has been used successfully to study and introduce change in General 
Practice for example it was used in South Wales to develop the teaching of 
undergraduate students in General Practice 41   It has also been used in the 
management of long term conditions to develop feasible changes in behaviour such 
as changing lifestyle behaviour for people with pre diabetes.42 
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The need for higher capacity care to support people living with epilepsy– high 
volume and low intensity interventions. 
 
Epilepsy – a Public Health Problem? 
Epilepsy is a common serious neurological condition affecting nearly 500,000 
people in the UK43  and in America it affects an estimated 2.5 million people     and 
each year accounts for $15.5 billion in direct costs (medical) and indirect costs (lost 
or reduced earnings and productivity). 44  
 
 There have been many calls to strengthen the input for epilepsy care given by 
General Practice both in England and America as the numbers involved are 
relatively large and the primary care workforce is required to contribute to 
supporting this group. 
 
The need to strengthen epilepsy care by primary care providers has been identified 
in the States and there is a call to clarify clinical pathways for referrals and for care 
by specialists. Primary care providers are acknowledged to frequently be the first to 
see the patient after an initial seizure as evidenced by an American community-
based survey of people with epilepsy, where 40 percent of respondents reported that 
they first saw a family or general practitioner, 32 percent a neurologist, 13 percent a 
paediatrician, 5 percent an internist, and 5 percent an emergency room physician45.  
 
In addition to this initial contact, primary care providers may often provide the long-
term management of epilepsy care for people whose seizures are well controlled. In 
a report by the Committee on the Public Health Dimensions of the Epilepsies in 
America 2012 they concluded that  
 
“as there is a significant role for primary care providers in the care of 
epilepsy patients (often over the lifetime of their patients), it is critical that 
they are knowledgeable about epilepsy care.”46 
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The Scottish guidelines for epilepsy care [Scottish Intercollegiate Guidelines 
Network, SIGN]  advise that Primary Care should provide a structured annual 
review and produce an epilepsy register, monitor seizures, assess the side effects of 
medication and facilitate structured withdrawal from medication where appropriate 
and agreed. Also to provide information to improve e the quality of life and address 
women’s issues and needs of patients with learning disabilities.47 
  
In the UK the NICE guidelines for epilepsy48  stated that Primary Care played a 
central role in the provision of medical care to adults with epilepsy.  In all of these 
guidelines the high level care of epilepsy including the diagnosis of epilepsy should 
rest in the hands of epilepsy specialists however the routine low impact care of this 
group should be placed in primary care. It is the service organisation and impact of 
this low impact care which this thesis addresses. 
 
  
General practice and primary care; the changing landscape 
 
The last decade has witnessed an increasing range of activities which are provided General 
Practice as GPs play an important role in co-ordinating care provided in other settings. In 
addition to this there is a trend towards larger practices, with federated models of working 
which has resulted in general practices being a stronger and better organised.   
 
This development has come in part, as a response to the increasing demand for health 
services especially from the growing numbers of elderly people who are living with 
comorbidities. This latter group require general practice to work in partnership with care 
givers where patients with complex problems receive care from multiple providers and 
indeed the patients themselves are empowered as much as possible to take an active part in 
their own health.  
  
The focus has turned away from merely responding to sickness, to one which promotes 
health not just of the individual but of the local community. This includes care for those who 
are most in need of care but currently do not receive it with a developing vision to improve 
the quality of care co-ordination for patients with long-term chronic and mental illnesses. 49   
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Introduction to the East Kent Primary Care Clinical Effectiveness programs: 
PRICCE-1, 1998 – 2000   [see page 200] 
 
This thesis follows the earlier development of the Primary Care Clinical 
Effectiveness program I (PRICCE 1) which was developed to promote primary care 
treatment of idiopathic epilepsy. The original hope was that by only selecting only 
one type of epilepsy it would facilitate the gradual introduction of the epilepsy care 
program however the term idiopathic was found to be confusing. Practices did not 
understand clearly what the term meant and the health managers also were not able 
to offer cohesive advice on what to include. Commissioning leads suggested that it 
was all epilepsy apart from people with acquired brain injury or else suffering from 
learning disability. There was a call to re write the program for PRICCE for epilepsy 
and as a consequence the author was invited to re-design the epilepsy component of 
the PRICCE 1 and it was launched as PRICCE 2 in 2002 and is studied further in 
this thesis. 
 
 
The East Kent model for evidence based and audit driven care for Long term 
Conditions including epilepsy: Primary Care Clinical Effectiveness program 
[PRICCE-1] 
The Primary Care Clinical Evaluation Project (PRICCE-1) was described as ‘a 
quality improvement programme50’ designed by East Kent Health Authority. Its 
purpose was to use the tools of audit and incentivisation to improve the care of 13 
selected long term conditions , one of which was Idiopathic Epilepsy. The other 
conditions selected for PRICCE I were Dyspepsia, UTI in children, Leg Ulcers, 
Angina, Myocardial infarction, Hypertension, Arial Fibrillation, Chronic Heart 
Failure, High Cholesterol , Asthma, Diabetes and Depression. 
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It commenced in 1998 and the author was involved with the first pilot program for 
epilepsy in PRICCE-1 and was the main author of the subsequent program of 
epilepsy care in PRICCE-2.   
 
 
The development of a computerised epilepsy disease registers 
For the PRICCE 1 pilot there was no comparative data available to assess the quality 
of care provided before the project started, so no formal comparison was possible 
however indirect evidence from the medical audit advisory group and anecdotally 
from individual practices suggested improvement in clinical care. This style of 
commissioning healthcare now seems fairly unremarkable however at the time it 
represented a change in mind-set of both clinicians and commissioners both of 
whom were surprised how many practices participated. 
 
 
Incentivisation used in the PRICCE program for epilepsy 
The metrics were intended to increase over a three year cycle and though ambitious 
over a third of GP Practices in the area participated in the scheme. By the end of 2 
years over 85% of practices were signed up to take part in PRICCE. 
 
The project cost £297,436 in payment to practices in the first year, but also resulted 
in increased Health Authority management time, increased audit support by the PCT 
[East Kent MAAG] and cost £20,000 p.a. to run  There were also additional 
prescribing costs, increased hospital referrals, especially to neurology, 
echocardiography, gastroscopy, and  increased pathology tests. Between £70,000 an 
£100,000 of financial support was provided directly or indirectly by the 
pharmaceutical industry. 
  
Practices that joined the scheme had a commitment to meet targets in all 13 clinical 
areas. GP’s received on average £3,000 per annum in advance to resource 
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administration needed to be set up in advance of entering the scheme. If the targets 
were not met this funding had to be returned to the Health Authority   
 
 
Education program for PRICCE 1 
To accompany the support of the specific disease areas was an education program 
and initially this took the form of a brief educational article at the start of the 
epilepsy disease area chapter for PRICCE.  With time this was adapted to be more 
helpful to the GPs in understanding how the epilepsy quality standards were drawn 
up and was followed by a local educational meeting in epilepsy having been 
requested by the local East Kent GPs. It was at this meeting in the late 1990’s that 
the author witnessed clearly the changing mind-set towards community based 
epilepsy care as the local GPs requested the author as a GP specialist in epilepsy to 
be the main presenter, with the support of the regional epileptologist . At the time I 
was far from comfortable at this arrangement but very much appreciate the foresight 
of Dr Lina Nashef in supporting this change in emphasis for a GP meeting. The GP 
audience required relatively basic general epilepsy knowledge in a style which was 
more focused on being pragmatic rather than academic and somewhat different in 
style and content to a similar talk presented to clinicians in Secondary and Tertiary 
Care. 
 
 
Audit in PRICCE 
Each practice had to satisfy the East Kent medical Audit Advisory Group that they 
possessed the necessary skills and software available to perform audit of medical 
records. A partnership formed between the audit team and GPs and the East Kent 
MAAG team remained a resource that practices accessed frequently during the 
program. 
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The criteria required by the practices before being permitted to take part in the 
program were; 
 Past involvement in audit. 
 Computers on consulting room desks which were used in the consultation.   
 Disease registers established for all areas in the project. 
 Written protocols approved by all the relevant Primary Care Team members. 
 Completed audits to demonstrate compliance with standards for each 
condition. 
 Ability to provide numbers of patients with each condition (in order to check 
against their expected prevalence) 
 All partners had to agree to be involved in the project and to sign an 
agreement to that effect. 
 
The author advised the Audit team and the PRICCE steering project to some degree 
for the PRICCE 1 pilot and was the lead advisor for PRICCE 2 having the major role 
in re writing the education supplement on epilepsy, re-defining the quality standards, 
being the first port of call from practices and from the Audit team for epilepsy 
related problems arising from the program. This work also extended to the 
commissioners of primary care epilepsy services and the pharmacy support team for 
East Kent on epilepsy related matters. 
 
 
Peer Pressure in PRICCE 
It was quickly identified that doctors tend to be competitive by nature and have often 
an inherent tendency to strive to become “top of the class.” There was discussion 
between practices of their level of PRICCE achievement and practices who had a 
reputation of being academic practices were drivers in this work. If practices had 
discovered templates that worked they would share this with other practices and the 
kudos of being ahead on this had a positive effect of staff morale. There was also 
accompanying this a sense that what was being done was worthwhile and did indeed 
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make a difference hence effort spent on PRICCE even though financially was 
relatively minor was seen as time well spent. 
Limitations of the original PRICCE 1 pilot 
Not only was there a weakness in the original PRICCE 1 pilot in the restricting of 
the study to only Idiopathic Epilepsy but also the language that accompanied the 
project tended to be somewhat specialised. Also the clinical metrics were limited 
and it was soon clear that there was more scope available in the project to improve 
the care of people with epilepsy in the primary care setting. .   
 
 
Targets selected for the PRICCE 1 pilot in the treatment of Idiopathic Epilepsy 
 The markers of epilepsy care selected to demonstrate the active care of epilepsy 
were 
 70 % of patients should be seizure-free two years from initial diagnosis by 
1.4.99 , this means in the previous 6 months and by 1.4.00  in the previous 12 
months (If this is not achieved, then the practice must be able to demonstrate 
why this is so).  
 People with epilepsy should be reviewed annually. 
 Practices to refer to specialist clinics at the first stage any with neurological 
signs including impaired learning, those under 16 years old, and those in 
whom the diagnosis was uncertain. The protocol needed to include the 
minimum data set and when to refer and factors to be included in a referral 
letter.   
In the original program practices took different views on what to include for 
epilepsy and whilst some practices selected only those with a firm diagnosis of 
Idiopathic Generalised Epilepsy and included people with a read code of Primary 
Generalised Epilepsy other practices who had general epilepsy indexed in their 
medical records, tended to put all cases into the review. The result was a wide 
variation in results on the prevalence of idiopathic epilepsy ranging from 0.4% to 
0.56% of the practice populations. Also this figure is generally a good deal higher 
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than the expected percentage diagnosed with primary generalized epilepsy. The first 
wave of the scheme started in April 1998. A second wave of practices joined in 
April 1999 and a third wave of practices in April 2000.   
 
 
Uptake of PRICCE-1 by Practices 
The pilot demonstrated how rapidly such a scheme would be taken up by eligible 
practices and by 2001 a total of 89% practices in East Kent were taking part. This 
uptake is described in the figure 1 below 
 
 
 
Figure 1 Courtesy of East Kent NHS Health Authority 2001 
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The uptake was greater than originally expected and continues to be very high 
throughout the PRICCE-2 project and so this thesis studies the ability of the 
practices taking part to perform simple review of epilepsy and also more complex 
measures of care for their epilepsy.  
 
From 2002 to 2004 PRICCE-2 
From 2002 following the realization that the category of idiopathic epilepsy was 
problematic for practices to accurately identify the focus was then placed on all 
people with epilepsy. Also there was a widening of the epilepsy metrics to include 
recording seizure freedom, matters relating to women and children with epilepsy and 
a review of people taking vigabatrin for epilepsy. To provide some comparison with 
previous data the separate category of Idiopathic epilepsy was retained. The term 
used to describe the population with Primary Generalized as well as Focal Epilepsy 
was chosen as ‘full,’ epilepsy. 
 
It was at this time that the PCT was re-organized and the previous 5 PCGs were 
amalgamated to 4 PCTS in the same catchment area. 
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The Quality and Outcomes Framework (QOF)51 
 
 
From 2004 following the change of the GP contract all practices in England 
Scotland, Wales and Northern Ireland were eligible to take part in the Quality and 
Outcomes framework and part of this included the treatment of people with epilepsy. 
The aim for the department of health was to develop a nationwide scheme whereby 
incentivised targets for specified diseases would be available. For the treatment of 
people with epilepsy the aim was to help standardise epilepsy care across the UK 
and also to rise up clinical standards.  
 
 
Computerisation for QOF 
To take part in the QOF program all practices had to be computerised and have 
guidance on how to accurately code on their medical systems the disease areas 
included in QOF and also to use approved coding systems in order for the health 
authority to extract the data from the GP computer systems and analyse it further. 
GPs were given financial assistance from the PCTs in order to be able to perform 
paperless audit of these chronic disease areas. 
 
 
Incentivisation: Rewarding quality and outcomes  52 
 The QOF is divided into 4 categories;  
(i) Clinical standards, covering coronary heart disease (CHD), stroke or transient 
Ischaemic attacks, hypertension, diabetes, chronic obstructive pulmonary disease 
(COPD), epilepsy, cancer, mental health, hypothyroidism and asthma 
(ii) Organisational standards covering records and information about patients, 
Information for patients, education and training, practice management and 
medicines management 
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(iii) Experience of patients covering the services provided, how they are provided 
and their involvement in service development plans 
(iv) Additional services. 
 
Figure 2 - 2004/05 quality scorecard of the potential ‘QOF’ points which could 
potentially be achieved 
 
 
Clinical indicators                              Totals 
 
CHD including LVD etc.                      
 
121 
 
Stroke or transient ischaemic attack 31 
 
Cancer 12 
 
Hypothyroidism 8 
 
Diabetes 99 
 
Hypertension 105 
 
Mental health 41 
 
Asthma 72 
 
COPD 45 
 
Epilepsy 16 
 
Clinical Maximum 550 
 
 
Clinical Care only represented a 550 of the new QOF payments scheme points. 
There were 1050 points in divided into 4 domains of clinical, organizational, patient 
experience and additional services. In 2004/05, based on current average list size, 
each point was worth £75 per practice with an average weighted population. The 
 57 
following year [2005/06,] this figure rose to £120.6 the incentivised scheme allowed 
for 16 points out of a total of 1050 to be allocated to epilepsy. 
 
 
Education for QOF 
There was no specific education programs developed to support the QOF program 
however personal development plans became the vehicles by which GPs could 
identify areas of educational need and tailor-make ways of meeting that need. Some 
preferred attending lectures; others used e-learning packages whilst others used 
textbooks on the subject. 
  
 
Audit for QOF using centralised data collection with verification 53using the 
Quality management and Analysis System (QMAS)  
The data collection has been improved however compared to PRICCE2 and a system 
called Quality Management and Analysis System (QMAS) was developed. It is a 
national system designed specifically to support QOF for use by practices in 
England. 
QMAS can accurately calculate: 
 Points achieved against aspiration 
 Pounds achieved against aspiration 
 Disease prevalence adjustment 
 Weighted list size in accordance with practice financial entitlements 
 National disease prevalence 
 National target population averages 
 
 A team of QOF Assessors employed by the PCT visit practices at least annually to 
check the accuracy of recording of diagnoses and the results of tests to ensure 
accuracy in QOF data. If following a visit to the practice.54 Significant areas of 
concern were identified and where the practice cannot offer a credible explanation, 
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the PCT then begin a process to investigate further and may even involve their Local 
Counter Fraud Specialist or NHS Counter Fraud and Security Management Service 
as appropriate.   
Peer pressure formally incentivised for QOF  
The use of peer pressure has not been introduced for epilepsy care. The emphasis on 
it however has steadily increased and the health authorities in the latest version of 
the QOF program have included the following areas which receive a considerable 
amount of Incentivisation to encourage practices to take part. The areas where 
finance and potential savings can be made by the practice tend to be the areas where 
peer group pressure is most heavily utilised by the department of health. 
 
Palliative Care; 
 PC2 The practice has regular (at least 3-monthly) multidisciplinary case 
review meetings where all patients on the palliative care register are 
discussed – 3 points 
 
Medicines Management; 
 Medicines 6 The practice meets the PCO prescribing adviser at least annually 
and agrees up to three actions related to prescribing – 4 points 
 Medicines 10 The practice meets the PCO prescribing adviser at least 
annually, has agreed up to three actions related to prescribing and 
subsequently provided evidence of change – 4 points 
 
Quality and productivity; 
 QP6 The practice meets internally to review the data on secondary care 
outpatient referrals provided by the PCO – 5 points  
 QP7 The practice participates in an external peer review with a group of 
practices to compare its secondary care outpatient referral data either with 
practices in the group of practices or with practices in the PCO area and 
proposes areas for commissioning or service design improvements to the 
PCO – 5 points  
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 QP8  The practice engages with the development of and follows three agreed 
care pathways for improving the management of patients in the primary care 
setting (unless in individual cases they justify clinical reasons for not doing 
this) to avoid inappropriate outpatient referrals and produces a report of the 
action taken to the PCO no later than 31 March 2012 – 11 points  
 QP9 The practice meets internally to review the data on emergency 
admissions provided by the PCO – 5 points 
 QP10 The practice participates in an external peer review with a group of 
practices to compare its data on emergency admissions either with practices 
in the group of practices or practices in the PCO area and proposes areas for 
commissioning or service design improvements to the PCO – 15 points 
 QP11 The practice engages with the development of and follows three 
agreed care pathways (unless in individual cases they justify clinical reasons 
for not doing this) in the management and treatment of patients in aiming to 
avoid emergency admissions and produces a report of the action taken to the 
PCO no later than 31 March 2012 - 27.5 points 
 QP12 The practice meets internally to review the data on accident and 
emergency attendances provided by the PCO no later than 31 July 2012. The 
review will include consideration of whether access to clinicians in the 
practice is appropriate, in light of the patterns on accident and emergency 
attendance New indicator-  7 points   
 QP13 The practice participates in an external peer review with a group of 
practices to compare its data on accident and emergency attendances, either 
with practices in the group of practices or practices in the PCO area and 
agrees an improvement plan firstly with the group and then with the PCO no 
later than 30 September 2012. The review should include, if appropriate, 
proposals for improvement to access arrangements in the practice in order to 
reduce avoidable A&E attendances and may also include proposals for 
commissioning or service design improvements to the PCO New indicator- 9 
points    
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 QP14 The practice implements the improvement plan that aims to reduce 
avoidable accident and emergency attendances and produces a report of the 
action taken to the PCO no later than 31 March 2013 New indicator – 15 
points    
   
 
National realisation that change was needed in the management of epilepsy 
The deficiencies on the provision of care for people with epilepsy are still being 
reported unfortunately and for the time being ensure that epilepsy continues to be 
included in the QOF program.  
 
In 2007 the All Party Parliamentary Group on epilepsy [APPG] published a 
document that set out sobering statistics about the state of epilepsy care in the UK.55 
The report highlighted that there were 400 avoidable deaths per year in the UK and 
that approximately 69,000 people were living with unnecessary seizures. On top of 
this £189 million pounds was needlessly spent each year as a consequence of gaps in 
provision. It describes how social stigma, secrecy and medical ignorance has led to a 
poor service where patients cannot confidently expect good treatment at primary or 
secondary care.  
 
The problem identifying people with epilepsy is a recurrent theme in reports 
assessing the provision of care for epilepsy.56 The American Epilepsy Society and in 
addition reported that without a structured program of care that the management of 
epilepsy tended to become confusing and needed clear guidelines. In America also 
there was a degree of confusion as to which group of clinicians should be actively 
involved in treating people with epilepsy. The program of care for epilepsy in QOF 
is certainly not perfect however it does facilitate everybody with epilepsy being 
offered an annual review. 
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Development of a Locally Enhanced Service (LES) for epilepsy 
 
Historical perspective 
When the Quality and Outcomes framework was launched nationally the standards 
set within it for epilepsy were less demanding and fewer in number than the 
PRICCE-2 project it replaced.  The care of epilepsy in East Kent therefore ran the 
real risk of taking a step backward.  To ensure that the high standards which were 
previously set were not lost a Locally Enhanced Service for Epilepsy was developed 
in 2006 and made provision for these higher standards to continue to be 
commissioned.   This was available for Eastern and Coastal Kent PCT only.  
 
 
Computerisation for the Locally Enhanced Service for Epilepsy 
This was by now fully established in East Kent and practice staff were proficient and 
accurate when indexing the requirement needed to be audited on computer. 
Incentivisation 
A Locally Enhanced Service offers GPs is defined as; 
 
“Enhanced services are: 
(i) Essential or additional services delivered to a higher specified standard, 
for example, extended minor surgery 
(ii) Services not provided through essential or additional services. These 
might include more specialised services undertaken by GPs or nurses with 
special interests and allied health professionals and other services at the 
primary-secondary care interface. They may also include services 
addressing specific local health needs or requirements, and innovative 
services that are being piloted and evaluated57.” 
 
The enhanced service was awarded 12 points which were set to have an equal value 
as 12 extra QOF points per practice on full attainment of the program for epilepsy. 
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Education arrangement for the epilepsy locally enhanced service 
The enhanced service required a lead GP to undergo extra training in epilepsy which 
was relatively informal and merely required a certificate of attendance at the 
education event.  
 
Audit for the epilepsy locally enhanced service 
The remit of the LES was to provide an incentivised level of service above the 
current standards required in QOF. These metrics include ensuring that more in 
depth questioning on epilepsy control and also wider issues such as social and 
emotional well-being. They also included female related issues. The discussion 
between the doctor and patient on these areas was then subject to end of year audit. 
The areas to audit were somewhat difficult to record for audit purposes as they 
included targets set to improve the wider health and social care needs with the GP’s 
taking part helping to provide the support where possible and if not sign posting the 
patients to suitable agencies The clinicians taking part had to record the fact that 
they had offered people who required information on driving, safety, employment 
and female issues where appropriate.   
 
 
Peer Pressure 
This tool was not specifically used in the enhanced service but as in PRICCE 
practices who were known to take a lead in primary care services tend to be the ones 
who took part in the scheme. Unfortunately with the loss of the central record within 
the changing PCT computer records more formal analysis on the impact of peer 
pressure is not possible 
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The potential role for the Community Pharmacist 
The department of health in recent years has promoted commissioning the location 
of care to be close to home 58and arguably the closest clinician to the patient with 
epilepsy is the community pharmacist. Community pharmacists are arguably the 
closest people to deliver care to people with epilepsy when judged by the pharmacist 
being the clinician who is at the end of the delivery of care pathway for everyone 
taking anticonvulsants. To receive their medication people with epilepsy will need to 
see their pharmacist to anti-epileptic drugs. The potential role which a community 
pharmacist can offer in supporting a person with epilepsy has yet to be fully 
realised59. They are ideally situated to provide literature, educate about disease 
therapy, encourage adherence, explain side effects and provide information of 
potential drug interactions.   
 
One American study, reported that most people with epilepsy used their pharmacists 
to answer queries on drug interaction and adverse effect information60. Patients also 
responded that they would welcome greater input from their pharmacists and indeed 
would value collaboration between their epilepsy specialists and their pharmacists. 
Areas of potential increased help included improved quality of life, help with 
medication compliance and help keeping a seizure diary. The question of who would 
pay for this service whilst being an issue in America is not so for the UK as the 
National Health Service includes currently for the provision for a medicines use 
review. 
 
Poor compliance with medication is a key factor in mortality and morbidity in 
epilepsy and the pharmacist as well as the family doctor are ideally placed to detect 
this61. The importance and prevalence of poor medicines adherence for people with 
epilepsy is well known and there are strategies and indeed practical ways for a non-
epilepsy specialist to help62. Amongst recommended actions clinicians can take is 
checking 
 For an agreement between doctor and patient before prescribing AEDs 
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 If prescription ordering shows a low medicine possession ratio [ordering 
prescriptions late] 
 Whether the patient conserves AEDs by missing or reducing a dose 
 Whether the patient has to skip doses to reduce side effects  
 If the patient misses doses unintentionally due to poor memory 
 If the patient sometimes skips doses 
 If the patient has missed at least a dose in the previous week 
  
 
Developing the role of the community pharmacist in England 
The Department of Health have recognised the opportunity for pharmacists to take a 
more prominent role in the care of patients. The provision of community pharmacist 
services in the UK ensures that community pharmacists are directly accessible by the 
public and are available in longer hours than most other primary care clinicians. 
They are in addition also situated usually in prominent and easy to access positions 
and can be seen as being as accessible as a local supermarket.  
 
In 2005 the department for Health introduced the Medicines Use Review (MUR)63 
whereby accredited pharmacists can undertake structured reviews with patients on 
multiple medicines, particularly those receiving medicines for long term conditions. 
The purpose of the MUR service is to maximise the benefits of the medication and 
also to reduce wastage. This was updated 2011 and received further minor 
amendments in 2012.  In this scheme pharmacies can perform up to 400 MURs per 
year. National target groups have been set to guide the selection of patients who will 
be offered the review and helps patients understand their therapy and looks to 
identify any problems they are experiencing along with offering possible solutions.   
 
In a typical MUR the patient's actual use and experience of taking their medicines is 
assessed and then the pharmacist offers assistance in cases of poor or ineffective use. 
By identifying problems such as side effects the pharmacist works to minimise 
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problems uncovered hence aiding their effective use. In an MUR, the pharmacist 
will consider all the medicines the patient is taking, including those which aren't 
prescribed 
 
From 1 October 2011, contractors were expected to perform at least 50% of MURs 
on patients in one (or more) national target groups. The three target groups are: 
 patients taking high risk medicines (on a national list)  
 patients recently discharged from hospital who had changes made to their 
medicines while they were in hospital  
 patients with respiratory disease. 
  
In addition to the above, MURs can still carried out on patients who are not within 
the target groups. Pharmacists are expected to select patients most likely to benefit 
from the MUR service.   
 
From 1 July 2012 the method for data capture was implemented which included 
changes to the data that need to be collected during the consultation and revised 
information being sent to the PCT on request.64 This information includes; 
 
 Patient demographic details,  
 
 Target group  
o respiratory  
o high risk medicine  
o post-discharge  
o not in a target group  
 
 Total number of medicines being used by patient:  
o prescribed  
o over the counter and complementary therapies  
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 Healthy living advice provided at MUR (using the following options):  
o diet and nutrition  
o smoking  
o physical activity  
o alcohol  
o sexual health  
o weight management  
o healthy living advice not applicable at this consultation  
 
 Matters identified during the MUR (using the following options):  
o patient not using a medicine as prescribed (non-adherence)  
o problem with pharmaceutical form of a medicine or use of a device  
o patient reports need for more information about a medicine or 
condition  
o patient reports side effects or other concern about a medicine  
o other (free text information can be entered in the clinical record)  
o no matters identified during MUR  
 Action taken / to be taken (using the following options):  
o information/advice provided  
o yellow card report submitted to MHRA  
o referral – patient’s issues raised with the medicine need to be 
considered by the GP practice or another primary health care 
provider  
o other (free text option in clinical record)  
 
 As a result of the MUR the pharmacist believes there will be an improvement 
in the patient’s adherence to the medicines as a result of the following (more 
than one may apply):  
o better understanding/reinforcement of why they are using the 
medicine/what is it for better understanding/reinforcement of when/ 
how to take the medicines  
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o better understanding/reinforcement of side effects and how to manage 
them  
o better understanding/reinforcement of the condition being treated  
 
 
From 1 September 2012 community pharmacists are only required to inform a 
patient's GP that an MUR has taken place if an issue has been raised that the 
pharmacist believes the GP should be aware of.  
The Target group introduced in 2012 MURs included patients taking any of the 
following high risk medicines:  non-steroidal anti-inflammatory medication, 
anticoagulants (including low molecular weight heparin) anti-platelets and diuretics.  
Also it includes patients who had recently been discharged from hospital and who 
have had a change in medicines during their hospital stay. In addition patients with 
respiratory disease were singled out for special care being focused on those taking 
the following medicines for asthma or COPD. The medicines included are 
adrenoreceptor agonists, antimuscarinic bronchodilators, theophylline compound 
bronchodilator preparations, corticosteroids, cromoglicate and related therapy, 
leukotriene receptor antagonists and phosphodiesterase type-4 inhibitors.  
Epilepsy was not included however it would seem an ideal long term disease to 
benefit from being made one of the target groups. It was not known if pharmacists 
could be trained to deliver such a service. The purpose of this pilot is to see if it 
would be possible to train and equip community pharmacists to offer support for 
people with epilepsy. The pilot went one stage further in that it offered the 
pharmacists the authorisation to refer people with epilepsy to the community 
epilepsy clinics run by the GPwSI for epilepsy.  
 
For the duration of the pilot, the community pharmacists using the medicines use 
review specifically looked for people who were exposed to an increased risk from 
their epilepsy AND were not currently accessing specialist health care. They were 
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given referral rights to specialist epilepsy care. One of the areas which a community 
pharmacist was to focus on was the monitoring of medication compliance and 
systems such as NexPhase pharmacy dispensing software can be used as it has the 
capability to note when prescriptions appear to be requested too infrequently.  
 
 
The need for additional support for people with epilepsy 
Also the study with community pharmacists included assessing whether it was 
feasible for a specially trained pharmacist to offer support and appropriate literature 
to people with epilepsy hence providing an extra source of support. Clinical 
confidence in the management of epilepsy was enhanced by a day’s educational 
update in epilepsy for Pharmacists delivered through the Medway School of 
Pharmacy. Information leaflets on living in epilepsy provided by Epilepsy Action 
were available for Pharmacists to use.   
 
 
The value of targeting Medicines Use Reviews 
Previously medicines use reviews were currently not targeted as they tended to be ad 
hoc and local informal comment suggested that they tended to be taken up by 
already well informed and well managed patients. The Pharmacist sends the GPs a 
notification list periodically and would offer recommendations which ran the risk of 
being lost in the practice’s paperwork. By allowing Pharmacists to refer directly 
within agreed parameters to Intermediate care the MUR becomes a dynamic and 
more effective tool in the hands of a very skilled and arguably currently 
underutilised pharmacist. 
 
  
Strengthening the place of community pharmacists in the Primary Care Team 
GPs will need to feel confident in their pharmacist colleagues in order to welcome 
them as partners in patient care. In addition to this they will be required to trust their 
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ability to refer patients who appear to have red flag symptoms to Intermediate Care. 
The study included training of pharmacists in the process of referral and utilised a 
referral template to help ensure the correct people were seen and that standards 
across the group were maintained by all. The possession of referral rights to 
pharmacists is a significant move into bringing pharmacists under the Primary Care 
Team and paves the way, if successful, to closer working and collaboration between 
the two groups  
 
 
The role of Epilepsy Specialist Nurses 
The development of epilepsy nurse specialists has taken place over the last few 
decades and has developed into a very skilled workforce to a standard where   18% 
of the U.K’s epilepsy specialist nurses are medication prescribers65. Most of this 
group prescribe a new drug weekly and most nurses titrate medication daily. This 
skill needs to be kept active as after gaining qualification there is evidence that 
nurses do not prescribe or prescribe infrequently. The value of nurse prescribing can 
be summarised as  
 Enabling a holistic approach 
 Overcoming delayed access to medicines 
 Response in a timely fashion 
 Increased the nurses autonomy66 
 
Investment in epilepsy specialist nurses to bridge the gap and increase capacity will 
help but more diversity is needed. The support nurses offer is different to that which 
a doctor offers. There is evidence to suggest that Epilepsy Specialist nurse history 
taking was reported to be similar with the neurologists  however the diagnostic 
process can produce a different result with a 25 % disagreement in diagnosis 67 It 
may be also that nurses are less certain of diagnosis and tend to order more 
investigations. It is certain that there will be some overlap of skills and that capacity 
and flexibility to a network of care can be increased but it would not surely be wise 
to see the role doctors and nurses offer as being identical.  
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Commissioning services for epilepsy requires a clear target of the outcomes to be 
expected from the clinical workforce and it would be a mistake to expect 
improvement in the wrong outcomes. Epilepsy Specialist Nurses have been found to 
achieve improved levels of communication with patients compared to other health 
professionals and also higher levels of patient satisfaction.68 It is not clear if there is 
improvement in health status and use of other health care services and may produce 
an adverse effect on patient’s perception of epilepsy affecting on patient’s everyday 
life. This has been postulated to be due to heightening awareness of the restricting 
effects of this illness. The role of the nurse as a support to people with epilepsy is 
undoubted but they cannot with the evidence to date, be expected to improve health 
outcomes but they play a valuable role in improving patient quality of life. 
 
 
Intermediate Care – the role of GPs with a Special Interest in Epilepsy 
(GPwSIs) 
The introduction of GPs with a special interest in epilepsy has been steadily 
increasing over the last decade69 and it was envisaged in 2002 that there was 
potential for this group of GPs with special training to contribute to the care of 
people with epilepsy in the UK Over time, certain areas have seen this take place 
and it has been suggested that they can be a focal point of epilepsy care in the 
community.70 With an aging population there is a pressing need to increase capacity 
and develop a better shared care model with the development of GPwSIs to act as 
focus at primary level. Within this structure the movement of the patient to the 
appropriate health care provider should be seamless and so the patient sees the ‘right 
person and the right place and at the right time,’ with mind given to the DH policy of 
a desire to see the patient receive ‘care closer to home71 
 
The Association of British Neurologists in their report looking at how they foresee 
neurology services developing over the next decade suggest that for the long term 
care of people with neurological conditions that whilst the initial diagnosis and 
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treatment be the domain of neurologists, care should be followed up in the 
community. This community team led by professionals with specialist expertise 
including nurse specialists, GPwSIs and professionals allied to health. These 
community teams should have close links and easy access to the appropriate DGH 
based neurologist.72.  
 
 
The scope of this thesis 
This thesis addresses the role of the primary care team which includes practice 
nurses but does not explore the role of the epilepsy nurse specialist who in East Kent 
hold their clinics within hospital out-patient clinics. 
 
The follow chapters describe this progression of epilepsy care development which 
took place in primary care and sets out to find answers to the aims set out in the 
thesis.  
 
 
The Link between the Studies 
The aim underpinning this work is to see primary care proactively supporting 
everybody with epilepsy rather than care being reactive being offered to only a sub 
group of the cohort. The need for specialist services is not diminished as inevitably 
more complex problems associated with the management of epilepsy are discovered 
and dealt with electively by epilepsy specialists.  
 
The author seeks to examine whether primary care is willing to become involved 
and goes on to explore the level of expertise that it is possible to deliver. The work 
regionally in study One; PRICCE-2 was used to develop the national program for 
epilepsy in QOF. Following this the Locally Enhanced Service for Epilepsy 
examined the extent to which GPs care for epilepsy can be more complex. The 
lessons learnt on the training and assurance of quality of advice given by the practice 
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staff were utilised in the community pharmacists Medicines Use Review pilot for 
epilepsy.  
 
If these schemes are successful it should be possible to see a change in the support 
offered by primary care when comparing the situation at the beginning of Study One  
to the end of Study Four.   
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METHODS 
1 Study One; PRICCE-2   2000 - 2004 
  
The study started in 2002 and followed on from the successful PRICCE-1 pilot. The 
overall aim of the study was to improve the care of people with epilepsy and to start 
a process of care for epilepsy which was pro-active rather than being simply reactive 
to problems and indeed crisis. As mentioned in the introduction one of the major 
differences was the expansion of the target group for epilepsy which was originally 
only those with idiopathic epilepsy and was widened to all people with epilepsy in 
PRICCE-2. The previous definition of idiopathic epilepsy [see page 17] was helpful 
initially but caused confusion in practices both in understanding which patients were 
to be included and also in lack of information in the medical notes defining the 
epilepsy classification. This led to non-conformity between practices and indeed it 
was unclear why the majority of people with epilepsy would not be included in this 
program. The term ‘full epilepsy,’ was used by the PRICCE team to highlight that 
all cases of epilepsy were to be included. All patients with epilepsy should be 
included in the audit as all epileptic fits regardless of aetiology have inherent 
dangers. 
 
Also in PRICCE-2 there was a widening of the epilepsy metrics which in PRICCE-1 
was to review people with idiopathic epilepsy annually, to undertake to refer people 
to specialist clinics at the first stage if they had any underlying neurological signs 
such as learning disability and if they were under 16 years old and to aim for seizure 
freedom in 70% of people with idiopathic epilepsy and if this was not achieved to be 
able to explain why it was not achieved.    
 
The PRICCE-2 study kept these standards for PRICCE-1 and added to them more 
complex tasks for the GPs to aim for all people with epilepsy. This expansion 
included proactively managing epilepsy related matters relating to women and 
children with epilepsy and also asked for a review of people taking vigabatrin for 
epilepsy. This was a unique opportunity for the author to become involved and 
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investigate whether practices would be able to attempt more complex requirements 
for the epilepsy component of PRICCE-2.  To provide some comparison with 
previous data the separate category of Idiopathic epilepsy was retained.   
 
It was at this time that the PCT was re-organized and the previous 5 PCGs were 
amalgamated to 4 PCTS in the same catchment area. 
 
The project team set in place the following pre requisite factors which were utilised 
to bring about change in proactive care for epilepsy and indeed other long term 
conditions. The factors selected to commence the change in the pattern of care for 
PRICCE were; 
 Computerisation 
 Incentivisation 
 Education 
 Support of audit team 
 Peer pressure 
 
Computerisation 
All practices ran computerised data bases and were well versed in indexing 
accurately the medical records to facilitate accurate audit. 
 
 
Incentivisation 
Following the successful practice visit by the PRICCE team the practice was invited 
onto the PRICCE scheme and an upfront payment of £3,000 was made to the 
practice to allow for the restructuring of systems required to be in place to run the 
project. A contract was then put in place with the practice to achieve the PRICCE 
targets 
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Education 
Background given to Practices informing them why improving control of epilepsy is 
necessary 
 
I. Epilepsy is one of the most common neurological disorders and affects 1.5 
million people at some time in their lives, especially during childhood and 
old age. With 1-2 new cases per 2-4,000 people a year     
II. In 1996 over 1,000 people died from epilepsy in the UK    
III. More people die from epilepsy a year than the combined mortality figures of 
cot deaths and HIV   
IV. A survey of patients attending The National Hospital for Nervous disorders 
Queens Square revealed that 1:200 patients of this clinic died due to their 
epilepsy each year    
V. Optimising the care of patients with epilepsy minimises this risk hence the 
need to promote the best possible care of all patients with epilepsy   
VI. A recent CSAG survey revealed that only 51.5% of the 1,652 patients 
surveyed had remained seizure free in the preceding year. Epilepsy clinics 
aim at 70% seizure free over the previous 2 years.  
 
 
Support of the Audit team 
The audit team worked closely with practices and to some degree became extended 
members of the practice and were usually warmly welcomed by the practices and 
become a useful source of information and advice 
 
 
Peer pressure 
This was informal and not incentivised however there was a strong professional 
rivalry between practices and practices that previously had little to do with each 
other and indeed started to form helpful relationships. The early achievers in 
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PRICCE were certainly seen as being ‘ahead’ of the others who were still waiting to 
reach the standard necessary to embark on PRICCE 
Setting the standards 
The standards were initially developed for all of the thirteen disease areas included 
below:  
Idiopathic Epilepsy  
Dyspepsia  
UTI in children  
Leg Ulcers  
Angina  
Myocardial infarction 
Hypertension  
Atrial Fibrillation  
Chronic Heart Failure  
High Cholesterol   
Asthma  
Diabetes  
Depression  
 
Validation Process 
The criteria for PRICCE with the standards for most areas being the product of a 
regional discussion group however the section on Idiopathic epilepsy was written by 
Dr Lina Nashef and was offered for comment to the author and Dr Henry Smithson.  
For PRICCE-2 however the standards were set by the author and ratified by Dr Tony 
Snell the East Kent medical director as well as the East Kent Medical Audit 
Advisory Group [East Kent MAAG.] The clinical literature was used to help set 
these standards73,74 and also a pragmatic approach to set baseline standards such as 
developing an epilepsy register 
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For each subsequent section in this chapter the rationale for selecting the standard is 
given 
 
Verification and Storage of Data 
As the programme was incentivised and money was paid for the achievement of 
PRICCE standards the health authority oversaw the collection of data at the end of 
each year of the scheme. As part of the scheme, participating practices conducted an 
audit of their achievement against the standards used for epilepsy. These were 
produced on standardised forms issued by the health authority an Excel spreadsheets 
and deviations from the standards had to be listed.  
 
The end of year reports were sent to the health authority and manual paper copies of 
these were saved in the health authority offices. Health authority staff intended to 
visit all practices at the half-year and year-end. The medical director of the Health 
Authority and members of the East Kent MAAG team carried out these visits in the 
first year of the project. This offered an opportunity for practices to raise issues and 
describe progress. At the year-end they report apparent failures to health authority 
for consideration.  It was the eventual achievement or otherwise of the standards that 
was measured and payment given if the standards had been achieved. 
 
This data was available to author at year end and to facilitate access to such a large 
volume of information the data was later summarised and tabulated electronically 
using a uniquely designed Microsoft Access programme by the East Kent MAAG 
team.  
 
 
1.1 Determine the extent to which participating primary care practices in 
East Kent are able to be involved in basic proactive care for epilepsy 
using a disease register following the PRICCE-2 programme 
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To be welcomed to take part in the program the practice4 was required to present 
evidence that it was willing to engage fully with the PRICCE program. This 
included being able to demonstrate the following criteria; 
 
 The practice should have a protocol for the evaluation of all new cases 
 The practice must be able to identify all patients with epilepsy 
 All new patients should be appropriately assessed and investigated so their 
seizure type and aetiology can be established wherever possible 
 There must be evidence of discussion amongst the primary health care team 
[and if applicable secondary care] around any critical events - including 
unexpected death in epilepsy, significant injuries, burns or drowning, status 
cases and near-miss cases. 
 A target of 70% seizure free during the previous year should be achieved. If 
this is not achieved despite good compliance the patient should be referred to 
a specialist clinic. 
This list of proactive care was developed largely on a pragmatic basis and the 
acquisition of a disease register for epilepsy is seen as the basis from which this 
study could advance. 
 
1.2 Determine the extent to which participating primary care practices in 
East Kent are able to identify potential problems which can arise as a 
consequence of suffering from epilepsy 
 
1.2.1 Identify people who are seizure free 
Using the practices structures described in 2.1.1 the practice was able to determine 
home many of their patients with epilepsy were seizure free. This standard of seizure 
freedom was chosen by Dr Lina Nashef and retained by the author for PRICCE-2 as 
it remains one of the key factors in reducing mortality and morbidity for epilepsy.  
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It was hard to verify the data offered by practices however practices who recorded 
higher than average rates of seizure freedom were questioned on this. Providing they 
could satisfy their health authority visit however the declared values were taken as 
being correct.  
 
The selection of seizure freedom as a quality standard was not formally validated as 
it was taken for granted at that stage by the author to be a key marker of quality of 
care. 
 
 
1.2.2 Ensure the people who are taking vigabatrin have their visual fields 
measured 
Vigabatrin is now known to cause peripheral field loss in the vision in 30% of 
patients [some studies have reported rate of up to 50%] .The onset can be gradual 
and unnoticed as central vision is not affected. Its occurrence can   be picked up 
early by formal visual field testing   All patients on vigabatrin were identified and 
their visual fields checked twice a year. If visual field loss is noted they should be 
referred to an epilepsy clinic urgently. The effects appear to be irreversible or 
incompletely reversible. Consideration should be given to referring all patients on 
vigabatrin to specialist clinics for further evaluation if not already under secondary 
or tertiary care.75  
 
The evidence from the available scientific literature was taken as the basis for 
justifying and indeed validating this standard. 
 
 
1.2.3 Identify women who are pregnant and also have epilepsy 
Pre natal advice to female patients with epilepsy must be offered and those on higher 
risk regimes for causing foetal abnormalities referred to specialist clinics. Also all 
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patients who become pregnant and have a diagnosis of epilepsy should be referred to 
specialist care - control often becoming more difficult during pregnancy.   
 
This standard was chosen as it was hoped to make the local GPs more aware of the 
teratogenic risks associated with anti convulsant medication. The GPs were 
encouraged to consult the British National Formulary and at the training given prior 
to the programme they were reminded that Phenobarbitone, Phenytoin and Sodium 
Valproate were all particularly know to be potentially teratogenic.    
 
 
1.2.4 Ensure women and children of childbearing age are taking folic acid 
Folic acid 5 mg  to be offered to all women and girls who are sexually active in the 
reproductive years should be offered folic acid 5 mg and this should be continued to 
the 16th week if they become pregnant76.  
 
This evidence from the scientific press was used by the author to validate this 
standard and as it was not widely known about by GPs and it was hoped that this 
standard would help to rectify this gap in knowledge.  
 
 
1.2.5 Ensure that women who are taking contraception medication are 
prescribed appropriate contraceptive medication 
All patients on enzyme inducing anti convulsants and oral contraceptive should have 
the dose of their contraceptive checked to ensure adequate contraception is provided.  
 
The validation of this standard was taken on pragmatic grounds at this time by the 
author.  GPs arguably should always consider whether the oral contraception 
prescribed interacts with their anti convulsant medication however many 
medications were prescribed on hand written scripts without the advantage of 
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computer software to warn of interaction. This standard was chosen to try and 
remedy this risk.   
 
 
1.3 A preliminary examination of local trends in hospitalisation. 
 
1.3.1 Trends in unplanned visits to hospital for acute problems arising from 
epilepsy  
 
This standard was chosen to assess whether there was any discernable impact on 
unplanned admission to hospital from the PRICCE-2 project. Even though this was   
uncontrolled and exposed to confounding factors, the link between improved 
elective care and unplanned admissions was made 
 
Analysis Plan 
 
The overall aim of the PRICCE-2 programme was to assess the utility and uptake of 
a low impact audit driven process of health care delivery at Primary Care level. It 
was the uptake and implementation by individual practices in East Kent which was 
being measured and so simple descriptive statistical analysis was chosen to evaluate 
the data.  
 
Descriptive statistics defined as; 
 
 “… measures of different aspects of a population (or a distribution of 
population values). The population may be finite, as is the case for example 
when it consists of a set of data, or it may be infinite.”77 
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The descriptive statistics were used to describe the main features of the practices 
both as they joined the scheme and as they performed in the programme. Inferential 
statistical methods were not utilised as it was only the sample which was studied and 
there was at this stage no plan to extrapolate to the wider population of all GP 
practices in East Kent or indeed England. It was for this reason that probability 
theory was not utilised. The data sets were presented by the author in graphical 
format.  There was no provision to explore non responding practices in this project. 
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2 Study Two; Quality and Outcomes Framework 
 
Following the success of the PRICCE-2 project the department of health 
commissioned the Quality and Outcomes Framework [QOF] which was developed 
as a national scheme which drew heavily from the lessons learnt in PRICCE. This 
heralded a new era whereby primary care provided a key role in the management of 
long term conditions. Included in this group was epilepsy and a good deal of the 
development put into place by the author in PRICCE-2 was then carried on in [see 
page 199] QOF  Following the introduction of QOF the care of people with epilepsy 
would benefit from being part of a pro-active and structured care program. The 
ability of primary care on a national scale to take part in proactive epilepsy care was 
examined in this study and included incentivised targets for people with epilepsy. It 
was not certain however how GPs across the country would receive this scheme and 
also how quickly they would reach the targets.  
 
The pre requisite factors which were needed for PRICCE also needed to be in place 
nationally and required the same ingredients of 
 Computerisation 
 Incentivisation 
 Education 
 Support of audit team 
 Peer pressure 
 
 
Standards for Epilepsy 
The targets set for epilepsy were standardised throughout the country and initially 
were set at a relatively basic level which required practices to develop an epilepsy 
disease register which could be accessed easily to help facilitate the proactive care of 
people with epilepsy. For the first time in the UK everybody with epilepsy would be 
invited to an appointment with their GP and asked how they felt their epilepsy care 
and control was doing. Also they received an epilepsy medication review and were 
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specifically asked if they were experiencing side effects. The target for seizure 
freedom was also introduced with the aim of achieving 70% seizure freedom. The 
standards used are set out in table 1 and each one carried a specified reward of QOF 
points. 
 
Setting the Standards  
 
The standards drew heavily from the East Kent work on PRICCE-2 and included the 
section including epilepsy. The level of care for epilepsy provided by general 
practice was limited at this time and the standards set were pragmatic and indeed 
basic such as developing a disease register however this formed the necessary pre 
requisite to develop the programme.  
 
Where national guidance was available the central QOF team built on this and the 
author was a member of the expert panel who developed these standards [see page 
207.] 
 
 
Reporting and Verification of results 
 
 It was intended from the beginning that all reporting of performance by the GP 
practices would be electronically gathered via the clinical software systems and a 
report would be run annually which can be submitted to the local health authority.   
 
 The standards chosen had an identifiable source in the clinical record and required 
GPs to accurately index their medical records to be able to extract this data 
accurately. In general the primary care organisations were expected to conduct 
detailed or intrusive verification procedures, unless there was a suspicion that 
incorrect figures may have been returned, or indeed if they suspected fraud. 
However on the annual visits by the health authority it was expected that the visiting 
team select cases for more detailed investigation from time to time on a random 
basis. 
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Quality Management and Analysis System [QMAS] 
 
The Quality Management and Analysis System (QMAS) was a national IT system 
developed by the Department for Health which was solely used by the primary care 
organisation and not the GPs themselves. It is used to produce an accurate evidence 
on the quality of care that practices deliver to patients. It could not be manipulated 
by the practices and it produced an electronic record of the practice achievement.  
 
The GP system suppliers of the various GP clinical software programs designed and 
integrated data communication which will send the information required overnight at 
the end of each month. The information sent is anonymized information, with the 
guarantee that the QMAS software did not interrogate GP computers so could not 
breach confidentiality.  
 
The data was then saved onto a national department of health central server and 
amalgamated to provide a large range of statistics on clinical activity both on a 
practice level as well as a local health authority level. This data was analysed 
primarily by the Public Health Observatories. 
 
The information is made public and can be accessed by the local primary care 
organizations to allow comparison with local and national averages. Information and 
results for this thesis regarding QOF were made possible by the very large 
infrastructure provided by the Department for Health electronic records generated 
and published using QMAS. 
 
Analysis Plan. 
 
The overall aim of the Quality and Outcomes Framework for epilepsy was to assess 
the utility and uptake of a low impact audit driven process of health care delivery at 
Primary Care level. It was the uptake and implementation by individual practices in 
England which was being measured and so simple descriptive statistical analysis 
was chosen to evaluate the data.  
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The assumption was made that the sample size was approaching the population size 
[i.e. approaching complete uptake from all the practices in England] and so 
inferences gained from the study could be reasonable assumed to near that of the 
general population. It was for this reason that probability theory was not utilised. 
 
The descriptive statistics were used to describe the main features of the practices 
both as they joined the scheme and as they performed in the programme.  There was 
no provision made in this study to explore non responding practices.   The data sets 
were presented by the author in graphical format.    
 
The data on mortality was gathered as described below [please see page 94] the 
available data on line was collected from the however it was not in an age 
standardised format. It was for this reason that the author contacted the local Public 
Health Observatory to enlist their help in converting it to a directly standardised rate 
from 2001 to 2010. They also recalculated my initial trend analysis [R2] which 
offered an insight into the trend in mortality for people with epilepsy in England.    
 
 
 
 
 
Table 1 Standards for Epilepsy 2004 
 
Indicator Points Payment Stages 
Records   
EPILEPSY 1. The practice can 
produce a register of patients 
receiving drug treatment for 
epilepsy 
2 
 
 
Ongoing Management   
EPILEPSY 2. The percentage 
of patients age 16 and over on 
drug treatment for epilepsy who 
have a record of seizure 
4 25 - 90% 
 
 88 
frequency in the previous 15 
months 
EPILEPSY 3.The percentage of 
patients age 16 and over on 
drug treatment for epilepsy who 
have a record of medication 
review in the previous 15 
months 
4 25 - 90% 
 
EPILEPSY 4. The percentage 
of patients age 16 and over on 
drug treatment for epilepsy who 
have been convulsion-free for 
last 12 months recorded in last 
15 months 
 
6 25 - 70% 
 
 
 
 
2.1 Determine the extent to which primary care practices in England are 
willing to be involved in basic proactive care for epilepsy using a disease 
register following the QOF programme 
 
2.1.1 Produce a register for people with epilepsy who are receiving treatment for 
epilepsy and are over 16 years old 
 Epilepsy Indicator 1: The practice is asked to produce a list of people who are 
receiving treatment for epilepsy; the fact that they are receiving treatment is taken to 
mean that they have a current rather than a previous history of epilepsy. The register 
is used to record patient over 16 yrs. old and this is on the assumption that patients 
under 16 yrs. are generally being treated by specialists. The epilepsy disease register 
of people with epilepsy over the age of 16 yrs. allows for Primary Care 
Organisations to compare the expected and the reported incidence of epilepsy. 
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The justification for this indicator is straightforward as a disease register forms the 
pre-requisite tool for subsequent indicators of epilepsy care. The register is only for 
people with active epilepsy and are ‘receiving treatment’.  Practices had to refine 
their previous disease register for epilepsy to exclude people who had epilepsy in the 
past but who were now off treatment and seizure free. 
 
2.1.2 Record the seizure frequency for people over 16 years old 
  Epilepsy Indicator 2: The percentage of patients aged 16 and over on drug 
treatment for epilepsy who have a record of seizure frequency in the previous 15 
months. Following the recommendation offered by the SIGN guideline 78it was 
expected that GP’s recorded the following details 
  
 Seizure type and frequency, including date of last seizure 
 Antiepileptic drug therapy and dosage 
 Any adverse drug reactions arising from antiepileptic drug therapy 
 Key indicators of the quality of care i.e. topics discussed and plans for future 
review 
 
 The definition for seizures and in particular whether this referred to only convulsive 
seizures or any form of seizure was not very clear in earlier documents but in 2008 
redraft of the QOF protocol it was clarified and made clear that this referred to all 
seizures independent of whether the person with epilepsy had lost awareness or not. 
 
The rationale for selecting this indicator was because it was recognised that epilepsy 
is often poorly managed in general practice, and there are insufficient specialist 
resources to provide specialist supervision for most patients. It is for this reason than 
the details in the preceding paragraph identified in the SIGN guidelines were chosen 
to begin a process whereby Primary Care can start to form a unified resource to 
support people with epilepsy and used to validate this standard. 
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No recommendation was made in the SIGN guidelines on the frequency of the 
review hence a pragmatic decision was made for this to be an annual one. 
 
2.1.3 Perform an epilepsy medication review for people over 16 years old 
Epilepsy Indicator 3: The percentage of patients aged 16 and over on drug 
treatment for epilepsy who have a record of medication review in the previous 15 
months. It was the first time in the UK that people with epilepsy were proactively 
asked annually if their anticonvulsant medication was satisfactory and if it was 
suiting them.  
 
It is established good practice for any prescriber of medication to review the 
medication and assess it both in terms of efficacy and tolerability but also to review 
the dosing instructions to ensure that no inadvertent slip up has occurred in the 
repeat prescription process. It seems natural to include this specifically for epilepsy. 
 
  
2.1.4 Identifying people on drug treatment for epilepsy who are seizure free over 
16years old 
Epilepsy Indicator 4: The percentage of patients aged 16 and over on drug 
treatment for epilepsy who have been seizure free for the last 12 months recorded in 
the last 15 months 
 
Seizure freedom was recognized as being a sensitive marker of good epilepsy care 
however it was recognized than due to multiple factors outside of the GP’s control 
e.g. refractory epilepsy or repeated patient non-compliance or not presenting 
themselves to appointments they GPs were allowed to ‘exception report,’ these 
people 
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2.1.5 Produce a register for people with epilepsy who are receiving treatment for 
epilepsy and over 18 years old 
Epilepsy 5: The practice can produce a register of patients receiving drug treatment 
for epilepsy aged from 16 to 18 years old and over in the 2006 review.   The 
decision to only include patients 18 yrs. and older was based on the assumption that 
people under this age are under Paediatric Specialist care. The introduction of the 
phrase ‘receiving treatment’ is included to exclude people who previously were 
diagnosed as having epilepsy but who are now seizure free and off medication. This 
helps to provide a clearer picture of seizure freedom as it reports only people with 
active epilepsy. The practice also provides prevalence data comparing those on the 
active epilepsy list with the total practice population which allows PCT’s to verify 
that those with previous history of epilepsy have been excluded.  
 
 
2.1.6 Record the seizure frequency for people over 18 years old 
Epilepsy 6: The percentage of patients age 18 and over on drug treatment for 
epilepsy who have a record of seizure frequency in the previous 15 months [4 Points 
Payment stages 40-90%] Epilepsy 6 and 7 follow recommendations that practices 
record in the notes the seizure type and frequency including the date of the last 
seizure and details about medication such as current anti-epileptic medication and a 
record of previous adverse reactions to anti epilepsy medication. This 
recommendation is based on NICE clinical guideline 79 (2004)   
 
 ‘all individuals with epilepsy should have a regular structured review …in adults 
this review should be carried out at least yearly by either a generalist or a 
specialist.’ This guidance therefore supports the current epilepsy indicators which 
are in essence the component parts of an annual structured review, where clinically 
appropriate.’ 
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2.1.7 Perform an epilepsy medication review for people over 18 years old 
Epilepsy 7: The percentage of patients age 18 and over on drug treatment for 
epilepsy who have a record of medication review involving the patient and/or carer 
in the previous 15 months [4 Points Payment stages 40-90%]  
  
 
2.1.8 Identifying people on drug treatment for epilepsy who are seizure free over 
18years old 
Epilepsy 8. The percentage of patients age 18 and over on drug treatment for 
epilepsy who have been seizure free for the last 12 months recorded in the previous 
15 months [6 points Payment stages 40-70%] Epilepsy 8 now applies to people over 
18 yrs. old and has been maintained as the importance of seizure freedom is still 
stressed in the guidelines. The assumption that exception reporting will be fairly 
high in this group is reflected by the lower seizure freedom being set at 70% which 
in reality is relatively high. The aim is for GP’s to record seizure freedom as 
accurately as possible. 
 
 
2.2 Determine if proactive care in England for epilepsy can successfully 
become more complex within the Quality Outcomes Framework. 
 
2.2.1 Ensure that women who are taking contraception medication are 
prescribed appropriate contraceptive medication 
In 2011 the QOF epilepsy standards started to become more challenging and the 
request was given for GPs to assess carefully a women with epilepsy’s 
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anticonvulsant and oral contraception to ensure they did not interact thereby 
exposing the women to increase risk of seizures or of pregnancy.  
 
Rationale for including a section of women and epilepsy 
 
In the UK is estimated that there are 131,000 women with epilepsy who are of child 
bearing age (12 or over and under the age of 50) and one in 200 women attending 
antenatal clinics are receiving antiepileptic drugs80. Around 2500 women with 
epilepsy will have a baby each year in the UK.  AEDs taken during pregnancy are 
associated with an increased risk of major congenital malformation. Women with 
epilepsy taking one AED have a chance of having a baby with a major congenital 
malformation of slightly over 3.5 per cent, which is higher than the background 
chance of 1-2% while those taking two or more anticonvulsants the level rises to 
6%. 81 
  
In a survey of women with epilepsy, only 28 per cent of participants aged 19 
between 19 and 34 years old had received information about oral contraception and 
epilepsy medication.82   NICE clinical guideline on epilepsy recommendations as a 
key priority for implementation: "Women and girls with epilepsy and their partners, 
as appropriate, must be given accurate information and counselling about 
contraception, conception, pregnancy, caring for children, breastfeeding and 
menopause”.83  
 
The Scottish guidelines for epilepsy states: "Advice on contraception should be 
given before young women are sexually active. Women with epilepsy should be 
advised to plan their pregnancies."84   Primary care is well positioned to offer this 
advice and the addition of this standard is important if somewhat ambitious. 
 
 
Epilepsy 9: The percentage of women under the age of 55 years who are taking 
antiepileptic drugs who have a record of information and counselling about 
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contraception, conception and pregnancy in the preceding 15 months  [3 points 
payment stages 40-90%.]   
 
2.2.2 Offer prenatal advice for women with epilepsy 
Also in Epilepsy 9 is the requirement for GPs to discuss issues relating to conception 
and an opportunity to review a woman’s anticonvulsant medication if she is planning 
to conceive. The GP is directed to identify women who are taking an unacceptably 
teratogenic anti-epileptic medication and also gives the opportunity to talk about 
pregnancy.  
  
 
2.3 A preliminary examination of national treads in mortality and 
hospitalisation during the Quality Outcomes Framework programme    
 
2.3.1 Preliminary examination of mortality from epilepsy in England 
The Office for National Statistics [ONS] publish data on avoidable mortality in 
England and Wales, and this includes deaths for epilepsy in age bands of 5 years for 
males and females. The author collected this data from the ONS web site85 and 
collated it to provide direct mortality statistics .The Public Health Information 
Specialist at the Kent and Medway Public Health Observatory was contacted and 
kindly supplied under my guidance, the directly standardised mortality rates for 
epilepsy for 2001 to 2010 using the pooled data which I had collected. [See page 
193]  They supplied data which included using trend analysis ( R2  ) statistical 
analysis.  
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2.3.2 Preliminary examination of unplanned visits to hospital for acute problems 
arising from epilepsy  
At the request of the author [see page 211] data on unplanned hospital attendance 
was collected from the Kent and Medway Primary Care Trust. The data was 
extracted from the Hospital Episode Statistics [HES] website which is described on 
the website as being  
 
‘a data warehouse containing details of all admissions, outpatient 
appointments and A&E attendances at NHS hospitals in England.’86   
 
To gain selective access of the very large volume of data a further computer 
software program was used called using a service provided by a program called ‘Dr 
Foster Intelligence,’ which their website describes as  
 
‘Dr Foster exists to make healthcare data better and help healthcare 
organizations improve the quality of care. We are the leading provider of 
healthcare information and benchmarking solutions in England – and 
increasingly, worldwide analyses HES data.’87.  
 
The PCT have a subscription to use the website and kindly recovered the data used 
in the thesis under my direction. [Please see page 234.]  
 
 
Evolution of the Standards set for Epilepsy in the QOF Framework 
Updates made to QOF in 2006 
In the same way that PRICCE was updated periodically the same has occurred with 
QOF and in 2008 the program was reviewed and the minimum age was raised from 
16 years old to 18 years old. The reason for this was as a generalised a GP could 
treat long term conditions of adults however the view was taken that paediatricians 
should be in charge of epilepsy up to the age of 18 years old. Also as mentioned 
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previously patients were now assessed against whether they were suffering from any 
form of seizure e.g. including absence attack, auras etc. rather than just being 
reported as being free from generalised convulsive seizures.  
 
 
Update made for QOF in 201188  
The working group [including the author] recommended an additional standard in 
2009 which was added in 201189 and was the percentage of women with epilepsy 
under the age of 55 who are taking antiepileptic drugs who have been given 
information and counselling about contraception, conception and pregnancy  
Epilepsy Standard 9: The percentage of women under the age of 55 years who are 
taking antiepileptic drugs who have a record of information and counselling about 
contraception, conception and pregnancy in the preceding 15 months. (3 points) 
  
  
Update introduced in 2012  
In 2012 GPs were permitted to included telephone consultations as a method of 
reviewing people with epilepsy. This introduction follows a trend in Primary Care 
towards managing people’s illnesses by telephone consultations rather than purely 
face to face consultations. The advantages and disadvantages of doing so are outside 
the scope of this thesis but it can be envisaged that it will be necessary to tailor make 
the review for people who find it hard to communicate effectively via the 
telephone90.   
 
Exception reporting for QOF 
As income for practices was dependant on achieved in the QOF program exception 
reporting was introduced to QOF so that practices should not be penalised for having 
a practice population who were more difficult to manage than their neighbouring 
practices.  The assumption was that to exception report the patient for not attending 
they would have not attended three appointments that year or had asked not to be 
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included in the project. This facility to exception report patients by GP’s was 
controversial but it was set in place so that a doctor was not penalised for having 
more difficult to control patients. Seizure control gives some indication of how 
effective the management of epilepsy is however and exception reporting was 
analysed closely by the health authority and if there were some practices who had 
exceptionally higher rates they were closely questioned to explain the reason for 
this. 
 
 
Indicators to permit a person to be awarded an exception report. 
There are occasions where people were exception reported for problems such as not 
attending appointments or frailty and this resulted in a lower denominator. In 2006 a 
clearer detail was provided on who could be exception reported and be excluded 
from QOF. This is provided to help remove GP’s receiving financial penalties from 
underachieving targets for reasons outside of their control. 
  
A. Patients who have been recorded as refusing to attend a review who have been 
invited on at least three occasions during the preceding twelve months.  
 
B. Patients for whom it is not appropriate to review the specific chronic disease 
parameters due to particular circumstances e.g. terminal illness, extreme frailty 
 
C. Patients newly diagnosed within the practice or who have recently registered 
with the practice, who should have measurements made within three months and 
delivery of clinical standards within nine months e.g. blood pressure or cholesterol 
measurements within target levels 
 
D. Patients who are on maximum tolerated doses of medication whose level of 
outcome remain sub-optimal 
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E. Patients for whom prescribing a medication is not clinically appropriate e.g. 
those who have an allergy, another contraindication or have experienced an adverse 
reaction 
 
F. Where a patient has not tolerated medication 
 
G. Where a patient does not agree to investigation or treatment (and after a 
reasonable discussion or written advice they have given their informed dissent), and 
this dissent has been recorded in their medical records 
 
H. Where the patient has a supervening condition which makes treatment of their 
condition inappropriate e.g. cholesterol reduction where the patient has liver 
disease 
 
I. Where an investigative service or secondary care service is unavailable.  
 
Achieved points as a percent of the points available for QOF.  
  
As the administration of the QOF project was linked to the payment for performance 
by the practices there was concern that some practices may be penalised financially f 
they did not have any patients for certain clinical areas and so would not be able to 
claim the points as they had no patients pertinent to an indicator. 
 
The end of year figures may therefore be at risk of misrepresenting the practices 
medical achievement. To allow for this the maximum number of points available for 
each practice were adjusted, effectively removing points from the calculation 
denominator where both of the following conditions apply: 
 the practice does not have any patients in the indicator denominator.  
 the practice has reported no exceptions for the indicator denominator 
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Hence using this calculation the indicator denominator plus indicator exceptions 
must equal zero. 91  
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3 Study Three. Locally Enhanced Service for Epilepsy 1 (2005 – 2006) 
 
 
First version of the Epilepsy Enhanced Service 2005-2006   
[see page 243] 
 
In Eastern and Coastal Kent Primary Care Trust GP’s commented that the standards 
which were set by the Quality and Outcomes Framework were less exacting and 
indeed more basic than the standards set for the Primary Care Clinical effectiveness 
project. This would have led to the standards of proactive care for people with 
epilepsy to have gone down and so the author proposed a further study whereby GP 
practices were invited to raise the standards even higher for epilepsy. This would 
allow the author to assess how much more regular GPs were able to provide in 
support of people with epilepsy. This was provided in a Locally Enhanced Service.  
The pre requisite factors which were needed for QOF were also needed to be in 
place by the practices taking part in the enhanced program locally and like QOF 
contained the same components of 
 Computerisation 
 Incentivisation 
 Education 
 Support of audit team 
 Peer pressure 
 
All practices ran computerised data bases and were well versed in indexing 
accurately the medical records to facilitate accurate audit. 
 
 
Incentivisation 
In 2005/06 each practice contracted to provide this service would receive the 
following ‘QOF’ points in table2 
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Questionnaire to all patients 
with epilepsy 
 
3 
Women with Epilepsy 4 
Driving 1 
Social 3 
Links to secondary care 4 
Total: 15 
Table 2 Points allocated to Epilepsy Locally Enhanced Service 2005/2006 
 
 
Education 
The education model was based on the suggestion made by the CSAG report on 
Epilepsy that a GP was nominated by the practice to take a lead for epilepsy. They 
had to attend basic training provided by the PCT [delivered by the researcher] that is 
provided as a prerequisite to providing this enhanced service. This is brief detail 
only, and only 1.5 hours. It was process driven with certificate of attendance rather 
than examination focused.  The training was open to all of the practice clinicians and 
in practice was delivered to several of their team 
 
The Introductory seminar contained the following topics; 
 Introductory video session: seizures,  
 Epidemiology of Epilepsy  
 Basic functional anatomy of the central nervous system     
 Overview of Epileptic Syndromes    
 Medical Treatment of Epilepsy  
 Some imaging techniques used to investigate epilepsy 
 Female Issues relating to epilepsy 
 Social Aspects of Epilepsy – Quality of life in epilepsy 
 Marriage Epilepsy and the family  
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 Sudden unexpected death in epilepsy 
 Employment 
 Drivers'  licenses 
 
 
Audit support 
The development of templates to both gather and to record information were 
developed by the PCT and offered to the practices to use. The audit leads in the 
practices taking part were by now expert in the skills required to run searches on 
their computer systems and they helped in the development of the audit tools which 
were shared by all participating practices. 
 
 
Patient Questionnaire 
The practices were asked to offer a questionnaire to patients regarding their epilepsy 
which was then handed in to the surgery to aid the identification of areas of need for 
the patient. If the patients required help to complete this form it was made available 
on request. Questions included in the questionnaire;   
 Basic demographic details   
 Question asking when they last saw their GP regarding   
 Seizure frequency  
 Details of any attendance to Accident & Emergency (A&E) as a result of 
their epilepsy  
 For those who had been to A&E whether their GP had seen them as a result 
of this to review their epilepsy 
 Details of their epilepsy medication 
 Whether they drive   
 If they are currently in paid employment with a supplementary question to 
those not in a job if they would wish so to be       
 Whether they live alone 
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 If they have someone you consider a carer for that person’s details   
 Asked if they had been made aware of the safety issues with regards to 
epilepsy?  
 If no, would you like to receive more information regarding safety issues? 
 The offer was given if they would you like to speak with someone with 
regard to your epilepsy? If they did who they would like to be placed in 
contact with e.g. GP, a GP who specialises in epilepsy or a specialist nurse, 
 Whether they would like to receive emotional advice regarding epilepsy 
 If they were under a hospital consultant for their epilepsy and if so who that 
was and when they were last seen  
 
For children under 16  
 If they were happy with the provision of help from their school with regard 
to their epilepsy. 
For women aged 14 – 55 
 Details of any contraception used 
 If  becoming pregnant is a real possibility whether they had talked about 
issues relating to pregnancy and epilepsy with their GP including advice of 
high dose folic acid 
  
Data Collection and Verification 
 
The achievements in reaching the set standards were self-reported by the participating 
practices. There was no formal process in place to validate the results and they were 
received in trust by the health authority. The results collected on an annual basis and 
submitted as pooled results to the PCT using an Epilepsy Local Enhanced Service 
Monitoring Sheet. Advice was also given on how to code the medical notes to allow for 
simpler auditing of the outcome of the consultations and of the services delivered to the 
patients. The service added the opportunity to gain extra 15 QOF points for the epilepsy 
component of QOF.  
 104 
 
 
Peer Pressure 
This was seen as being purely supportive and practices tended to pool useful tips 
together and would share templates between each other on an informal basis. It was not 
incentivised. 
 
 
 
3.1 To determine if primary care can proactively identify social consequences 
of active epilepsy 
 
Development of Templates 
The practices were directed to provide more detailed datasets of their patients with 
epilepsy and care was extended to social care in addition to medical care alone. The 
practice should develop (or maintain if they already exist) templates for annual 
review of all patients [both paediatric and adult] with epilepsy to include the 
following factors.  
 
This can be seen as an extension to the process used in PRICCE-2 and QOF to set a 
register in place at the start of the programme 
 
Social factors [target 80% in year 1 and 90% in year 2] 
 
3.1.1 Record driving status 
There was no formal validation of this standard which was developed by the author. 
The rationale for choosing it was as a surrogate marker of well controlled epilepsy as 
it required people with epilepsy to be seizure free for a year. Also it was seen as a 
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way of raising the profile of personal independence for people with epilepsy and the 
introduction of a wider holistic approach to epilepsy care by GPs.  
 
 
3.1.2 Record social factors affected by epilepsy 
This was an opportunity to identify areas where epilepsy is known to negatively 
affect social well-being and practices were given information leaflets and resources 
to help sign-post additional services if they identified areas of need. Included within 
this were education issues for paediatric patients and the encouragement to ensure 
that schools made adaption’s to the needs of children with epilepsy.  
 
Employment status was also explored and again if someone with epilepsy felt they 
were be discriminated against they were given information of epilepsy and 
employment. Also the Royal British Legion employment service was recommended 
for those who required support to enter the workplace once more.  
 
The social circumstance of the person with epilepsy was also explored and factors 
such as whether they lived alone or with family was noted in the patient health 
record. The isolation that can occur as a result of epilepsy was explained to the 
participating GPs at the preliminary educational session and GPs were encouraged to 
find clubs and societies for people who were lonely or socially isolated to join. 
 
GP’s were also encouraged to discuss basic safety issues e.g. bathing, cooking, etc. 
and supply the patients with information which they could take away and referrer to 
later. The main leaflet used for this was the Epilepsy Action’s leaflet on safety. 
 
For some of the people with epilepsy they may be still having problems with the 
stigma associated with the illness and this group of patients were offered counselling 
or an appointment with an epilepsy specialist to discuss further.   
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This area was selected by the author for use and did not follow any formal 
validation. As was true for driving status and epilepsy this standard was to facilitate 
a holistic approach to care rather than a simple medical one.                                                                                                                                   
 
 
3.2 Women with Epilepsy: rationale and validation 
 
One of the purposes of the Locally Enhanced Service for epilepsy was to allow local 
practices to continue with the higher standard of care they provided for women with 
epilepsy than was required for QOF. The justification and the validation of this 
section mirrors that which was used in the QOF section of women of childbearing 
age. [See page 92.] 
3.2.1 Identify the number of women and children of child bearing age who have 
epilepsy 
 To take part in the locally enhanced service the practices were required to be 
conversant with the list of Anti-Epileptic Drugs (AEDs) that interact with the Oral 
Contraceptive Pill (OCP) – as tabulated in the NICE guideline for epilepsy. [Target 
100%]. They also had to ensure that women of child bearing age were placed on an 
appropriate contraception if required [i.e. not on anti-convulsant medication that 
interacts with ICP, etc.]   
 
The rationale for this is that this standard is the pre –requirement for more targeted 
support for women with epilepsy 
 
3.2.2 Offer women and children of childbearing age folic acid 
It was explained in the educational event that that folic acid at a dose of 5mg was 
useful in preventing neural tube defects for women of childbearing age and all 
women who could possibly conceive were offered it. The prescribing of folic acid 
was therefore a natural standard to include in this programme 
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3.2.3 Offer women and children of child bearing age pre conception advice 
Women of child bearing age were asked if they intended to become pregnant in the 
near future and if so their anticonvulsants were reviewed to ensure that they were on 
the least teratogenic medication. If the GP discovered that they were taking a high 
risk anticonvulsant they were then referred to specialist epilepsy services to review 
their care and to see if less teratogenic therapy was possible. Also the need for a 
target of seizure freedom was highlighted and women were encouraged to aim for 
seizure freedom and referred when appropriate to specialist services. 
 
Once again, the rationale for this was taken by the author directly from the PRICCE-
2 programme and this was what the standard was validated from. 
 
 
3.2.4 Ensure that women who are taking contraception medication are 
prescribed appropriate contraceptive medication 
The participating practices were also asked to review the women of child bearing 
age who were using contraception to ensure that the method used was effective and 
did not interact with their anti convulsant medication.  
 
Once again, this standard draws its origins from the PRICCE-2 project and rather 
than take a step backward in care following the less onerous requirements of QOF in 
the early years it was taken by the author as the basis to validate this standard. 
 
3.3 Identify people with epilepsy under hospital care 
At the time when the enhanced service was running, data from hospitals was still 
occasionally incomplete and GPs were required to ask the people with epilepsy if 
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they were being seen in a specialist epilepsy clinic and indeed if so who they were 
under. This also gave the PCT information about the number of people who were 
receiving specialist care in each practice.  
 
Also if the specialist clinic had recommended changes in anticonvulsant medication, 
the GPs were required to check that the medication titration and doses were correct. 
Also to ensure they had offered patients the therapeutic manoeuvres suggested by 
the clinics and had been seen to follow the suggestions outlined in the clinic letters. 
This was developed following the experience of running epilepsy clinics and 
witnessing patients returning who had not had these changes acted upon from one 
clinic to the next.    
 
The validation for this was not from the literature but rather from observation by 
neurology colleagues and by the author. It was based on the experience of seeing 
that many people with epilepsy returned to out patient’s clinic with none of the 
recommended changes in their anti convulsant medication having been put into 
place from the last visit. This is not an ideal situation and is both inefficient use of 
specialist services but also potentially detrimental to the patient. This standard was 
aimed to identify people who were under hospital care and ensure that there was 
good shared care in place between the hospital and the GP.  
 
Study Design: The outcomes of two practices compared 
The original aim was for this study to take the form of a study which served as an 
extension of PRICCE-2 and shared with this first study its aim to explore the utility 
and uptake of an audit driven process of health care delivery at Primary Care level. 
The difference in this study was however that it took the level of care higher and 
involved the addition of social and psychological aspects of care for people with 
epilepsy.  The results of the study were gathered electronically by the participating 
practices and collated in a pooled data set design by the PCT. This was then stored 
electronically onto the Eastern and Coastal Kent computer. The author was then 
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allowed access to this pooled data after the health authority had calculated the 
payment due to the practice.  
 
In addition results from two practices were compared in detail, both of whom had 
retained their complete data sets on their computer server. The data from these 
practices was delivered electronically to the author which allowed analysis to take 
place. They were both large practices and one held a GPwSI clinic for epilepsy 
whilst the other one did not. The data from these two practices had been collected by 
the practice staff but no verification process was utilised.  
 
Analysis Plan and Loss of Local Data 
 
 
As the original aim was to study effectively an extension of PRICCE-2 it shared 
with this first study its aim to explore the utility and uptake of an audit driven 
process of health care delivery at Primary Care level. The difference in this study 
was however that it took the level of care higher and involved the addition of social 
and psychological aspects of care for people with epilepsy. It was the uptake and 
implementation by individual practices in Eastern and Coastal which was being 
measured and so simple descriptive statistical analysis was chosen to evaluate the 
data.  
 
Inferential statistical methods were not utilised as it was only the sample which was 
studied and there was at this stage no plan to extrapolate to the wider population of 
all GP practices in East Kent. The data collected by the health authority were stored 
on the Primary Care Trust [PCT] central offices and were to be downloaded by the 
author for further analysis. No analysis of the data was undertaken by the PCT. 
Unfortunately the data was deleted from the PCT server without the knowledge of 
the author or indeed the PCT commissioner Mrs Sheila Pitt who oversaw the 
programme from the PCT perspective. This occurred at a time of substantial 
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upheaval with the merging of the East Kent PCTs and then the devolution of 
commissioning to the Clinical Commissioning Groups. 
 
However the author managed to obtain achieved results from the two practices who 
still had their complete data sets stored on their practice computers.    
 
The information sets were presented by the author in graphical format and the 
performance of the two practices was compared. 
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4 Study Four. Targeted Medicines Use Review for Epilepsy; Feasibility Study 
 
This final study continues the lessons learnt in the first three studies and explores whether 
community pharmacists are able and willing to support people with epilepsy in the 
community. If builds on the work of PRICCE-2 and QOF in offering low input care to all 
people with epilepsy but also adopts the more advanced features of the Locally Enhanced 
Service for Epilepsy. The community pharmacists underwent training which was centred 
around the Medicines Use Review (MUR) for epilepsy and offered general community 
pharmacists the opportunity to deliver more advanced care for epilepsy. In addition to 
education the author also provided them with a source of literature which was linked 
specifically to the various components of the MUR and was supplied by Epilepsy Action. 
This ensured that the information given by the pharmacists to the patients was of a 
reliable and accredited standard.  
 
In addition to this the community pharmacists were awarded referral rites to the GP with 
Specialist Interest clinics in the community for epilepsy. The referral could take place for 
defined parameters and was a step to include pharmacists into the primary care team. In 
contrast to the work with GPs the community pharmacists were working with little in the 
way of incentivisation with the payment for the completed MUR being part of their basic 
income. 
 
There is arguably nobody better placed than the pharmacist to support people with 
epilepsy as they are easily accessible and are usually conveniently located in the 
community with pharmacies often being situated in the high street. It was not known if 
pharmacists could perform this task and the study took the form of a pilot to establish if 
this were possible and to gain an early insight into its effectiveness. 
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Overview of the method used to develop, run and analyse the medicines use review 
pilot. 
As with the previous studies the components put in place were developed and the 
majority was developed by the author with support from the Medway School of 
pharmacy to help with providing a teaching environment that was familiar to the 
pharmacists.[ see page 260] They also provided the information packs describing the 
project to the pharmacists who took part.[ see page 272] The pre requisite factors which 
were needed to take part in the targeted MUR for epilepsy pilot were put into place and 
contained the same components of 
 Computerisation 
 Incentivisation 
 Education 
 Support of audit team 
 Peer pressure 
 
Computerisation 
The community pharmacists utilise a database which is different to that of general 
practice and which in future work could possibly have been explored more. The patients 
were selected largely by the prior knowledge of the pharmacists, some were opportunistic 
and others were targeted from the pharmacy database. The MURs were completed using 
computerised template on the pharmacy computerised system. 
 
Incentivisation 
Unlike the primary care projects the community pharmacists did not receive any financial 
incentives above that which they could already receive but performing a routine non 
targeted MUR. The incentive for many was the prospect of using their skills to a greater 
degree than currently offered in the pharmacy. Also the opportunity to be involved in a 
pilot was an incentive for other.  
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Even though the project had very little cost involved permission was required from the 
local community pharmacy service commissioners who were consulted to explore 
whether this project was practicable and to gain their consent to its trial. Following this a 
wider series of meetings with the primary Care Trust and GP commissioners was made to 
gain their approval to go ahead with the project. A small amount of money was received 
to pay for the hire and refreshments needed on the educational event and also some back 
fill costs for locum pharmacy cover. 
 
 
Education 
Following their approval an invite to all community pharmacists practicing in Thanet, 
East Kent was sent out inviting them to take part. In order for them to be involved in the 
pilot they were asked to attend a training day for epilepsy run by the author at the 
Medway School of Pharmacy. The Training on Epilepsy was both developed and 
delivered by the author and the areas covered were; 
 Classification of Epilepsy 
 Basic neuroanatomy revision to assist the understanding for focal epilepsy 
 Examples of different types of seizures – videos 
 Revision of anti-epileptic medication 
 Basic Epidemiology of epilepsy 
 Mortality and epilepsy 
 Women and epilepsy 
 Sexual dysfunction and epilepsy 
 Psychological consequences of epilepsy 
 Epilepsy and the family 
 Social aspects of epilepsy 
 Employment and epilepsy 
 Driving 
 Referral Criteria to the Epilepsy Specialist services 
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During this training appropriate patient information leaflets were suggested to support the 
pharmacists when talking with the patients as supplied by epilepsy action and they were 
freely available on the day for the pharmacists to familiarise themselves with. Following 
the training the pharmacists split into groups and had a series of role plays where they 
practiced their skills with imaginary patients [role playing based on a series of scenarios 
that individuals were given to act from] and then their colleagues offered directed 
feedback on their performance. [See page 285] 
 
 
Studying adherence of medication 
A standardised method of assessing medication adherence was discussed and comprised 
the percentage of anti convulsant medication taken on the best week and on the worst 
week.  The method added the number of times a week the medication was successfully 
taken at the appropriate time divided by the ideal number of times it should have been 
taken and then expressed as a percentage. 
 
 For example if a medication is taken twice a day the first line to check is how many of 
the morning tablets were taken in a good week and how many in a bad week. Then the 
same process for the evening dose. By adding the best morning and evening doses and 
dividing by 14 this can be turned to a best percentage adherence and the same then 
repeated for the worse week. This produces a range of adherence than can be shared with 
the patient and used to communicate in a numeric form between health care professionals 
Following this an agreed start and finish date for the project was set by the group of 
willing pharmacists and the project ran its course in October 2011. 
 
Validation of the importance and inclusion of medicines adherence 
 
The NICE Guidelines advising on medicines adherence92 offers a case for including this 
area in medicines review and hence is a good candidate for the pharmacists targeted 
MUR for epilepsy. It states that between a third and a half of medicines that are 
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prescribed for long-term conditions are not used correctly which represent both sub-
optimal benefit for patients and also represents an economic waste of resource.  
Pharmacists are directly involved in the provision of medication to patients and it seemed 
appropriate for the author to include this area. The guidelines advise that non-adherence 
should not be considered the patient’s problem as it often results from a failure to gain the 
patients intent to take the medication or from practical considerations which hinder the 
patient taking the tablets. 
 
The pharmacists are trained to follow a patient-centred approach which encourages 
informed adherence with the identification of barriers to adherence.  
Support by Audit team 
To provide specialist advice above that supplied on the training day the author was 
available to offer support and advice to the community pharmacists in order to maintain a 
seamless link between the pharmacists and epilepsy services.  
 
 
Steps were taken to avoid the key risks  
  
1. Lack of expertise in epilepsy amongst the pharmacy team was acknowledged and 
addressed. There was an assessment questionnaire to assess the level of 
knowledge before the training and the subsequent questionnaire to assess the 
effectiveness of the epilepsy training. The standardisation of advice given by the 
community pharmacists was ensured by ensuring they shared information from 
the relevant Epilepsy Action patient support leaflets. This was seen as accredited 
information which was being imparted to the patient. The patients were able to 
take the leaflets home with them to ensure that information was not mistaken and 
could be referenced by the patient at a later date. 
2. Overload the Intermediate Care Team – Space was cleared in the appointment to 
allow room for potential increase in the number of referrals and additional clinics 
earmarked if required.   
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3. Complaints of equality of care from people with epilepsy in other localities in 
East Kent. This is an inevitable problem with running a pilot of a new service 
however ensuring that the pilot is evaluated quickly to estimate feasibility for a 
wider roll out of the service will help to minimise this.   
4. Daily and weekly pharmacy workload-  There was a need to ensure that there is 
protected time for doing the epilepsy MURs and that the funding for the work 
done be guaranteed 
  
Referrals to the epilepsy specialist services were received during this time and triaged by 
the author.  Following the month’s trial in October 2011 the outcomes were collated and 
a plenary meeting was help with those involved and with input from the Primary Care 
Trust and Clinical Commissioning Group to draw conclusions from the exercise. 
 
 
Peer pressure 
This was not incentivised and indeed the whole pilot rested on the laudable 
professionalism of the community pharmacists to take part. For many the opportunity to 
move out from the general work of community pharmacy dispensing was the only 
necessary trigger but contained in that was some degree of peer pressure to take part. 
 
 
4.1 To determine the extent to which community pharmacists can be trained to 
proactively support people with epilepsy 
The effectiveness of the training session was performed in a very simple manner with a 
series of questions which are outline below set to the community pharmacists both before 
and then after the training day. These questions were not validated and the numbers of 
pharmacists involved were small but it did help to gain a picture of whether the project 
could be feasible to develop on a larger scale. 
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The questionnaire used to assess the pharmacist’s grasp of knowledge was developed 
pragmatically by the author and was not formally validated. The justification for this was 
that there was little time spare for a formal clinical knowledge examination and the 
results were used to help inform the pilot. If the study is extended, then it would be worth 
considering a more formalised assessment of pre and post training clinical acquisition of 
knowledge and also of skills in the clinical simulations. 
 
4.1.1 To be able to answer an anticonvulsant query from a patient with confidence 
The scenarios used were relatively simple ones, which the author developed to test the 
pharmacist’s ability to answer a patient who was asking about issues relating to their 
medication. This process is currently one of the core features of the standard medicines 
use review. The clinical scenarios used which could reasonably be faced by any 
pharmacist supporting a person with epilepsy. 
4.1.2 To become familiar with epilepsy classification and explain them to customers 
This was assessed by a simple question presented at the start of the educational event and 
repeated at the end of the day and aimed to form a basic assessment of how well the 
pharmacists had grasped the basic classification of seizures. It was included to promote 
the uptake of information later on in the training session of basic seizure classification 
and the use of the leaflet by Epilepsy Action ‘Seizures Explained.’93 
4.1.3 To be able to advise a customer with epilepsy when they could re-apply for their 
driving licence 
This question regarding eligibility to drive for a person with epilepsy and was specifically 
covered on the education program. It was used to promote the awareness of the need to 
have this information correctly at hand and later was a useful way to promote the booklet 
by Epilepsy Action ‘Driving and Epilepsy.’94 
4.1.4 Feel confident in being able to assess how well a patient was taking their anti 
convulsant medication 
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Community pharmacists are trained to assess patient medication adherence and this 
question was included to establish if this skill was already present at the start of the 
day and if it were possible to improve it further. Later on in the training event 
techniques for assessing this were discussed. 
 
4.2 Determine if the advice given by the community pharmacists during a MUR 
was of benefit to the customers 
 
This again was a simple assessment which was completed by the customers to the 
pharmacy before and after they had received a targeted MUR in epilepsy. The format was 
that of a simple questionnaire which although not a validated one, was very specific to 
the situation in which people with epilepsy could expect help from their community 
pharmacist. There were four questions to this questionnaire and its use on patients was 
approved by the Kent and Medway PCT research and audit team who considered that the 
questionnaire was being run on a basis of service evaluation. The fuller documentation 
for this is included in the appendix. 
 
4.2.1 Improving their understanding of the underlying causes of epilepsy 
The first question was to gain insight into the person with epilepsy’s knowledge of their 
condition. It offered some insight into how much understanding the patient had of their 
illness and if they knew how their epilepsy had been classified either in general terms or 
more specifically. 
4.2.2 Understanding how to lessen the risk of having a seizure 
It was not known if it would be possible to reduce the risk of a person with epilepsy 
suffering a seizure and this was asked before and after the MUR. This question was 
designed to see if the community pharmacists were able to empower the people with 
epilepsy and help them to better manage their own risks of having a seizure. 
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4.2.3 Determine if the customer was more likely to approach their pharmacist for 
advice about their epilepsy in the future 
Having undertaken a targeted MUR for epilepsy it was interesting to see if the person 
with epilepsy in any way altered their prior view of the role of a community pharmacist. 
The questionnaires were anonymous and allowed the patients opportunity to be frank in 
their answers.  
 
4.3 Determine if community pharmacists can recognise red flag symptoms to 
allow direct referral to specialist epilepsy services 
 
The community pharmacists were taught in the education session about red flags for 
epilepsy and if they identified anybody who had one of these they were then asked to 
refer the patient to the community GPwSI epilepsy service. The referral form went to the 
GPwSI administrative centre and included a copy of the completed MUR plus the brief 
single sided referral form which explained the reason for the referral.  
 
The referrals on reaching the GPwSI administrative centre were triaged by the author 
who communicated with them on a case by case basis about whether their referral fell 
into the criteria to be seen. The author is the clinical lead of the primary care epilepsy 
service and this would be true for all referrals to the service however temporary provision 
was put in place during the study by which both the community pharmacist and the 
patients GP were keep fully aware of the referral and the action s leading from the 
referral. It was also agreed that the first clinic letter would be sent to the community 
pharmacists [as well as to the GP and patient,] by way of feedback following the referral. 
 
Referral to Specialist epilepsy services  
In order to try and ensure that the number of referrals was to some degree controlled the 
author liaised with the PCT and agreed upon a set of criteria or ‘red flag symptoms,’ which 
were eligible to be refereed [see page 269]. The eligibility to meet the criteria for people 
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who were over 16yrs and not under specialist epilepsy care already had to be met and the 
indications for referral were; 
 Emergency admission to A&E or treatment by Paramedic Ambulance Service within 
the past 12months 
 On-going seizures / worsening seizures.  
 Pre-natal hazard identified in women receiving medication which is potentially 
teratogenic. 
 Hazardous poor concordance of medication [taken as being estimated as less than 
80%] 
These red flags were pragmatically chosen by the author as being reasons where a referral 
to be seen in an epilepsy specialist clinic would be straightforward to establish and also 
on some degree of urgency. The referral criteria were then discussed by the local Thanet 
Clinical Commissioning Group and approved for the duration of the pilot. 
 
Analysis Plan and Data Storage 
The overall aim of the targeted Medicines Use Review for epilepsy was to assess the 
utility and observe the novel method of health care delivery to support people with 
epilepsy delivered by community pharmacists. It was primarily a feasibility study of the 
assimilation and application of epilepsy knowledge by the community pharmacists which 
was measured and also the response to the input from patients. For this small pilot study 
simple descriptive statistical analysis was chosen to evaluate the data. As it was small 
pilot study aimed at probability theory was not utilised. 
 
The pre and post education questionnaires were recorded on paper and the results held by 
the author. The MURs were conducted by the pharmacists and a copy of each of the 
reports was held by the health authority and by the author in paper format. The analysis 
was decided upon by Mrs Trudy Thomas Head of Post Graduate Education at Medway 
School of Pharmacy and the author. None of the questionnaires were validated however 
as this was primarily a feasibility study and the numbers were small. Inferential statistics 
would need too high a power to be feasible in this small locally funded study.  The data 
sets were presented by the author in graphical format.    
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Support from the Under Secretary of state for Health – Paul Burstow 
The author discussed the original idea of this study with Mrs Laura Sandys MP for 
Thanet South who is both his MP and also the Chair of the All Party Parliamentary Group 
on Epilepsy.  She was keen to see the project put into action and discussed it with Mr 
Paul Burstow the under-secretary of state for health and he gave a written confirmation of 
his support to the local health authority managers. This helped to secure the funding 
necessary [£3,000] to undertake the study and a copy of this correspondence is enclosed 
in the appendix. [See page 283.]   
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The algorithm used for the referral process 
 
Patient having ongoing or 
worsening seizures 
Usual adherence to anti 
convulsants medication less 
than 80% 
Patient pregnant or  
planning pregnancy  
   
 Refer  
   
   
 Seeing specialist for 
epilepsy care?? 
 
   
 Yes  No 
    
   
When seeing next?  
  
 
Within next 
6 months 
 
Not for 
longer than 
6 months 
 
 
      
   
Suggest patient 
mentions issue 
to specialist 
and shows copy 
of MUR form 
 
Send copy of 
MUR form to 
GP and suggest 
referral to 
specialist is 
brought 
forward 
 
Refer to Greg 
using Thanet 
referral form 
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RESULTS 
1 Study One; Primary Care Clinical Effectiveness program, PRICCE-2 
 
Non responders 
For all of the aims in this section there was no information obtained to offer an insight as 
to what made a practice take part in the project. The management team [Medical Director 
and the East Kent MAAG] considered this to be due to practices who were not fully 
computerised and also due to the lack of expertise within the practices to accurately code 
their electronic records. This was not however formally assessed. 
 
 
Aims, 
1.1 Determine the extent to which participating primary care practices in East Kent 
are willing to be involved in basic proactive care for epilepsy using a disease 
register following the PRICCE-2 programme 
 
In table 3 we see that the number of people identified as having epilepsy by the 
participating practices started off fairly low with practices initially in 2002 only 
identifying epilepsy as occurring in 0.27% of their practices populations however by the 
end of the program this number had been extended to 0.51% of the population who were 
identified as having epilepsy. In Figure 2 this figure can be seen to rise significantly as 
the practices become more adept at identifying patients reflecting that their disease 
registers where becoming more accurate.  [For raw data please see Appendix page 219] 
 
Year 
Number of people 
included in the 
study 
Percentage of the 
participating 
group with 
epilepsy 
2002 986 0.27 
2003 2605 0.48 
2004 2969 0.51 
   
Table 3 Percentage of People with all Epilepsy included by Participating practices for PRICCE-2 
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Year 
The number of 
people with 
epilepsy reviewed 
Percentage of 
people with 
epilepsy reviewed  
2002 955 96.43 
2003 2491 96.06 
2004 2821 95 
   
Table 4 Percentage of people with epilepsy reviewed with time for PRICCE-2 
    
Figure 2 Graphs showing the percentage of people with epilepsy in the participating groups between 
2002-2004 and the percentage of these who were reviewed. 
 
 
 
1.2 Determine the extent to which participating primary care practices in East 
Kent are able to identify potential problems which can arise as a consequence 
of suffering from epilepsy 
 
 
1.2.1 Identify people who are seizure free 
Table 5 demonstrates how practices became more proficient at identifying people who 
were seizure free and as the numbers increased during the course of the study the 
percentage of people who found to be seizure free decreased slightly as demonstrated in 
figure 3.  [For raw data please see appendix page 219.] 
 
 125 
 
Year 
Number of 
people Seizure 
Free 
Percentage of 
People seizure 
free 
2002 731 73.46 
2003 1882 73.61 
2004 2074 71.25 
   
Table 5 Patients identified as being seizure free 2002 - 2004 
 
    
Figure 3 Graphs showing the number and percentage of people seizure free 2002 - 2004 
 
1.2.2 Ensure the people who are taking vigabatrin have their visual fields measured 
  
Vigabatrin 
Table 6 demonstrate that GPs can proactively become able to identify people with 
epilepsy who are at risk of peripheral field visual loss as a result of the use of vigabatrin 
and is further represented in figure 4. This would arguably have been outside of the 
normal scope of the GPs. The trend over the 3 years of the study was for the number of 
people identified and to have completed visual field testing is to increase year on year. 
This supports the theory that if directed, GPs can perform more selective audit of their 
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patients and oversee the necessary steps to minimise untoward risk from treatment with 
Vigabatrin. [For raw data please see appendix page 219.] 
 
 
 
Year 
Number of 
people with 
Epilepsy in 
Vigabatrin 
Number of people on 
vigabatrin who had 
visual field tests in 
previous 6 months 
Percentage of people 
on vigabatrin who 
had visual field tests 
in previous 6 months 
2002 5 3 66.7 
2003 18 10 54.16 
2004 21 12 55.95 
Table 6 Review of people with Epilepsy on Vigabatrin for PRICCE-2 2002-2004 
 
   
Figure 4 Graphs showing the number of people identified as being on vigabatrin and the percentage 
to have received a visual field examination in the previous 6 months  
 
1.2.3 Identify women who are pregnant and also have epilepsy 
Pregnancy 
Women with epilepsy were proactively identified by the project and as a result received a 
program of care as prescribed by the PRICCE protocol. [For raw data please see appendix 
page 219.] 
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Year 
Number of 
women with 
epilepsy who 
were pregnant 
2002 11 
2003 21 
2004 16 
Table 7 Women identified during the PRICCE project as being pregnant 
The results in table 7 above demonstrate only limited success in that the numbers 
reported are low and the practices ability to identify and proactively manage women with 
epilepsy and who were pregnant did not improve during the course of the project. The 
denominator for the quality standard was not known however can be extrapolated from 
work conducted at this time on the pregnancy rates for people with epilepsy.   
 
 
1.2.4 Ensure women and children of childbearing age are taking folic acid 
 
Number of Women on folic acid 
With doubt cast onto the accuracy of GPs to record and monitor pregnancies in women 
with epilepsy the study of whether they can reliable offer folic acid supplementation to 
this group is called into doubt. Table 8 below presents the number of women who finally 
received folic acid supplementation in pregnancy and the results are a good deal lower 
than were to be expected. [|For raw data please see appendix page 219.] 
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Year 
Number of 
women 
receiving folic 
acid 
Percentage of 
pregnant 
women on folic 
acid 
2002 8 71% 
2003 13 67% 
2004 12 81% 
 
Table 8 Number of pregnant women with epilepsy receiving folic acid 
No specific cause was identified at the time which helped to understand why the adoption 
of this standard was so low by the participating GP practices. 
 
 
1.2.5  Ensure that women who are taking contraception medication are prescribed 
appropriate contraceptive medication 
 
Women with Epilepsy who have had their contraceptive checked 
The results for this standard are recorded in table 9 below. 
 
Year 
Number of 
women on 
enzyme 
inducing AED 
and oral 
contraceptive   
Number of 
women in 
whom no 
change was 
required 
Percentage of 
women who 
required no 
change in 
contraception 
2002 19 9 57 
2003 25 24 100 
2004 53 24 19 
Table 9 Women on oral contraception who have had their contraception checked 
  
 129 
These results appear to reveal that the number of women to have their anticonvulsant 
checked increases during the project however the outcome of this check seems to vary 
widely. In 2004 only around half of the women appeared to be taking adequate 
contraception however the year before none of the women appeared to require a change. 
Also the number of women included for this standard in the PRICCE-2, project appear to 
be very low in number. In table 14 it would seem that there were over 150 women with 
epilepsy and in the peak of fertility [aged 25-34yrs] and many more who were of child 
bearing age as presented in table 10 below. [For raw data please see appendix page 219.] 
 
 
Year 
Total female 
population 
included in 
PRICCE-2 
Total number of 
women aged 15-
44yrs  included in 
PRICCE-2 
Total number of 
women aged 25 - 
34yrs 
Expected 
number of 
women with 
epilepsy aged 
25-34 * 
Total number of 
women included in 
PRICCE-2 aged 15-
44 
Expected number of 
women aged 15-44 
in PRICCE-2 to 
have epilepsy* 
2002 238591 85843 27327 139 85843 438 
2003 303135 103707 32939 168 103707 529 
2004 292251 104822 31828 162 104822 535 
       
* using the prevalence recorded in 2004 of 0.51% of the population with epilepsy    
Table 10 Number of women included in PRICCE-2 who were of child bearing age 
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1.3 A preliminary examination of local trends in hospitalisation. 
 
1.3.1 A preliminary examination of trends in unplanned visits to hospital for acute 
problems arising from epilepsy  
The national trend over the previous decade for unplanned epilepsy admissions was fairly 
stable 95 but at the time of the PRICCE project the numbers admitted appears to be 
increasing as demonstrated in figure 5 below. The numbers admitted does seem 
somewhat erratic and may reflect poor quality data however with epilepsy featuring in the 
admission data regardless of whether an admission was primarily due to the epilepsy.   
[For raw data from Eastern and Coastal Kent PCT please see appendix page 232.] 
  
 
Figure 5 The number unplanned visits to hospital for acute problems arising from epilepsy 
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2 Study Two; The results from the Quality and Outcomes Framework 
 
The results for QOF are collected and published by the department of health. [See 
page 235] The results obtained in this manner have supplied the results for the aims 
listed for QOF below. 
 
Non-participating Practices 
 
There was no formal study on practices who did not take part in the Quality and 
Outcomes Framework project however the participation in the UK of practices has 
remained very high with very few practices not being involved96.  Although the 
participation by practices in QOF is voluntary, a large proportion of income for the 
practices rests upon joining in with the framework of care and largely ensures 
participation. In addition league tables are available to the general public which quote 
the practices performance in QOF as a marker of quality of care. This too is a strong 
incentive for practices to take part. 
 
 
2.1 Determine the extent to which primary care practices in England are 
willing to be involved in basic proactive care for epilepsy using a disease 
register following the QOF programme 
 
 
2.1.1 Produce a register for people with epilepsy who are receiving treatment for 
epilepsy and are over 16 years old. 
Just as was seen in PRICCE-2 the uptake of QOF by practices in England was 
swift and widespread. The amount of information obtainable varied a little in the 
earlier years of QOF with detailed information available England in 2004/05 97 
and 2005/06.   
The results taken from these QOF statistical publications revealed that  
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 The number of practices involved was 8576 with 119,168.3 epilepsy points 
achieved representing 86.8% of the total achievable for Epilepsy 1-4 
 This uptake was improved further in 2005/2006 with an average of 93.7% 
of the available points being achieved for Epilepsy 1-4 
 
   
Figure 6 The uptake of QOF areas by practices in England 2004/05 
   
Whilst the uptake was remarkably good the results from the English practices 
revealed that the least successful clinical areas were chronic obstructive 
pulmonary disease (COPD) and epilepsy (figure 6.) From April 2006 onwards 
more information was available and allows greater analysis as is tabulated below 
 
QOF Achievement for Epilepsy 1 (alongside data for seizure frequency for 
people over 18 years old from 2008) [For raw data please see appendix page 235.] 
 
 
 
 
 
Year Achievement 
2004/05 86.8 total average 
2005/06 93.7 total average 
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2006/07 99.9 
2007/08 99.9  
2008/09 99.9 
2009/10 99.6 
2010/11 99.8 
 
  
These results reveal that not only is Primary care willing to be involved in basic 
proactive care it is able to engage and identify problems arising from epilepsy as 
measure by the Standards involved with seizure frequency, and medication review 
[Epilepsy Standards 6, 7 and 8 from 2006 onwards.] [For raw achievement figures 
please see page 235.] 
 
 
2.1.2 Record the seizure frequency for people over 16 years old (alongside data for 
seizure frequency for people over 18 years old from 2008) 
The ability for practices to become organised and able to record the seizure frequency 
for people with epilepsy steadily increased from 2006 to 2011 as illustrated in figure 7 
below and laid out in table 11. 
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Figure 7  Ep 6 Achievement 2006-2011                                Table 11 Ep 6 Achievement tabulated  
 
These results demonstrate very clearly that practices are highly successful in 
identifying the frequency of seizures for people with epilepsy in their practice. [For 
raw data please see appendix page 235 
2.1.3 Perform an epilepsy medication review for people over 16 years old 
(alongside data for seizure frequency for people over 18 years old from 
2008) 
In addition to being able to determine a patient’s seizure frequent the GP practices 
were also able to invite patients in on an annual basis and ask them if they had any 
side effects of indeed other issues relating to their anti-convulsant medication. 
Although this standard is process driven it does begin a process whereby a person 
with epilepsy can express their satisfaction or otherwise of their epilepsy treatment in 
a proactive fashion. [Figure 8, Table 12.] 
 
Figure 8  Ep 7 achievement 2006- 2011              Table 12 Ep 7 achievement tabulated 
 
Quality and Outcome Framework Results Epilepsy 6 
 Achieved/Available% Sum of 
indicators/Sum of 
denominators% 
2006/07 98.1 95.6 
2007/08 98.4 95.6 
2008/09 98.6 95.6 
2009/10 98.3 95.3 
2010/11 99.7 95.6 
Quality and Outcome Framework Results Epilepsy 7 
 Achieved/Available% Sum of 
indicators/Sum of 
denominators% 
2006/07 97.8 95.2 
2007/08 98.3 95.2 
2008/09 98.4 95.2 
2009/10 98.2 95 
2010/11 98.5 95.2 
 135 
Practices are highly successful reviewing the anti-convulsant medication for people 
with epilepsy in their practice.  
 
 
 
 
2.1.4 Identifying people on drug treatment for epilepsy who are seizure free over 
16years old (alongside data for seizure frequency for people over 18 years 
old from 2008) 
Identifying people who were seizure free was somewhat harder and practices were 
only just able to achieve the 70 % target for this as demonstrated below in figure 9 
and table 13. 
 
Figure 9 Ep 8 achievement 2006 - 2011                             Table 13 Ep 8 achievement tabulated 
 
 
The level of seizure freedom has risen modestly over the 5 years of the program rising 
from 73% in 2006 to 73.9% in 2011 
 
 
 
Quality and Outcome Framework Results Epilepsy 8 
 Achieved/Available% Sum of indicators/Sum 
of denominators% 
2006/07 87.3 73 
2007/08 88 73.2 
2008/09 88.8 73.4 
2009/10 89.1 74.4 
2010/11 89.5 73.9 
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In 2006 the program was reviewed and the minimum age was raised to 
18years old 
 
The results from 2006 onward only included people who were 18 years old 
and older rather than the previous figure of 16 years. This had little effect on 
the data overall and have been grouped together in the figures and tables seen 
above. The areas affected by this age change are as follows; 
 
1.1.1. Produce a register for people with epilepsy who are receiving 
treatment for epilepsy and over 18 years old 
 Data included in 3.2.1. 
1.1.2. Record the seizure frequency for people over 18 years old 
 Data included in 3.2.1.1 
1.1.3. Perform an epilepsy medication review for people over 18 years old 
 Data included in 3.2.1.2 
1.1.4. Identifying people on drug treatment for epilepsy who are seizure 
free over 18years old 
 Data included in 3.2.1.3 
 
[For raw data please see appendix page 235.] 
 
 
2.2 Determine if proactive care in England for epilepsy can successfully 
become more complex within the Quality Outcomes Framework. 
 
2.2.1 Ensure that women who are taking contraception medication are prescribed 
appropriate contraceptive medication –Epilepsy 9 
 
2.2.2 Offer prenatal advice for women with epilepsy – Epilepsy 9 
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 “Epilepsy 9. The percentage of women under the age of 55 years who are 
taking antiepileptic drugs who have a record of information and counselling 
about contraception, conception and pregnancy in the preceding 15 months” 
 
The introduction of Epilepsy 9 as a marker is still relatively early on it it’s 
development but the first year of use has now been reported and like PRICCE-2 
reveals that this has been quite a challenge for practices to achieve. It has the second 
highest exception report rate of 36.7% [For raw data please see appendix page 235.] 
 
 
A detailed breakdown of Epilepsy QOF 2011/12 is not available at the time of 
writing this thesis 
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Exception Reporting 
Exception reporting was introduced to offer a legitimate way forward for GPs to 
maintain their income when faced with a population who have epilepsy which is 
difficult to control. It is a way of allowing doctors not to be penalised for having hard 
to treat patients on their practice register however it can also have the potential of 
being used where targets need to be met and the practice are slightly short of the 
target. It is a clinical judgement invariably on who is on the maximum tolerated 
treatment or who is deemed as ‘not suitable,’ to include in the QOF analysis. To help 
counter this the exception reporting percentages between neighbouring practices are 
compared and a practice who is using this route more than their peers explored in 
greater depth. 
 
There are visits paid by the PCT twice a year and now for yearly to assess the data 
quality and check that correct protocol is being used. 
 
Exception reporting has been going down however it has risen again of late and this 
figure is difficult to interpret. [Figure 10] 
 
      
Figure 10 Overall exception reporting rate for epilepsy 2005 - 2011 
Exception reporting for Epilepsy 8 [percentage of patients reported as being seizure 
free] The exception reporting rate the more challenging standard of achieving seizure 
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freedom in 70% of the included practice patients with epilepsy is higher than the 
overall exception reporting rates as indicated in figure 11. 
    
Figure 11 Exception reporting for Epilepsy 8 2006 - 2011 
Tabulated results of seizure overall exception reporting and in particular the 
challenging Epilepsy 8 (70% seizure freedom) as demonstrated below in table 14. 
 Overall Epilepsy Exception report Exception Reported 8 
2005/06 8.05  
2006/07 8.12 16.69 
2007/08 7.92 16.21 
2008/09 7.85 16.13 
2009/10 7.82 15.75 
2010/11 8.1 16.2 
                                                                                                         
1.2. Table 14 Quality and Outcome Framework Results exception report overall compared to epilepsy 8 
 
[For raw data on exception reporting please see page 225.] 
2.3 A preliminary examination of national trends in mortality and 
hospitalisation during the Quality and Outcomes Framework programme. 
 
2.3.1 A preliminary examination of trends in mortality from epilepsy in England 
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 The mortality rates for England and Wales have been static for many decades but 
over the past 3 years they appear to be reducing. It is hard to estimate how much of 
this is due to the Primary Care increasing involvement in the long term management 
of epilepsy but it may reasonably be considered as a factor. The figures obtained in 
figure 12 were obtained from public health data for England and are not age 
standardised. The R2 
un-standardised regression coefficient is 0.531 as demonstrated in table 19 where 
p=0.01 
[For information on the raw data please see the appendix 214.] 
 
Figure 12 Death rate for both sexes per 100,000 in England and Wales 
Model Summary 
Model R R Square Adjusted R Square Std. Error of the Estimate 
1 .764a .583 .531 .05234 
a. Predictors: (Constant), Year of Study 
 ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 
Regression .031 1 .031 11.186 .010b 
Residual .022 8 .003   
Total .053 9    
a. Dependent Variable: Death rate per 100,000 in England and Wales 
 b. Predictors: (Constant), Year of Study 
Table 15 Tabulated regression analysis of mortality rates 2001-2010 
To obtain age standardised mortality rates the author approached the public health 
observatory to assist in producing age standardised data which is presented in figures 
13 to 19 below and this confirms the trend for deaths from epilepsy to be decreasing 
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over the past 10 years. This represents the first time since accurate records have begun 
that the mortality for epilepsy in the UK is decreasing. The mortality rates appear to 
be a downwards trend, more noticeable among males than females, with gender rates 
converging over the period. [For the correspondence with this group please see 
appendix page 211.] 
 
The Public Health Observatory for Kent and Medway confirmed these findings as follows; 
Figure 13 Mortality from epilepsy 2001 – 2010 [age-standardised] 
 
 
 Year / directly age-standardised mortality per 100,000 residents aged under 75  
Population 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010  
Male 1.96 1.91 1.97 1.88 2.02 1.89 1.72 1.89 1.76 1.63  
Female 1.32 1.07 1.22 1.12 1.18 1.17 1.11 1.09 1.09 1.06  
Both sexes 1.64 1.48 1.59 1.50 1.60 1.52 1.41 1.49 1.42 1.34  
Source: Office for National Statistics, KMPHO        
 
 Year / numbers of deaths aged under 75 
Population 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
Male 459 449 469 449 489 461 424 468 440 411 
Female 317 253 296 274 288 287 275 268 280 269 
Both sexes 776 702 765 723 777 748 699 736 720 680 
Source: Office for National Statistics, KMPHO       
Table 16 Mortality from epilepsy – age standardised for 2001 - 2010 
Mortality from epilepsy, 2001-2010, England, <75
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Figure 14 Mortality from epilepsy – age standardised for males 
 
[For data as sent to author by the Kent and Medway PHO please see appendix page 
216.] 
 
Figure 15 Graph representing mortality from epilepsy – age standardised for males 
The reduction in mortality rates for men appears to have taken place towards the 
second half of the decade. 
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Figure 16 Trend analysis for mortality from epilepsy – both sexes 
 
 
 
Figure 17 Graph represent the age standardised mortality for epilepsy for both sexes 
The early part of the decade had a somewhat erratic mortality rate however the second 
part of the decade shows a trend for the combined mortality rate to have reduced over 
this period starting around 2005 and continuing to the end of the decade. 
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Figure 18 Mortality from epilepsy – age standardised for females 
The reduction in mortality rates for women appears to have taken place towards the 
second half of the decade and the low rate in 2002 has weakened the trend analysis. 
 
 
Figure 19 Graph demonstrating trend analysis for mortality from epilepsy – age standardised 
for females 
 
 
 
 
 
 
Mortality from epilepsy, 2001-2010, England, <75
R2 = 0.4212
0.0
1.0
2.0
1 2 3 4 5 6 7 8 9 10A
ge
-s
ta
n
d
ar
d
is
e
d
 m
o
rt
al
it
y 
p
e
r 
1
0
0
,0
0
0
 r
e
si
d
e
n
ts
Female
Source: Office for National Statistics , KMPHO
 145 
 
2.3.2 A preliminary examination of trends in unplanned visits to hospital for 
acute problems arising from epilepsy  
 
To obtain this data required support from the Primary Care Trust [see page 241] 
information team and using Dr Foster hospital analysis data they supplied the 
information in figures 20 and 21 which is also tabulated in tables 17 and 18. The data 
first describes the number of actual admissions for epilepsy as displayed in figure 20 
and also reports the number of people seen in hospital for epilepsy but not necessarily 
admitted in figure 21. 
 
Hospital Admission rate for East Kent 
 
                                                                                                                     Table 17 Bed 
Days 
 
 
Figure20 Epilepsy Admissions for East Kent PCT from Epilepsy [all bed days]  
  
 
Total bed days for epilepsy 
from 2000 to 2012 
Year Total Bed days 
2000/01 2947 
2001/02 3822 
2002/03 3264 
2003/04 3409 
2004/05 3533 
2005/06 4000 
2006/07 3045 
2007/08 2986 
2008/09 2665 
2009/10 2653 
2010/11 3401 
2011/12 3282 
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The number of bed days has been steadily reducing until 2010 and from here the 
number has risen sharply. This rise in admissions coincides with the opening of the 
neurology unit at Kent and Canterbury hospital with the addition of a video telemetry 
service. By looking at the number of ‘epilepsy spells,’ the figures are steadily rising 
with time for East Kent which represents the number of unplanned attendances to 
A&E. 
 
 
 
Figure 21  Graph of epilepsy spells per year                                                 Table 18 Bed days + 
Spells 
 
This represents a general increase in the number of people being seen for epilepsy by 
the East Kent Hospitals.     
 
 
[For raw data please see appendix page 232.]
Total bed days and 'epilepsy spells’ for 
epilepsy from 2000 to 2012 
Year Total Bed days Spells 
2000/01 2947 796 
2001/02 3822 950 
2002/03 3264 879 
2003/04 3409 1026 
2004/05 3533 933 
2005/06 4000 1041 
2006/07 3045 986 
2007/08 2986 1088 
2008/09 2665 1010 
2009/10 2653 1075 
2010/11 3401 1143 
2011/12 3282 1306 
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3 Locally Enhanced Service for Epilepsy  
 
Loss of data 
 
The data which was collected by surgeries and organised onto an Excel spreadsheet 
designed by the PCT was submitted at the end of the financial year and placed onto 
the Canterbury and Coastal PCT computer system. The data was then pooled by the 
technical team there and processed to identify payment due to the practices following 
their achievements in the epilepsy care according to the standards set in the LES. 
Following this the data was to be made available to the author for analysis following 
the study design as laid out in the aims of this thesis. 
 
Unfortunately this coincided with the merging of the local Primary care trusts into one 
single one call East Kent PCT ad in the merger the data was deleted from the health 
authority’s computer before the author had opportunity to analyse it. A search was 
conducted for several months to try and track down this data by myself and the PCT 
information technology team and the Long Term Conditions commissioning team but 
unfortunately none of the data could be rescued.  
 
The pro-forma of the spread sheets is included in the appendix please see page 250 .  
 
Data compared from two practices 
Two large practices retained the information they had submitted for the Locally 
Enhanced Service for Epilepsy [LES] and this was made available to the author for 
further analysis.  Practice A had prior expertise in epilepsy [the author being based 
there] and Practice B had no special grounding in epilepsy but received basic training 
in epilepsy by the author as a pre requisite to take part in the LES.  
 
Practice B is noted to be very well organised and the majority of its partners have 
gained Fellowship status on the Royal College of GPs. Practice A started before 
Practice B but found the work involved too onerous and stopped completing the LES 
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after their second year in 2007. Practice B had less difficulty and continued on until 
the withdrawal of the service in 2009   
 
3.1 To determine if primary care can proactively identify social consequences 
of active epilepsy 
 
3.1.1 Record driving status 
The results from Practice A and Practice B are displayed in table 19 below and show 
that practice B were able to identify nearly twice as many drivers with epilepsy than 
practice A. [For full set of data please see appendix page 251 for practice A and page 
253 for practice B.] 
 
Approval from the Research and Development lead to use the pooled data is recorded 
in the appendix page 255 
 
 
 
 
Table 19 Results from Practice A and Practice B 
 
3.1.2 Record social factors affected by epilepsy 
These results were collected by the practice and any points raised in it were discussed 
at the epilepsy review and are displayed below in table 20. Practice B were able to 
identify nearly twice as many social factors included in the LES compared to Practice 
A 
 
year
Practice A 
List size
Practice B 
list size
Practice A 
people 
with 
epilepsy
Practice B 
People 
with 
epilepsy
Practice A 
prevelanc
e
Practice B 
Prevelanc
e
Practice A 
med, age 
and sex 
recorded
Practice B 
Med,agd 
and sex 
recorded
Practice A 
driving 
status
Practice B 
Driving 
status
2005 to 2006 12891 107 0.83 107 57
2006 to 2007 13442 13786 100 126 0.74 0.91 100 126 44 76
2007 to 2008 13985 124 0.89 124 88
2008 to 2009 14172 114 0.8 114 90
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Year 
Practice 
A social 
factors 
Practice 
B Social 
factors 
2005 to 2006 57  
2006 to 2007 54 101 
2007 to 2008  96 
2008 to 2009  106 
 
Table 20 The number of records of social factors affected by epilepsy 
 
 
 
 
3.2 Identify the number of women and children of child bearing age who have 
epilepsy 
 
3.2.1 Offer women and children of childbearing age folic acid 
These results displayed in table 21 reveal that both practices were able to identify 
women of childbearing age with epilepsy and were able to perform fairly uniformly in 
their ability to offer folic acid.  
 
3.2.2 Offer women and children of child bearing age pre conception advice 
It is interesting to note that the practice with no prior epilepsy training but good 
practice organisation were able to offer a slightly higher level of pre conceptual 
advice when compared to the practice who had previous experience of epilepsy.  
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3.2.3 Ensure that women who are taking contraception medication are prescribed 
appropriate contraceptive medication 
These results were collected by the practice if there was a conflict to resolve with the 
interaction between their anti-epileptic drug and oral contraceptive this was dealt with 
or advice was sought. 
 
 
 
Table 21 The number of women taking contraception who are taking contraception medication 
are prescribed appropriate contraceptive medication 
 
 
3.3 Identify people with epilepsy under hospital care 
Both practices were able to create a clear record of who was receiving specialist care 
for their epilepsy and who was solely under the care of their GP. There seems to be 
little difference overall in the number under specialist care [table 22]. Practice B 
reported that they were able to carry out advice suggested in hospital letters 
completely 
 
Table 22 The number of people with epilepsy under hospital care 
Year
Practice A 
women 
with 
epilepsy
Practice B 
Women 
with 
epilepsy
Practice A 
women of 
childbeari
ng age
Practice B 
Women of 
child 
bearing 
age
Practice A 
CBA 
offered 
folic acid
Practice B 
CBA 
offered 
folic acid
Practice A 
CBA 
offered 
preconcep
tion advice
Practice B 
CBA 
offered 
preconcep
tion advice
Practice A 
CBS and 
aed vs 
cointracep
tion Check
Practice B 
CBS and 
aed vs 
contracept
ion check
2005 to 2006 52 29 2 0 1
2006 to 2007 48 61 23 25 7 3 1 4 6 4
2007 to 2008 58 26 3 6 11
2008 to 2009 50 24 2 7 15
Year
Practice A 
under 
hospital 
care
Practice B 
Under 
hospital 
care
Practice A 
AED 
actively 
managed
Practice B 
AED 
actively 
managed
2005 to 2006 34 107
2006 to 2007 20 37 ? 37
2007 to 2008 11 11
2008 to 2009 19 19
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4 Study Four: Targeted Medicines Use Review for Epilepsy  
 
Educational Event for Community Pharmacists on Epilepsy 
Thirteen community pharmacists spent a day preparing for the targeted medicines use 
review for epilepsy. Of these thirteen, ten pharmacists went on to conduct the MURs 
in Thanet, the other three pharmacists worked outside of the study geographical 
boundary unfortunately and could not take part in the project at this stage but wished 
to be included if the project was spread to a wider area.  
 
The event consisted of a full morning lectures and videos updating their epilepsy 
knowledge and in the afternoon was devoted to role playing the targeted MURs with 
their peers. The month’s pilot was undertaken following this and the community 
pharmacists demonstrated their ability to pro-actively support people with epilepsy by 
assessing medication concordance, counselling on relevant areas of epilepsy care as 
dictated by the consultations and offering appropriate literature. 
 
 
 
4.1 To determine the extent to which community pharmacists can be trained to 
proactively support people with epilepsy 
 
4.1.1 To be able to answer and anticonvulsant query from a patient with 
confidence 
The training day started with a questionnaire to measure self-perceived knowledge of 
epilepsy and was followed up with a questionnaire following the training. At the start 
of the day the pharmacists reported that they felt confident to help a customer with a 
query regarding their epilepsy medication before the training day the pharmacists 
were relatively unsure however by the end of the day they were certainly more 
confident as demonstrated by figure 22 
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Figure 22 Graphs demonstrating the pre and post training confidence at answering AED queries 
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4.1.2 To become familiar with epilepsy classification and explain them to 
customers 
 
When the pharmacists were asked if they were confident to help a customer who 
wanted information about complex partial seizures initially they were not very 
confident but after the training they were significantly more confident as 
demonstrated in figure 23 
 
 
 
Figure 23 Graphs demonstrating the pre and post training confidence at answering classification 
queries 
 
4.1.3 To be able to advise a customer with epilepsy when they could re-apply for 
their driving licence 
 
The third question reported in figure 24 had the biggest improvement when 
comparing the before and after responses and that was relating to their ability to 
advise a customer when they could re-apply for their driving licence. The confident 
intervals for this question did not cross over suggesting that the response was certainly 
significant. 
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Figure 24 Graphs demonstrating the pre and post training confidence at answering driving 
queries 
 
 
 
 
4.1.4 Feel confident in being able to assess how well a patient was taking their 
anti convulsant medication 
 
Finally the pharmacists were asked to rate their knowledge of being able to assess 
how well a patient was taking their epilepsy medication reported in figure 25. This is 
the most generic question of the four and the principles could hold true for all long 
term conditions however there was still an improvement in their self-rating by the end 
of the day. 
 
 
 
 
 
155 
Figure 25 Graphs demonstrating the pre and post training confidence at assessing concordance 
 
4.2 Determine if the advice given by the community pharmacists during a MUR 
was of benefit to the customers  
 
4.2.1 Improving their understanding of the underlying causes of epilepsy 
There were 17 patients interviewed for their MUR and of these 13 completed 
questionnaires and four did not complete one. Three of these patients were not given 
one by the pharmacist at all and one only answered one or two of the questions. 
Despite the low numbers the questionnaires which were obtained, revealed that the 
patients with epilepsy had quite a wide variation of knowledge about their epilepsy 
however by the end of the MUR this was more unified and either stayed the same or 
was improved as displayed in figure 26.  
 
 
Figure 26 Customers pre and post MUR understanding of the underlying causes of epilepsy 
 
 
4.2.2 Understanding how to lessen the risk of having a seizure 
When the people with epilepsy were questioned on their knowledge of how to lessen 
the risk of having a seizure this was initially fairly evenly spread however after the 
MUR as demonstrated in figure 27 it polarised to being more confident about 
minimising the risk. 
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Figure 27 Customers pre and post MUR understanding of reducing the risk of having a seizure 
 
 
4.2.3 Determine if the customer was more likely to approach their pharmacist for 
advice about their epilepsy in the future 
The final question revealed the most impact with people with epilepsy reporting that 
they were unlikely to consult their pharmacist if they required advice about their 
epilepsy however after the MURs this had increased. It was good to see that the 
pharmacists had gained the trust of the patients very effectively and as displayed in 
figure 28 it improved following the MUR. 
 
 
Figure 28 Customers pre and post MUR likelihood of using their pharmacist for epilepsy advice in 
the future 
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4.2.4 Determine if community pharmacists can recognise red flag symptoms to 
allow direct referral to specialist epilepsy services 
  
During the month’s pilot there were five referrals made to specialist services from two 
of the ten pharmacists involved in the pilot which were all rejected by the author who 
triaged all the referrals to the GPwSI community epilepsy service. These referrals 
were outside of the parameters of the referral guidelines.   
 
 36 year old male – rejected as already under specialist care 
 32 year old male – rejected as not diagnosed as having epilepsy 
 17 year old male – rejected as already under specialist care 
 75 year old female – rejected as did not fit referral criteria 
 65 year old male – rejected as does not fit criteria 
  
The information gained at the MUR was of high quality and the pharmacists 
demonstrated that they could record their discussions well and also list the 
information given to the patients successfully as below in table 23. 
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5 Results from Targeted Medicines Use Review pilot for epilepsy 
     
Patient Action Plan Recommendation AED Adherence 
% 
1 Not Sure of Seizure Type Seizures Explained CB 95 
   VNS Makes her cough See ESN LTG  
  Memory problems Memory and Epilepsy 
booklet given 
RTG  
 Occasionally uses alcohol Alcohol and epilepsy 
discussed 
VPA  
     
2 Unsure of epilepsy 
knowledge 
Seizures Explained LVT 98-100 
 Seizure triggers unknown  PGB  
     
3 Unsure about her epilepsy Seizures Explained LVT 90 
 Seizures worsening Safety and Epilepsy - 
remain under specialist 
  
 Has two seizures a year 
that require hospitalisation 
   
 discussion about weight 
and alcohol 
   
     
4 Unsure of seizure type seizures explained CBZ 85 
 Ongoing seizures see specialist every 6 
months 
VPA  
 Driving [non driver  TPM   
     
5 Ongoing seizures Sees GPwSI PHT 90 
 Unsure of triggers Seizures Explained CBZ  
  Epilepsy and safety   
 Memory problems Memory and epilepsy   
     
6 Ongoing seizures Declined leaflets CBZ 100 
  Adv to bring appt 
forward for specialist 
ZNS  
     
7 Ongoing seizures DNAs QEQM 
specialist - adv see GP 
to re arrange 
GBP 100 
  Safety and epilepsy   
     
8 On going seizures NEAD    
 Referred to the Marsden- 
has not heard back yet 
Chase referral via Dr 
Rogers GPwSI 
VPA  
 If NEAD consider on 
going usage of VPA 
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9 Last seizure 2010 - no 
longer under specialist 
care 
Safety and epilepsy VPA 100 
  See GP if has any 
further seizures 
CBZ  
     
10 Discussion about the 
course of epilepsy Last sz 
3 yrs ago 
Under specialist care PHT 100 
 Tiredness possible side effects of 
DZ and PHT 
DZP  
     
11 Did not understand 
epilepsy 
Seizures explained PHT  
 Problem with bright lights Photosensitivity and 
epilepsy 
PGB  
     
12 On-going seizures - under 
Prof Shorvon  
Seizures explained   
 Not sure about seizure 
type? Focal? NEAD 
   
 Strips lights a problem Photosensitivity and 
epilepsy 
CBZ  
 Hormonal triggers and 
epilepsy 
Women and epilepsy   
  Memory and epilepsy   
     
13 Unsure about her epilepsy 
type 
Seizures explained CBZ  
 Avoids flashing lights Photosensitivity and 
epilepsy 
  
 Driving and stopping 
medication discussed and 
driving Very unkeen to 
loose licence 
Driving and Epilepsy   
     
14 Does not know type of 
epilepsy 
Seizures Explained VPA  
 Does not like flashing 
lights 
Photosensitivity   
     
15 Unsure what type of 
epilepsy she has 
Seizures explained LTG  
 On-going seizures x4 last 
week and admitted 
Under neurologist, 
safety leaflet 
LVT  
 Driving discussed - keen 
to regain licence 
Driving and epilepsy VPA  
 Female issues Women and epilepsy CB  
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16 On-going seizures and has 
VNS. Mixed sz type 
Seizures Explained LCS 100 
 Can have daily seizures Safety and epilepsy, 
under 2' and 3' care 
LTG  
   LVT  
   CBZ  
     
17 Unsure about which type 
of epilepsy 
Seizures Explained VPA  
 Feels unsafe going out 
doors  
Safety and epilepsy LVT  
  On-going seizures Wants a second 
opinion about their 
epilepsy->GP 
TPM   
 
Table 23 Tabulated outcomes of the Medicine’s Use Reviews 
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DISCUSSION 
Study One: Primary Care Clinical Effectiveness program 2 [PRICCE-2] 
 
Summary of the main results of PRICCE-2  
 
The PRICCE-2 project successfully demonstrated that doctors in primary care are 
generally willing to become more involved in the management of epilepsy. The 
impact of PRICCE-2 could possibly be called a milestone in the management of long 
term conditions in the UK as it marked the beginning of pro-active evidence based 
care for the whole population. It is hard to recall how patchy and generally inadequate 
the provision of care was in the late 1990’s. Then, care tended to be reactive to crisis 
and was delivered to those who presented for treatment, rather than to pro-actively 
offer care to people identified as having epilepsy.  
 
 
Strengths of PRICCE-2  
The major positive impact however was that it marked the start of the mind-set in 
primary care where the person with epilepsy was firmly placed in the centre of care. 
The simple fact of asking somebody how they perceive their illnesses to currently be 
and if there are any hitherto unknown problems with their treatment started a snowball 
effect. It gave people with epilepsy a voice that previously was rarely heard and 
started to raise expectations in healthcare for epilepsy. The take up rate for PRICCE-2 
was far higher than was initially predicted and this high take up rate was echoed in the 
national roll out of the program in QOF. 
 
I. Practice Register.  
The development of a disease register was certainly possible and it became clear 
that the primary care team were able to engage with computerised systems to 
identify and invite people with epilepsy to attend for an annual review. This 
process revealed that the disease indexing on medical systems had to be accurate 
and that GPs and practice staff could only operate a pro-active care program for 
long term diseases if they used computerised rather than written notes. In parallel 
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to this it was seen to be important also for GPs and practice staff to be accurate in 
their computer usage and for the need to use diagnostic terms and labels 
accurately on their computer systems.  
 
II. Seizure Freedom.  
GPs found it fairly hard to identify people who were seizure free initially and 
required training to fully comprehend the different forms that a seizure could take. 
This study however demonstrates that within the structure of primary care it is 
possible to record seizure freedom proactively and in doing so identify people 
who are at risk from ongoing seizures. The practices reached the target however of 
over 70% of patients being seizure free from the start.  
 
III. Vigabatrin.  
The identification of people on vigabatrin was successful and the number of 
people identified is similar to what one would have expected. The training for the 
program included information about the hazards of peripheral field loss with 
vigabatrin and GPs understood the need to identify people taking this drug who 
were not being followed up by optometrists who would perform 6 monthly visual 
field tests in this group.  When a person with epilepsy moves they can lose contact 
with the epilepsy clinician who commenced vigabatrin and as for many it worked 
very effectively there were occasions when a new referral to a neurologist did not 
seem necessary hence the drug was unmonitored. Also if a patient chose not 
attend a follow up clinic and was removed from the epilepsy follow up they too 
took vigabatrin without monitoring and it was these two groups in particular who 
benefited by this program in PRICCE-2 as they were referred to specialist clinics 
once more. 
 
IV. National prescribing of Vigabatrin 
In order to assess whether the number of people identified in PRICCE-2 correlated 
to the numbers one would expect to be taking it a review of the prescribing habits 
of clinicians was undertaken and the numbers of people with epilepsy who one 
would expect to be taking vigabatrin were extrapolated. In England 2002 the 
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Prescription Costs Analysis data reported that 30,200 prescriptions of Vigabatrin 
issued98. England had a population of 49,649,100 according to ONS Population 
statistics for 2002, which equates to approximately one script of vigabatrin for 
every 19,773 person in the population. This is based on the assumption than 
scripts are issued monthly and then the medication is contained in one script per 
person and not in smaller composites. There assumptions would lead this figure to 
likely represent the highest figure likely to be calculated for and average person in 
the English population and the real answer is likely to be less prevalent. On this 
basis with a population of 427,232 which is the denominator used for the PRICCE 
Project in 2002 [see table 24 below] one would expect around 22 scripts for 
Vigabatrin in 2002. By 2004 the knowledge of the side effects of using vigabatrin 
were more widespread and its use had stated to decline resulting in 23,500 scripts 
being issued in England.   
 
The number of participants for PRICCE at this time was illustrated in Table 25 
below. With a recorded population of  England being 50,109,700 and using the 
same assumptions as above the top estimate of vigabatrin usage would be one 
script for every 25,587 person in the population hence in East Kent in 2004 one 
could assume a maximum of 20 people to have been taking vigabatrin on a 
monthly basis. 
 
 
 
 
2002 Ashford  PCG 103,440.00 
2002 Canterbury  PCG 162,199.00 
2002 East Kent Coastal  PCG 89,907.00 
2002 Shepway  PCG 81,686.00 
  Total Population 437,232.00 
Table 24 Population details of the number of participants in PRICCE as 
recorded by the Health Authority in 2002 and 2004 
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Col1 PCG/PCT RegPop 
2004 Ashford  PCT 105,345.00 
2004 Canterbury and Coastal  PCT 140,712.00 
2004 East Kent Coastal  PCT 191,247.00 
2004 Shepway  PCT 99,118.00 
    536,422.00 
Table 25 The individual populations of the four PCTs in 2004. 
The figure reported in 2002 is lower than this predicted figure99 however by 2004 
it is 21 people who were reported which is surprisingly close to this predicted 
figure and would suggest that the data reflects expected population norms by the 
end of the study.  
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V. Profile of Epilepsy.   
Another area of success for the PRICCE-2 project was the raising of the profile of 
people with epilepsy. Previously GPs had a vague notion of how many people 
they had on their lists with epilepsy and who they were whereas now the GPs 
knew with greater confidence who required epilepsy medication. At medical 
educational events epilepsy was mention more frequently and in a sense epilepsy 
was re-discovered by the GPs in East Kent. As a direct result of this the failings of 
the current epilepsy service were identified and the medical commissioners started 
to look at the unmet needs of people with epilepsy in East Kent and started to 
commission a more robust epilepsy service.  
 
VI. Programmes of care 
Developing a program for epilepsy and indeed other long term diseases also 
offered medical managers a useful tool to improve patient services as the 
combination of computerisation, incentivisation, education, support and peer 
group pressure is relatively easy to manage. The new era whereby general practice 
could be shaped to deliver co-ordinated and evidence based care for people, which 
was targeted by means of audit to identify entire populations with specific 
diseases had begun. 
 
VII. Education 
General practitioners and their ancillary staff demonstrated that with sufficient 
training and support from administrative staff they are able to identify people who 
are seizure free and also be commissioned to perform specific tasks such as 
ensuring that everybody in the practice taking an anticonvulsant such as vigabatrin 
have the necessary care and follow up.  
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Weaknesses of PRICCE-2 
 
There were certainly weaknesses apparent in the PRICCE-2 programme.  Epilepsy 
has long been considered to be a Cinderella subject and this has been compounded by 
GPs feeling and indeed being perceived as being, unskilled in that area 11.  When a 
patient reveals that they have a specific problem related to epilepsy the GP is then 
placed in a position to help the patient either using their own skills or by referring the 
patient for specialist help.    
 
I. Process driven project 
One of the prime weaknesses of PRICCE-2 was the principle of the programme 
being focussed on process rather than outcome.  The practices were tasked to 
complete the processes which had been requested rather than be measured against 
a change in the outcome. The advantages of this have been discussed already 
[please see page 40,] however the counter argument would be that patients’ 
improved health outcome was assumed to occur rather than be accurately 
evaluated.  
 
II. Reporter bias 
A recurrent problem that was first high – lighted in the PRICCE project and has 
been seen in the subsequent incentivised programs of care is the influence of 
reporter bias. It would seem to be an inevitable consequence of any system 
whereby the providers of care report their outcomes and are then paid accordingly. 
The overarching aim was to provide a vehicle to improve care rather than to 
produce a scientific audit and from a commissioning viewpoint this is tolerated. 
This does not reflect fraudulent activity as data extracted by computer searches 
however was directly from the medical records and deviation from the truth would 
amount to a serious breach of professional conduct and there were no reports 
during the project of this having occurred. It is more likely to influence clinical 
judgement as to whether someone can be exempted on medical grounds from 
reaching a target. 
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III. Exception reporting  
The concept of exception reporting whereby people with epilepsy would not be 
included in the denominator if their epilepsy control proved refractory to 
treatment. This was decided in many cases by the GP involved and the presence of 
reporter bias had not been controlled against. This was all the more likely as high 
achievement in PRICCE-2 was linked to higher reward for the reporter. Where 
payment is linked to performance as it does in all of the schemes studied this 
continues to be an important factor to take into consideration. 
 
IV. Management of clinical issues for women with epilepsy 
 It is unclear why GPs found that this was difficult and the reported number of 
women reviewed was lower than expected. It is hard to speculate why this could 
have been and was reflected in the other areas relating to health related areas for 
women with epilepsy.   
 
 
Low reported numbers of women with epilepsy 
 
 
To estimate what the predicted number of women with epilepsy in this population 
the author drew from literature written at around the same time as the study to 
offer an indication of the number of women likely to have been present with 
epilepsy. The pregnancy rate for women with epilepsy in a study of women with 
epilepsy in 2000 revealed a pregnancy rate of 6.1/1000 100. Using this pregnancy 
rate the number of women expected to be pregnant in East Kent in 2002, 2003 and 
2004 are calculated below in table 26. The report by Fairgrieve et al reports that 
the proportion of all pregnancies to women with epilepsy to be 6.1/1000.) Of the 
359/400 known pregnancy outcomes in the study there were 330 live births (three 
sets of twins); two medical terminations, two stillbirths, 22 miscarriages, and five 
terminations. To calculate a figure for the women of East Kent the figures below 
use the same 6.1/1000 figure and then reduce it by 330/359 = 0.836 to allow for 
pregnancies that would not go on to require ante natal care.   
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Table 26. Predicted number of pregnant women who also have epilepsy in East Kent 2002 - 
2004 
  Code  Population Live Births (Thousands)  
2002          
Kent     1,331.2  14.5    
  Ashford  29UB  103.0  1.3    
  Canterbury  29UC  135.4  1.3    
  Dover  29UE  104.6  1.0    
  Shepway  29UL  96.3  1.0    
  Thanet  29UN  126.8  1.3    
     East Kent 5.9    
 Expected number of pregnancies for women with epilepsy = 35     
 Expected number of live births  = 32      
          
2003          
Kent     1,337.8  14.8    
  Ashford  29UB  104.3  1.3    
  Canterbury  29UC  137.1  1.4    
  Dover  29UE  104.7  1.0    
  Shepway  29UL  96.4  1.0    
  Thanet  29UN  127.6  1.3    
     East Kent 6.0    
 Expected number of pregnancies for women with epilepsy = 37    
 Expected number of live births = 34      
          
2004          
Kent     1,346.5  15.3    
  Ashford  29UB  105.4  1.3    
  Canterbury  29UC  139.5  1.4    
  Dover  29UE  105.3  1.0    
  Shepway  29UL  97.1  1.1    
  Thanet  29UN  128.0  1.4    
     East Kent 6.2    
 Expected number of pregnancies for women with epilepsy = 38    
 Expected number of live births = 35      
          
Expected birth rates for women with epilepsy calculated at a rate of 6.1 births per 1000 births in the population 
Expected number of live births approximated at 92% of the total number of pregnancies  
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When the expected figures are tabulated with the reported figures there is clearly 
quite a large discrepancy as described in table 27 below. From these figures it 
would seem that only approximately a third of the expected number of women 
with epilepsy were included in the study. 
 
Year 
Number of 
Women in 
PRICCE-2 
who were 
pregnant 
Total number 
of women aged 
25 - 34yrs 
Expected 
number of 
live births 
2002 11 27327 32 
2003 21 32939 34 
2004 12 31828 35 
Table 27 Expected verses the recorded number of women 2002-2004 with epilepsy 
who are pregnant 
Folic Acid. It follows that the number of women offered folic acid was also 
reduced as it did not seem that GPs had fully understood the need for folic acid 
supplements in women with epilepsy and the numbers of women treated  and to 
have only 10 women a year in East Kent receiving this is somewhat disappointing.  
 
 
Contraception. The potential interaction between anticonvulsant medication and 
the oral contraceptive pills was likely already known by GP and hopefully would 
have been addressed prior to the PRICCE-2 project however the figures of women 
who have had this checked are surprisingly low. It may be because it was hard to 
record accurately in the notes and the coding used to identify it not used and so it 
was not picked up by the end of year computer audit.  
 
V. Reduced access to GPs 
As practices needed to set aside more appointments for proactive care, the 
numbers of appointments, the number of acute appointments was effectively 
reduced. Up until this point it was usually relatively easy to obtain a GP 
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appointment however from here onwards it was more difficult to gain access to a 
GP 
 
In an attempt to provide more appointments this number of practice nurses grew to 
provide extra resource to perform the disease specific clinics and blood testing 
specified in the long term disease management plan. When the author started as a 
GP in his current practice there was only one practice employed nurse however 
currently with a practice only around 15% in size there are now 4 staff nurses and 
3 health care assistants. The request to identify women who were pregnant with 
epilepsy and who were in need of pre natal advice however was not as successful 
and many practices did not take this up fully. It is not clear why this occurred and 
would require further study to find out why it occurred. 
 
VI. Unplanned hospital visits.  
The impact on the number of emergency admissions to the local three hospitals for 
epilepsy steadily increased with a background that the epilepsy admissions to 
remain stable over the previous decade 101 . The data collected on hospital 
admissions however in the first decade of this century was known to be fairly poor 
with inaccurate computer indexing being used. It was not always clear if epilepsy 
was included in a patient’s admission computer entry whether this was the cause 
of the admission or if this was a co-incidental illness. Also blackouts and seizures 
could be mislabelled as being epilepsy. The data available to the eye appears 
inconsistent with numbers appearing to alternate high then low on alternate years. 
The GP computer systems were being improved during PRICCE-2 as was the data 
quality but this had not quite started in hospital data for acute admissions.   
 
In addition the data in 2002 was of relatively poor quality because the indexing of 
the cause for admission was given a low priority and was entered into the hospital 
activity reports by non-medical staff who gathered the diagnosis from hospital 
discharge letters. If the patient’s discharge letter was not always clear it was 
difficult to determine if they had been diagnosed with epilepsy or else suffered an 
isolated non epileptic seizure. Also if the epilepsy code was used it was not always 
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possible to tell whether epilepsy was the cause of the admission or a secondary 
and non-contributory long term condition. These mitigating factors  however 
where constant throughout the two years of the study and so the data was 
requested from the East Kent MAAG team to see if there was any visible trend in 
activity. 
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The results of PRICCE-2 in Context 
 
 
The introduction of PRICCE-2 was at perhaps ahead of its time and it is hard to recall 
back when GPs did not run electronic disease registers and tended to practice 
reactionary medicine. The advent of computerisation and pro-active audit to identify 
people who could benefit from being offered evidence based treatments of care was in 
its infancy. From this basis the primary care contribution of care for people with 
epilepsy developed and though many parts of the process as indicated above were 
flawed, the overall impact for an increased awareness and responsibility by GPs to 
look after people with epilepsy is undoubted.  
 
The scope of what GPs could offer was not tested in PRICCE-2 nor was the impact of 
the primary care led provision at grass roots level to any successful degree but a 
process certainly had started whereby people with epilepsy were being brought 
directly to the attention and care of GPs. 
 
Ideas for future study following PRICCE-2 
 
The GPs in East Kent were led in this project by an enthusiastic team and it was 
welcomed with remarkable acceptance by the local GPs. It was not clear if this was in 
part due to the charisma of the medical director or the support from the clinicians 
[including the author for epilepsy] and audit team. It had gained the Department of 
Health’s attention and it seemed logical to roll this programme out nationally to see if 
the same enthusiasm for pro-active care could be generated nationally as well as 
locally. To do so would require standards to be set lower so that all GPs were able to 
feel part of the programme and perhaps the standards set at a lower common 
denominator albeit with the very best evidence base to guide them. 
 
PRICCE-2: support for the hypothesis 
Consideration of the results for PRICCE-2 in supporting the hypothesis that high 
volume and low impact care for epilepsy is possible to achieve by use of a programme 
of care has offered support to the hypothesis. The only caveat to this was that women 
and epilepsy required more attention and perhaps exploration of why practices failed 
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to achieve as well in this area compared to how they fared in the other sections of 
PRICCE-2  
 
 
 Study Two - Quality Outcomes framework 
 
Summary of the main results of the Quality Outcomes Framework 
 
The lessons gained in PRICCE were now extended to form a national program for 
pro-active, audit driven evidence based care and epilepsy had the benefit of being 
included in this program. It was not clear how practices would respond to evidence 
based care being imposed on them and indeed how they would respond to incentivised 
targets to reach the disease standards. The lesson learnt from PRICCE was that GPs 
welcome it and joined in rapidly and achieve high standards quickly and this was the 
case with QOF. The uptake by practices took the government by surprise and resulted 
in the new General Medical Services Contract of 2004 resulting in a higher than 
planned pay rise to GPs who hit the targets which were thought to be aspiration. The 
achievement of 87% of the epilepsy target in 2004/05 was very good indeed but more 
was possible and by 2010/11 99.8% of the epilepsy achievement had been reached.   
 
 
The strengths of the Quality and Outcomes Framework 
 
I. Seizure frequency.  
It was clear from the start of the program in 2004 that GPs were able to organise their 
practices to pro-actively manage epilepsy and more detailed information was 
available in 2006 to analyse this further. The ration of sum of indicators by the sum of 
denominators stayed high throughout with almost 96% of the practices achieving full 
achievement. The process of inviting people with epilepsy into a GP surgery and 
asking them on an annual basis sounds initially very simple and unlikely to achieve 
anything of significance however it marks a definite change in mind-set for epilepsy 
care in the UK. Prior to this time people with epilepsy would largely only see their GP 
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if there were problems with their epilepsy which they wanted to remedy. People who 
did not realise that their seizures were poorly controlled, those who generally avoided 
seeking medical help and those who were in some way impeded from seeking help 
either by frailty or by reduced mental ability would generally not seek help. Most GPs 
would re-authorise the patients prescriptions periodically and if they had not seen the 
person recently invite them in however this was not formalised on a national level. 
 
By obtaining the knowledge on seizure frequency GPs would then be made aware of 
people hitherto unknown to them who had poor control of their seizures. The method 
of resolving this was left up to the GP and not included in the guidelines for QOF 
 
II. Epilepsy medication review.  
This was also a step forward in the management of people with epilepsy because 
through it GPs became aware of some of their patients who were taking their 
medication but suffering considerably from side effects of their medication. With 
around 95% of the total score being achieved by the practice it ensured that most 
people with epilepsy were able to inform their GPs if they had side effects from their 
medication. If they did it was possible for GPs not to take action but again the 
opportunity was made available for the patient to be heard. The QOF study did not 
give prescriptive guidance on what to do when side effects were reported but it was 
possible for GPs either to answer some of the queries themselves or else to seek 
expert help on alternatives. There was no formal suggestion to assess concordance 
with medication however during the review of medication people with very poor 
concordance would be quickly apparent. 
 
III. Seizure freedom reported in QOF.  
This is arguably the most important standard used in QOF for the management of 
epilepsy in primary care as if offers a surrogate marker of good care. The results from 
QOF revealed that 73% of people with epilepsy were seizure free in 2006/7 rising to 
74% by 2010/11. Community based surveys report a lower seizure freedom rate 
would have been expected 11 however this figures only relates to the number of people 
in the epilepsy denominator for the practice and not the total number of people in with 
epilepsy in the surgery. The use of exception reports, for example to exclude people 
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who have declined being offered an epilepsy review, means that the QOF figures 
reporting seizure freedom cannot be used to determine the true seizure freedom rate in 
the community. Nonetheless it is still a very useful tool to help reduce the number of 
people with on-going seizures and neighbouring practices can be compared to see 
who has excluded an excessive number of patients to achieve the target. 
 
IV. Mortality trends for epilepsy 
In the second half of the decade the mortality rates for epilepsy appear to be falling. 
This is truly very encouraging and represents the first time in recent history whereby 
the mortality of epilepsy in England has been seen to fall.  
 
The reasons for this reduction are surely diverse but it is of interest that they coincide 
with the introduction of study two with the commencement of a national program to 
pro-actively manage epilepsy available to the entire population with epilepsy. This 
may have played a part in the reduction of epilepsy related deaths however it is 
impossible to firmly link the two.  
 
Other factors which could have been involved include the increase in neurologists as 
depicted in figure 29 which is taken from the centre for workforce intelligence report 
in August 2011102 
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Figure 29 Cumulative historical workforce supply for service delivery in neurology 
 
Another factor which may be implicated is the increased number of anticonvulsant 
medications with the introduction of 7 anticonvulsants during this time 
[eslicarbazepine, lacosamide, levetiracetam, oxcarbazepine, pregabalin, stiripentol, 
and zonisamide.] 
 
There have also been several influential report published over this decade starting 
with The Clinical Standards Advisory group report of the working group on services 
for people with epilepsy in 2000 11 Then in 2002 there was a report following the 
publication of  the ‘National Audit into epilepsy related deaths :epilepsy death in the 
shadows’ 12 . In 2004 NICE produced its guidelines ‘The epilepsies. The diagnosis 
and management of the epilepsies in adults and children in primary and secondary 
care,’ 51. Then in 2008 the report ‘Wasted money, wasted lives: the human and 
economic cost of epilepsy in England,’ by the all-party parliamentary group on 
epilepsy 30.  
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It would be highly presumptive and indeed misleading to suggest that this study 
supports the notion that the Quality and Outcomes Framework was instrumental in 
this trend of a slight fall in mortality for epilepsy however it is more reassuring than 
an increase in deaths would have been since its inception. Further work is required to 
explore this observation more fully. 
 
 
The weaknesses of the Quality and Outcomes Framework 
 
I. Process driven rather than outcomes based 
Much of the QOF like PRICCE-2 is simply ‘process driven,’ and it was unclear if 
measuring process rather than outcome would achieve positive results for patients. 
This thesis assesses the impact of a largely process driven system of care. Others have 
also studied the impact of QOF and report that comparing figures between 2004 and 
2008 it seems likely that QOF has led to improvements in patient outcomes103.  One 
cautionary note is that such programs of care could create incentives for practices to 
avoid caring for more chronically unwell and medically fragile patients.  This aspect 
of process verses outcomes as a tool to improve care is explored above in the section 
for PRICCE-2 and the principles remain the same. [Please see page 166.] 
 
II. Exception reporting.  
An area of contention for QOF is the use of exclusion criteria for ‘unsuitable,’ 
patients. The results from the quality outcomes framework in 2005 were analysed and 
the mean pay-performance gap for 65 indicators was studied and this included the 
targets for epilepsy104. It revealed the existence of a treatment gap and part of this gap 
whereby eligible patients are potentially excluded and this was seen to be due to 
targets being set at less than 100%. Another cause of this treatment gap was suggested 
as being due to patients being exception reported.   
 
With time however the number of people who had been exception reported slowly 
reduced but would never likely become zero for example those with terminal illness 
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and extreme frailty. This number is likely to be a constant background figure in the 
community as are those excepted because they have only recently been diagnosed 
with epilepsy. The group of people however who had refused to attend a review 
despite three invites where steadily encouraged with time and were drawn into the 
system and so the levels of exception reports steadily fell. Also people who were 
reported to be on the maximum tolerated drugs were offered opportunity to be 
considered for alternative medication. 
 
As a result of these measures the overall exception report for epilepsy fell from 8.05% 
to 7.82% in 2009/10 and a drop in the exception reporting for Standard 8 – seizure 
freedom falling from 16.7% in 2006/07 to 15.75% in 2009/10. In 2010/11 however 
there was a rise in exception reporting and it is unclear why this could be however 
practices by this stage were somewhat selective in which areas they put their 
resources into.   
III. Gamesmanship in QOF 
Some areas of QOF offer points that are easy to achieve and there are others such as 
epilepsy where some components are more difficult. Also some areas such as the 
quality improvement section in QOF offer high numbers of points to perform 
processes such as peer review that are on relatively easy to perform ( although 
powerful in influencing clinicians care) and other such as epilepsy where there are 
fewer points on offer to practices. This can lead to practices choosing to place less 
effort and indeed resource in certain areas to allow them to divert attention to areas 
where the rewards are higher or easier to achieve. This phenomenon is not universal 
however and reassurance can be gained by reports of areas around the UK who strive 
to achieve the best for people with epilepsy. In a study of a resource poor area of 
Wales it was revealed that GPs are motivated to prioritise epilepsy care despite its 
challenges with a steady rise in quality of care105. This contrasts to some areas of 
England where the attainment in some practices appears to have dropped since the 
introduction of newer and more lucrative QOF targets.    
 
IV. Female issues relating to the management of epilepsy 
The introduction of the QOF medical standard ‘epilepsy 9’, whereby women were 
offered prenatal advice which included counselling about contraception, conception 
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and pregnancy was a difficult task for GPs. This echoes the low levels of attainment 
for the corresponding section of PRICCE-2. The detailed breakdown of achievement 
figures are not yet available and have still to be processed by the department of health 
however we do know that the exception reporting is very high at 36.7% which is the 
second highest exception report percentage in the entire QOF long term disease 
portfolio. 
 
It would be helpful to study this further and determine why this group is not being 
looked after as well as the other areas. Factors involved may be due to lack of 
education for GPs on female issues relating to epilepsy. It may also be due to poor 
provision of specialist services for women with epilepsy to meet any need that 
potentially could be uncovered. 
 
V. Admission rates for epilepsy 
The admission data for people with epilepsy is still tending to increase despite these 
interventions however many other factors are involved here such as changing 
demographics, different patterns of behaviour by people with epilepsy, changing 
patterns of behaviours by community and front line services who are involved when 
someone suffers from a seizure. The change of out of hours health care also changed 
during the past decade, since the introduction of the new GP contract in 2004, GPs did 
not work through the night on call as they had done so previously and it became 
common practice for out of hours clinicians to suggest that an ambulance is called 
when somebody had a seizure. Another factor may be the reluctance to administer 
rectal diazepam to abort a seizure from carers involved in the paediatric and learning 
disability community for fear of incrimination of abuse106. As the use of buccal 
midazolam increases over rectal diazepam the previous reluctance to intervene by 
using rectal diazepam for acute seizure control will be overcome in favour of the 
buccal route.  Time will tell if this becomes a factor in reducing unscheduled hospital 
admissions. 
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Putting the results from the Quality and Outcomes study in context 
The lessons learnt in PRICCE-2 were mirrored almost exactly by the Quality and 
Outcomes Framework. The response to the challenge to deliver pro-active care by 
GPs exceeded expectations and the uptake was higher than expected. The ability to 
identify people with epilepsy and treat them pro-actively was successfully undertaken 
across the country. The recent introduction of standards of care for women with 
epilepsy also lower than expected and the number of exception reports for this group 
was the second highest of any area examined in QOF. 
It supports the theory that GPs are both a willing and able workforce to deliver 
evidence based care for people with long term conditions and pertinent to this thesis 
this includes people with epilepsy 
Ideas for future study 
There are clearly several areas which require further study which include: 
I. Repeat the study with the support of robust statistical analysis, in an attempt to 
determine of outcomes of unplanned admission to hospital as a result of 
epilepsy and indeed if mortality from epilepsy is influenced by high volume 
and low impact care.  
II. Explore why female aspects of epilepsy care appear to be difficult for GPs to 
undertake. This research may start with a study of why women have been 
excluded from QOF. In addition the impact of this style of programme of care 
has with regard to contraception failure due to accidental interaction with anti-
convulsant medication and also the effect on subsequent pregnancies. 
III. For the future extending this study to involve wider aspects of care such as the 
psychosocial aspects of care for people with epilepsy which can be undertaken 
in primary care would also be of value. 
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QOF – Support for the hypothesis 
 
Consideration of the results for QOF in supporting the hypothesis that high volume 
and low impact care for epilepsy is possible to achieve by use of a programme of care 
has offered support to the hypothesis.  Once again, the only caveat to this would be 
that women and epilepsy required more attention and perhaps exploration of why 
practices failed to achieve as well in this area compared to how they fared in the other 
sections of QOF. 
 
Study Three - Locally Enhanced Service for Epilepsy for East Kent 
 
Summary of the main results from the Locally Enhanced Service for Epilepsy 
 
Although the results from the LES for epilepsy were limited it did support the idea 
that GPs were able to offer a wider support for epilepsy than had already been offered 
in the Quality and Outcomes framework. This study required the GPs to ask people 
with epilepsy about psychosocial aspects of their epilepsy care and in addition 
facilitated the delivery of accredited information where needed. The variation between 
practice A&B however illustrates that this more in depth support requires organisation 
and commitment by the whole primary care team rather than having one or two 
enthusiast supported of epilepsy care [as was the case in Practice A,] to make it a 
success 
 
The Strengths of the Locally Enhanced Service for Epilepsy 
 
I. Ability to identify social factors affected by epilepsy   
It was relatively straightforward to enquire about driving status and both practices 
managed to answer this part with ease. Practice B however were able to provide 
almost double the number of reports on social factors including enquiring about the 
adequacy of education provision for children and whether the patients were currently 
employed. 
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They were also better able to enquire about family support and provide information 
about safety to people with epilepsy on their register. The prior experience regarding 
epilepsy for Practice A did not seem to be of great benefit here and this gives some 
indication that the personnel rather than the knowledge of the practice plays a very 
important role. 
 
II. Ability to identify problems relating to women and girls with epilepsy in the 
epilepsy Locally Enhanced Service 
 
Both practices were able to supply support and information on an equal basis and 
reported that they had consulted with their female patients on contraception, prenatal 
and natal advice. This was continued from the work in PRICCE-2 and later was taken 
up nationally in QOF where the exception reporting was very high. Whilst PRICCE-2 
and QOF reveal that GPs find it challenging to discuss epilepsy related matters to this 
group the LES did not seem to find it so.  It is unclear why this was but it may be due 
to the GPs taking part having exposure to training which specifically dealt with the 
problems involved. 
 
III. Links with Hospital Care 
 
Both practices could identify people with epilepsy who were under hospital care and 
there was little difference between the two practices 
 
III. Education about epilepsy prior to enlisting into the programme 
 
The education event for GPs in the area to a higher level in epilepsy from what was 
required for QOF was received enthusiastically and opportunity was provided to 
speak to the GPs in the area in preparation for the LES at educational events locally. 
Since the time many of the LES the lead GPs in each practice have remained 
interested in epilepsy and referrals to the community epilepsy service frequently come 
from these former lead GPs.  
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IV. Use of accredited literature to support people with epilepsy 
 
The method of using accredited literature from epilepsy action was useful and leaflets 
on specific topics were signposted for GPs and practice nurses to use with people with 
epilepsy successfully. This process ensured that the information given was correct in 
its content and also by offering a leaflet could be accurately referenced at a later date 
by the patients.   
 
 
 
 
 
 
Weaknesses of the Locally Enhanced Service for people with epilepsy 
 
I. Low Uptake 
 
One of the areas of the LES which was not successful was the low uptake amongst 
GPs following the initial launch. The reason for this was not studied in this thesis 
however it did come at a time when the finance invested into general practice was 
high following the new GMS contract. As a consequence GPs had less incentive to 
earn extra income particularly the relatively low level of income from the epilepsy 
LES.  
 
In addition there was a large amount of change already taking place in primary care 
and practices tended to focus their effects and indeed staff training on QOF rather 
than focusing on the LES.   
 
II. Fragmented support from the Primary care Trust 
 
The introduction of the Locally Enhanced Service for epilepsy coincided with a major 
structural re-organisation within the PCTs and this had the consequence that only part 
of the new PCT area were able to offer the LES and it was denied to other areas. This 
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had the effect of not being promoted by the PCT and the management of it was 
weaker than it had been before. It became clear that the administrative support was 
vital to support such a programme which although it was available for practices in the 
East Kent area it was not actively promoted and as a result have a very low profile. 
This would likely not have enhanced the uptake of the study by GP practices. 
 
 
The contrasts between Practice A and Practice B 
 
Two practices were reported on in detail for this thesis.  Practice A has had prior 
expertise in epilepsy [the author being based here] and Practice B with no special 
grounding in epilepsy but received basic training in epilepsy and were noted to be 
very well organised with the majority of its partners have gained fellowship status on 
the Royal College of GPs. Practice A started before practice B but found the work 
involved too onerous and stopped completing the LES after their second year in 2007. 
Practice B had less difficulty and continued on until the withdrawal of the service in 
2009. 
 
This highlights the need for appropriate incentives [financial or otherwise] to be 
necessary to ensure engagement in programs of care for epilepsy. Practice A had 
elected to focus their resources on other projects. This despite the active lobbying of 
the author and was largely due to a change in practice manager and lead practise nurse 
necessitating rationalisation of resources. Practice B however where highly organised 
and were able to absorb the extra work required to complete the LES for epilepsy with 
greater ease.  
 
Putting the results of the Locally Enhanced Service into context 
 
I. National merging of PCTs in 2006 
 
The launch of the Locally Enhanced Service was initially successful but the duration 
of the enhanced service was limited to only one Primary Care Trust and when the 
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groups were merged in 2006  to form larger Primary Care Trusts it was one of many 
enhanced services which was not actively promoted and eventually withdrawn in 
2009. It was difficult for the PCT to hold different enhanced services for practices 
who were in the same jurisdiction and as a result the study had only limited success. 
 
Also the support needed to run the service was limited with priorities including 
realignment of commissioning of services by the previous PCTs. Practices ran the 
enhanced service somewhat in isolation and PCT monitoring of it was limited.  
 
II. Future roles for primary care in the treatment and support of people with 
epilepsy 
 
The locally enhanced service demonstrated that primary care can be trained to 
proactively identify social consequences of active epilepsy and then be able to offer 
information and advice to help meet these needs. If can also signpost people to 
appropriate services for problems that are outside of its scope. Until the introduction 
of the LES primary care was focused more in dealing with people who reported 
relatively mild symptoms relating to epilepsy and the rest it tended to refer and not to 
actively manage. In this new program it demonstrated that it could also offer support 
to people with refractory epilepsy and could help to improve their quality of life. This 
group were still almost invariably under the care of secondary or tertiary epilepsy 
centres however there was addition care that could be offered by general practice 
between appointments. 
 
III. Holistic care for Epilepsy 
 
It provided an opportunity for GPs to realise that their general skills in epilepsy were 
relevant and useful when treating people with epilepsy included questioning on the 
need for counselling and social issues. It proved helpful to view people with epilepsy 
as not only having mediation and disease control related problems but also emotional 
and social consequences of their illness. 
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Ideas for Future Study 
 
This study was weakened by the loss of local data and it would be helpful to repeat 
the study on a wider number of practices and with good statistical support to help 
evaluate the impact of holistic care for people with epilepsy including studying any 
impact it may have on their quality of life. 
 
The reasons for Practice A dropping out of the scheme early were not formally 
studied and if the study was repeated any non-responding practices and indeed 
practices who abandoned the study mid-way could be questioned more fully.  
 
The ability for these practices to successfully manage to address issues relating to 
women and their epilepsy was noted. It would be of interest to explore the factors in 
more detail to compare how these practices managed to do so and if it were the 
training which features of the training were useful so that it could be replicated. 
 
Support of the Locally Enhanced Service for Epilepsy of the Hypothesis 
 
 This study supports the hypothesis that practices are able to provide a low impact 
care for people with epilepsy and indeed that the care may be developed to include 
psychosocial aspects of epilepsy care. It does not confirm that they have the necessary 
capacity however as demonstrated by Practice A left the study early. The exact reason 
for it doing so was not fully answerable by this study nor is the actual impact on the 
people with epilepsy who were seen during the study. 
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Study Four. Targeted medicines use review for epilepsy 
  
Summary of the main results from the targeted Medicines Use Review for 
epilepsy by community pharmacists 
 
The Pharmacists in this pilot study have demonstrated that they are able to be trained 
to pro-actively support people with epilepsy and the response from the pharmacy 
customers indicates that their input into the care of this group is well received and 
they will look to utilise the skills of their pharmacists more in the future. The training 
on referral protocol will need to be reviewed and clarified in future targeted MUR 
programs. 
 
The strengths of the targeted Medicines Use Review for Epilepsy 
I. Education event used to train community pharmacists 
The community pharmacists presented themselves voluntarily to be trained in 
epilepsy and in doing so likely self-selected a group who were enthusiastic to learn 
more about epilepsy. The group however were not particularly confident about their 
knowledge of epilepsy and when they entered the training day many politely 
expressed that they felt they needed to be taught a good deal about epilepsy before 
commencing the study. The questionnaires before and after he training express this 
low starting point clearly however by the end of the day they were more confident in 
their knowledge. 
II. Epilepsy related questions from customers 
The pharmacists answered that they were initially unconfident about answering 
epilepsy related queries from customers but by the end of the simple training they 
were either quite confident or very confident to be able to do so. There had been some 
doubt expressed by commissioners whether it was possible to train community 
pharmacists to become confident in advising people with epilepsy and this pilot 
demonstrated this concern appears unfounded. Pharmacists receive a good deal of 
neurological training in their undergraduate studies and their knowledge of the 
pharmaceutical properties of anticonvulsants is certainly of a high standard. What did 
not appear to happen was the linking of this knowledge to their day to day dealing 
with customers. The training built on the lessons learnt in the LES for epilepsy in 
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using patient support leaflets as a reference library for the pharmacists to use. In doing 
so they did not have to retain every detail about epilepsy in their minds and also it 
ensured that the information given to patients was reliable and accredited. Their 
former training in neurology was certainly robust enough to place these tools and they 
were generally confident by the end and wanting use these new skills and tools with 
their customers.  
III. Concordance with medication 
The pharmacists were not sure if they would be able to accurately assess their patents 
to see if they were taking their medication regularly. The initial answer was replaced 
by the end by being very confident on being able to assess their patients. This role of 
community pharmacists is one which I gather is taught in some depth at the Medway 
School of Pharmacy and needed simple practical advice to develop a uniform way of 
assessing and recording concordance amongst their customers. Poor concordance was 
a red flag reason for referral in the study however during the four weeks of the 
targeted MR project none of the referrals were for poor compliance.  
IV. Patient perspective – education about their epilepsy 
The targeted MUR for epilepsy was a new experience for the customers and the first 
question was a challenging on whereby they answered of the MUR had helped them 
to understand the underlying causes of their epilepsy more. Despite the complexity of 
this the post MUR results generally revealed that they had learned more about their 
epilepsy and the leaflet by epilepsy action ‘Seizures Explained,’ was found to be very 
useful 107 being taken by 12 people seen during the study.  They also received advice 
on a regular lifestyle and good concordance and again the majority of people 
improved their scoring when asked if they felt confident that they could minimise 
their risk of a seizure.  
V. Future intentions for people with epilepsy to seek support from their 
pharmacist 
This question had the greatest change in response with the majority reporting that 
prior to the MUR they would be very unlikely to seek advice or support from their 
pharmacist. By the end of the MUR however the majority answered that they would 
be very likely to seek help or advice when they required t from their pharmacist. This 
reveals that based on this feasibility study patients are willing to see their community 
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pharmacist as a legitimate clinician who is well placed to offer them help with their 
epilepsy. Currently this provision has been very limited in the UK and is likely to be 
sporadic however it may be possible to develop this further and further studies may be 
helpful in determining the potential scope which is available from the community 
pharmacist.  
 
VI. The content of the MURs for Epilepsy 
In the documentation from the MURs it was clear that a good deal of counselling on 
epilepsy had taken place.  Many people had expressed their interest in understanding 
their epilepsy more and 12 leaflets on seizures explained were taken. Also safety and 
epilepsy was a frequent topic and 4 people took a copy of the leaflet ‘safety and 
epilepsy,’ by Epilepsy Action108. Other areas covered were memory and a leaflet 
‘memory and epilepsy,’ by Epilepsy Action109  was given and so to was a leaflet on 
‘alcohol and epilepsy,’ again by Epilepsy Action110 to one patient. Photosensitivity 
was mentioned by several and the Epilepsy Action leaflet on ‘Photosensitivity,’111 
was given to four patients. Issues relating to driving were discussed and two patients 
were given the leaflet ‘Driving and Epilepsy,’112 by Epilepsy Action and finally two 
women has questions relating to epilepsy and were given a copy of the epilepsy action 
leaflet ‘Women and Epilepsy.’ 113 
 
 
 
Weaknesses of the targeted Medicines Use Review for epilepsy 
 
I. Referral rights for community pharmacists 
Initially there was understandable concern raised by the medical commissioners over 
the possibility that there would be a large increase in the number of people being 
referred to specialist care and the resultant increase in costs incurred to the health 
authority. This feasibility study however did not demonstrate any such link.  There 
was however several inappropriate referrals to the GPwSI epilepsy clinic and for 
future MUR programs for epilepsy will require more careful explanation to help 
minimise this problem. Community pharmacists currently do not make referral as a 
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rule to specialist services and it is not something they have encountered to any degree 
previously.  
 
The problem was averted by the author offering simple triage and reviewing all of the 
referrals before the appointments were sent out and was able to easily re-direct these 
to the appropriate care. Each pharmacist was contacted and had the reason for the 
redirection of referral explained and the patient’s GP was informed as well. The 
referral form in all of these cases was not followed and the referrals were clearly not 
in the remit of the study however it would be made even clearer in any potential 
future studies.  
 
I would recommend persevering the with referral pathways from the community 
pharmacists as they are undoubtedly the people closest to the patient on the clinical 
care pathway. This places them in an ideal position to identify people who are not 
currently accessing specialist care for epilepsy and are in need of having their epilepsy 
treatment optimised. 
 
 
Putting the results of the Medicines Use Review in context 
 
The locally enhanced service provided useful lessons in how to provide high quality 
advice from non-specialists using accredited information and led to the development 
of targeted epilepsy medicines use reviews being piloted. The pilot was successful and 
plans are underway to offer epilepsy targeted MURs in Wales later this year. This will 
offer a new method of outreach to identify people who are in need of treatment but 
who are currently not accessing specialist epilepsy services... It will also produce a 
widespread network of support for people with epilepsy and help to engage 
community pharmacists into the proactive care of people with epilepsy. 
 
Ideas for future study 
 
I. Hospital admission rates 
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If there were to be further study into the use of community pharmacists in supporting 
people with epilepsy if would be interesting to compare the admission rates to hospital 
for people before and after the intervention by the pharmacist to see if there were any 
significance difference. The group particularly to focus on would be the group who 
are currently at risk of morbidity and mortality from their epilepsy as they do not 
access conventional care via their GP or their neurology services 
II. Medicines Adherence 
 
Also it of interest to see if the intervention by the community pharmacists had any 
impact on the medicines adherence by the people with epilepsy. The pharmacists 
training includes study on medicines adherence and this skill could be brought to bear 
on the population with epilepsy. An additional arm to this study could explore in the 
group who were non adherent to their anticonvulsant medication if the encounter with 
the community pharmacist altered either their unscheduled care or indeed their 
psychosocial consequences of their epilepsy.   This recommendation comes as a 
consequence of this short study identifying two people who were noted to be suffering 
from uncontrolled seizures and one was advised to contact their epilepsy specialist 
nurse and the other to see if their consultant appointment could be brought forward. 
 
III. The impact of a Pharmacist with a Special Interest in Epilepsy [PhwSI 
epilepsy] 
 
The study of having the support of a Pharmacist with a Special Interest in Epilepsy 
would add an extra dimension to any future studies as they would hold in depth 
knowledge both of the role and skills of a community pharmacist in addition to the 
epilepsy skills of a PhwSI.   
 
 Support of the targeted Medicines Use Review of the Hypothesis 
 
The targeted Medicines Use Reviews for epilepsy support the hypothesis that low 
interventions with a system that potentially has a high capacity is feasible. This small 
pilot study took a group of pharmacists whose pre training knowledge of epilepsy was 
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limited and by the end increased their confidence and knowledge in epilepsy. This 
was assessed using a simple and unverified assessment of their knowledge however in 
all cases their responses improved. In addition the impact of their intervention on 
people with epilepsy was both well received and helpful with a swing in response by 
the patients to suggest that they would use their pharmacists again in the future to 
support them with their epilepsy. 
 
In addition the use of accredited information given by the pharmacists to the patients 
appeared to have been used appropriately and was seen as being successful. These 
features all support the hypothesis that it is feasible for primary care to offer low 
impact and high capacity care to people with epilepsy. It also suggests that the 
patients find benefit from this intervention. No statistical analysis was possible due to 
the small sample size and if the study was extended would be necessary to extrapolate 
with confidence the benefit or otherwise of their role in supporting people with 
epilepsy. In addition an economic model could be developed to assess the impact on 
the health economy following such an intervention. 
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CONCLUSION 
 
Re-organisation of the model of care for epilepsy 
These four studies explore the scope for primary care to play an augmented role in the 
management of people with epilepsy. The criticisms by many national reports over the 
last 50 years is that the care for people with epilepsy has been disjointed and poorly 
organised and if at the very least primary care is the common ground to help co-
ordinate these resources then the outlook for people with epilepsy will surely be 
improved. As everybody in the UK currently has a GP who holds their medical 
records and also oversees their medication , it should be possible to ensure that 
everybody with epilepsy is offered access to the appropriate level of epilepsy service 
to keep the impact of their epilepsy on daily living to the minimum possible.  
 
PRICCE was highly significant in that it started a process whereby the person with 
epilepsy had a say in their care. They were asked if they were still having seizures and 
also if their medication suited them thereby starting a chain of events to see the 
provision and care of epilepsy in the U.K. increase steadily with time. It is only the 
GP who holds the disease register that makes this possible and the QOF program 
shows how relatively simple it is to organise an evidence based program of care to 
monitor a long term condition such as epilepsy 
 
It would seem reasonable however to adopt a degree of optimism for the future of 
epilepsy care. It is not difficult to imagine that this is set to improve over the next 
decade. The current trend is for the focus of developing services offering personalised 
care for people which is close to home. In this model the patient is at the centre of the 
care making process and is able to make informed choices on their treatment and have 
an input into what services they would prefer. This is likely to require greater capacity 
in epilepsy care provision than is present at the moment and at a cost that is 
sustainable by the health service. This thesis identifies ways in which this may be 
promoted and how the capacity for care in the community be increased.  
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Pro-active Care 
The early work with the PRICCE-2 study paved the way for evidence based medicine 
for epilepsy to be offered to everyone with the illness using the tools of an accurate 
disease register and computer driven audit. At that stage only basic functions appeared 
possible in Primary care but it still generated the impetus for people with epilepsy to 
be taken notice of and the process of patient centred care began. The more 
complicated aspects of living with epilepsy especially for women was not initially 
successful however with time this has now become within the grasp of most GPs.  
 
 
National Programs of Care for Epilepsy 
For the population as a whole to benefit, the regional study needed to be adopted 
nationally and whilst the study was directly linked in with the author’s work the 
magnitude of scale necessitated the program to be run and managed by the department 
of health. This has been a great success and steadily the level of care managed 
regionally has been adopted on a national level. This may have in part contributed to 
the rise in the profile of epilepsy which is arguably higher now than it was a decade 
ago. 
 
 
  
Patient education 
If one accepts that the capacity of care for people with epilepsy needs to be increased 
then focus should be placed on the epilepsy care pathway.  Support needs to be 
increased not only at the acute presentation of epilepsy but also consideration given 
for improving sources of support for people living with epilepsy. There is a need to 
mobilise as wide an ongoing support network as possible for the long term  
management of people with epilepsy114 which includes the patient themselves being 
given greater responsibility for their welfare. This can be achieved by encouraging the 
patient to actively participate in looking after their own epilepsy, developing shared 
care for epilepsy, implement management guidelines and facilitate the use of clinical 
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information systems. Education is a key role in this process and a lack of education 
for people with epilepsy has been identified for many years. It is surprising to see that 
some of the concerns about the lack of patient information 17 yrs. ago are 
unfortunately much the same as they are now.115 Some of the aims of patient 
education is to improve their understanding of their illness, thereby promoting 
improved compliance with medication and being more aware of triggers116. The 
providers of this information could be quite varied ranging from epilepsy charities, 
community pharmacists, practice nurses, GPs, GPwSIs in epilepsy and epilepsy 
specialist nurses who traditionally offer a major lead in this area. A specialist nurse is 
epilepsy already has a very established role in providing advice and information and 
performs the role of educator to the patient thereby encouraging self-management.117 
Nurses also play a role in helping to co-ordinate patient care and improve a patient’s 
quality of life118. 
 
 
Community Pharmacists support for people with epilepsy 
This thesis also looks at the feasibility of establishing community pharmacists as a 
support for people with epilepsy. The community pharmacists involved in the pilot 
were highly motivated and professional in their approach to studying epilepsy and 
offered a service which was appreciated by people with epilepsy. They were receptive 
to training and could apply the information they learned well with their patients and 
tailored the advice and information required by the patients effectively. The post 
MUR scores given by the patients indeed confirmed that they were successful in 
doing so and they were seen as being a useful point of contact which the majority said 
they would turn to in the future. With a health care system now geared to place the 
patient in the centre of their care and that the care should be a close to the patient’s 
home, the input of community pharmacists would seem ideally placed. 
 
 
The role of the General Practitioner in the care for people with epilepsy 
This thesis has demonstrated that the regular general practitioner also has a role to 
play in the on-going care for people with epilepsy. After initial assessment by 
secondary care the majority of people with epilepsy are referred back to their GP 
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however in the past epilepsy reviews were somewhat haphazard until the new GP 
contract 2004 was introduced, which included the quality and outcomes framework 
for epilepsy119.  
 
The introduction of the National Institute for Clinical Effectiveness [NICE] in 1999 
led to the development of developing standardised care in England, based on evidence 
based research. In 2005 joined the Health Development Agency and though still 
referred to as NICE changed its title to The National Institute for Health and Clinical 
Excellence. In addition to raising standards of health care general practitioners have 
steadily become paperless and the use of electronic databases has led the way for 
targeted patient care using audit tools and for improved sharing of information120. 
 
Recommendation has been made that the routine ongoing management of epilepsy 
should take place in primary care however it would seem that without incentivisation, 
general practitioners readiness to take on this role is lacking121.  With the right factors 
in place however this thesis supports the move to provide high capacity, low impact 
care for people in epilepsy in general practice...  
 
 
Impact of QOF on Epilepsy reviews in general practice 
It appears clear that QOF has improved aspects of epilepsy care in the UK. In an audit 
of epilepsy care at the introduction of QOF and followed up 4 yrs. later, it revealed 
that the introduction of QOF for 13 practices in the Chester area had significantly 
increased the annual review rate of people with epilepsy and was sustained. The 
number of people under shared care fell over this time which may be due to tighter 
influence by hospital managers to reduce the number of follow up episodes in out 
patient’s clinics. Within the report is caution that the care pathways for epilepsy are  
by no means perfect with a surprisingly high figure of 48% of people were who had 
poorly controlled epilepsy were found not to be under specialist care.    
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The next decade of care for epilepsy in the community 
The next decade of clinical care for epilepsy is likely to change considerably and 
some insight into these changes may be possible by taking a review of the processes 
described in this thesis exploring how services for people with epilepsy have 
developed over the past decade. It seems likely that the move towards community 
based care will continue and that the incentivisation for primary care involvement in 
epilepsy will continue. The standards will steadily become more challenging to 
achieve and social aspects of epilepsy care could be added to the current framework. 
The delivery of care for people with epilepsy will likely take on a more complex form 
with devolved health planning to the different regions in the UK resulting in a range 
of solutions to local population challenges and preferences.   
  
The epilepsy team of the future will hopefully include more clinicians as the numbers 
with epilepsy appears set to rise and in the future a team may include a 
psychogeriatrican who can offer advice to their colleagues on epilepsy which 
associated with dementia. The role of community pharmacists may also increase 
further and specially trained Pharmacists with a special interest in epilepsy may well 
soon be available to help support the work of the general community pharmacists. 
 
The involvement of the voluntary sector may also develop further with greater 
involvement being given to the service users in designing services. It may be that 
services such as GPwSIs in epilepsy and community based epilepsy specialist nurses 
will be employed by the epilepsy charities as providers of care and commissioned by 
the clinical commissioning groups 87. This will help to focus the care on people with 
epilepsy and help to avoid the competing interest of profits over service.  
 
If the current trend to improve epilepsy services continues and its profile continues to 
rise the Cinderella status of epilepsy care as it was 10 years ago hopefully should be 
relegated permanently to history. Alongside these changes the next decade will 
undoubtedly bring new advances in the understanding and treatment of people with 
epilepsy. Those involved with the care and support of people with epilepsy will surely 
need to keep reviewing their care for this group of people and hopefully go on to 
witness a significant change in the outlook for people with epilepsy. 
 
 
 
198 
The primary aim of this thesis has I believe been demonstrated, with the four studies 
successfully promoting greater involvement of primary care in the treatment of 
epilepsy. Clearly defined programs of high capacity, low interventional care for 
people with epilepsy appear to be both feasible and effective in primary care.. 
 
The influence on admission rates and mortality for epilepsy is less clear. There are 
many influences on the admission rates for epilepsy which would need to be taken 
into account before the impact of primary care programs could be clearly 
demonstrated. In addition, it would be highly presumptive and indeed misleading to 
suggest that this study supports the notion that the Quality and Outcomes Framework 
was instrumental in this trend of a slight fall in mortality for epilepsy. Further work is 
required to explore this observation more fully. 
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APPENDIX 
1 Correspondence between PRICCE and QOF 
 
 
 
 
Email from Dr Tony Snell – former Medical Director of East Kent PCT to 
confirm the researcher’s link with the Primary Care Clinical Effectiveness 
Project and thereby with the Quality and Outcomes Framework 
 
 
 
 
From: Tony Snell [mailto:Tony.Snell@harmonicpo.com]  
Sent: 23 July 2008 16:57 
To: G ROGERS 
Subject: RE: Hello 
  
You are correct – PRICCE turned into QOF. Therefore all you say is correct, 
so go for it. In fact you can say you wrote chapter in PRICCE and whatever 
turned up in QOF that is same is all down to you 
 
 
Kind Regards, 
 
Dr Tony Snell 
 
Medical Director, 
Harmoni,  
Regus Building, Cardinal Point, Park Road, 
Rickmansworth, Herts WD3 1RE 
T: +44 (0) 1923 715 043 
F: +44 (0) 1923 715 001  
M: 0752 5986308 
E: tony.snell@harmonicpo.com  
W: www.harmonicpo.com 
  
  
   200 
 
2   Document describing PRICCE-1 Protocol 
 
SUMMARY OF PRICCE 1 STANDARDS  1998 26 
 
 
The following criteria must apply to all disease areas : 
 
Disease registers must be set up for all disease areas covered by the project. 
 
There will be a written protocol approved by all the relevant Primary Care team members. 
 
Complete audits to demonstrate compliance with standards for each disease 
 
If a practice can demonstrate clearly any particular reason why they are so disadvantaged as 
to be unable to meet a particular standard, then a discussion can take place between 
practice/EKHA/MAAG/LMC. 
 
 
Idiopathic Epilepsy 
 
Definition - Fit in last 2 years or on medication. 
 
Examples of patients to be referred to suitable specialist at the first stage: 
 
Those with neurological signs, including impaired learning. 
 
Those under 16 years old. 
 
Those whose diagnosis is uncertain. 
 
The protocol must include documenting the minimum data set and when to refer and factors 
to be included in a referral letter. 
 
70 % of patients should be seizure-free two years from initial diagnosis by 1.4.99 , this means 
in the previous 6 months and by 1.4.00  in the previous 12 months (If this is not achieved, 
then the practice must be able to demonstrate why this is so). 
 
The review of patients must be audited annually. 
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3 Document describing the PRICCE-2 Protocol 
 
PRICCE 2 Chapter 3 Epilepsy Standards 
 
STANDARDS FOR TREATMENT OF EPILEPSY 
 
Information on Epilepsy 
 
Epilepsy is one of the most common neurological disorders and is defined as a tendency to 
recurrent seizures; thus patients who have a single epileptic seizure do not have epilepsy.  
(Patients with a single epileptic seizure should be advised not to drive). 
 
3.2   The patient's epilepsy needs to be assessed in terms of: 
Seizure type 
Epilepsy syndrome 
   Relevant aetiology 
   
 
International League Against Epilepsy : Classification of Epileptic Seizures 
 
Partial Seizures (seizures beginning locally) 
Simple partial seizures (consciousness not impaired) 
With somatosensory or special sensory symptoms 
With automatic symptoms 
With psychic symptoms 
Complex partial seizures (with impairment of consciousness) 
Beginning as simple partial seizures and progressing to impairment of consciousness (with 
or without automatism) 
With impairment of consciousness at onset (with or without automatism) 
Partial seizures secondarily generalized  
Secondary to simple partial seizures 
Secondary to complex partial seizures 
 
Generalised Seizures (bilaterally symmetric and without local onset) 
 
Absence 
Myoclonic 
Clonic 
Tonic 
Tonic-clonic 
Atonic 
 
Unclassified Epileptic Seizures (due to inadequate or incomplete data) 
 
Adapted from Commission on Classification and Terminology of the International League Against 
Epilepsy 
    
 
The establishment of a patient's seizure type should occur within the framework of the 
seizure classification of the International League Against Epilepsy 
 
 
3.3 Patients may experience more than one type of seizure, as shown in table 2. 
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The Three most Common Syndromes of Idiopathic Generalized epilepsy  
 
 
 
Absence 
 
 JME 
 
 GTCS 
 
Age at onset (y) 
 
5 to 15 
 
9 to 18 
 
Any Age 
 
Seizure Type(s)* 
 
Absence 
 
Myoclonic 
Generalized 
Tonic-clonic 
 
Generalized 
Tonic-clonic 
 
EEG 
 
3 Hz S & W 
 
>3 Hz S&W 
Polyspikes 
 
Generalized 
S&W Normal 
 
Photosensitivity 
 
Childhood 15% 
Juvenile 7.5% 
 
30% 
 
10% 
GTCS on awakening 
13% 
 
Likelihood of remission 
 
Excellent 
 
Poor  
 
Good 
 
* Most common seizures at presentation JME = juvenile myoclonic epilepsy; GTCS = generalisec 
tonic-clonic seizures S & W = Spike and wave 
  
 
The cause of epilepsy varies from genetically determined, space-occupying lesions (such as 
tumours), to damage caused by vascular events such as thromboses and clots. 
   
Epidemiology of epilepsy: 
 
Incidence  50-70/100,000/year 
                              1-1.5/2,000/year 
 
Prevalence  20-30/1,000/life time 
 
Point prevalence 5-7/1,000 
                             10-14/2,000 of these 6 will be fully controlled 
     3 will have less than one fit per month 
                     4 will have more than one fit per 
month 
  
3.5 There is a raised mortality in the disease due to accident and drowning and to the 
etiological factors behind the disease such as progressive tumour; but that apart there is an 
incidence of Sudden Unexpected Death in epilepsy (SUDEP), all factors leading to a 
mortality ratio of 2.8.  However, epilepsy has a good prognosis with those going into 
remission doing so early in the illness.  Figures from Goodridge (Tonbridge) 1984 show that 
19 years after the initial diagnosis 19% of patients still had no fits, 65% going into remission 
within 5 years of onset. 
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3.6 Each GP will have approximately 1-2 new cases per year, or 4 cases in a 
practice of 4 GPs. 
 
There should be an awareness of differential diagnosis (at least 10% of cases are 
wrongly positively diagnosed).  Table 4 lists the differential diagnosis for epilepsy. 
 
Differential diagnosis for epilepsy: 
 
 Transient ischaemic attacks 
 Syncopal attacks, NB. Cardiac causes 
 Anoxic seizures 
 Acute vertigo 
 Hyperventilation 
 Drop attacks 
 Breath holding attacks 
 Non epileptic attack disorder (Pseudo-seizures) 
 
    
Table 5 lists the minimum data set for epilepsy. 
 
Minimum data set for epilepsy: 
 
Clear history – diagnosis is based on the description, all efforts should be made to interview 
witnesses. Record the events before, during and after the attack, the circumstances in which the 
attack occurred, the speed of onset and the speed of recovery.  
History of drugs and alcohol 
Family history 
Neurological examination  
Electroencephalogram (EEG) for all children, and adolescents and young adults and/or computed 
tomograph (CT) scan (CT scan in children is not routine), or MRI depending on clinical 
circumstances. 
  
 
3.9 The practice must have policies for referral of individuals at the first stage. 
Table 6 lists examples.  Ideally all new patients should be referred to a specialist 
clinic.  If resources do not allow this, then as a minimum the following referral 
policies should be considered 
 
Examples of patients to be referred to neurologist or paediatrician as appropriate at the first 
stage: 
 
Those whose diagnosis is uncertain 
Children and young adults 
Those with neurological signs, including impaired learning 
Those who wish it 
Those requiring identification of underlying cause 
 
  
 
3.10 There should also be consideration of referral to a psychologist. 
 
3.11   There should be an agreed policy with the neurologist (or evidence of 
discussions between the practice and the secondary health care provider) to include 
the following (see Table 7). 
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Factors to be considered in shared policy for patients suspected of having epilepsy: 
 
Which patients to be referred to the neurologist at first diagnosis 
Reasonable waiting times before the patient is seen in outpatients is agreed by the Primary 
Care Organisation. All patients must be seen within a certain number of weeks (which must 
not be greater than the number set out in the Patient's Charter). 
Driving regulations must be discussed at referral. 
Drug therapy is not usually started at this stage. 
Offering information about local and national self help groups. 
Offering advice on safety issues. 
 
  
 
3.12 The practice should have a template for a referral letter where a diagnosis of 
epilepsy is suspected.  Table 8 lists factors, which could be included in the template. 
 
Factors to be included in a referral letter to a neurologist: 
 
Fit timing and frequency 
Aura 
Witness description of ictus and post-ictal period 
Medical History 
 
    
3.13 There should be an annual review of patients with epilepsy.  Table 9 lists the 
checks, which should be carried out. 
 
Checks which should be carried out at review of epileptic patients: 
 
Compliance with driving regulations 
Fit frequency from chart 
Manipulate drug regime on basis of frequency and side effect 
Drug levels measured where appropriate 
i.    For compliance 
      ii.   Toxicity 
iii.  Possibility of increasing dose of poor control. 
Pre conceptual counselling, (OCP and enzyme induces)  
Referral for specialist opinion during pregnancy 
Discuss safety issues, e.g., lifestyle in relation to bathing, working and leisure at heights, 
waterfronts, and dealing with heat and fire. 
Folic acid supplementation to females of reproductive age. 
Side effects of medications counselling. 
Seizure triggers such as alcohol or binges, sleep deprivation, and photosensitivity. 
 
 
  
Standards for the Diagnosis and Management of Epilepsy 
 
3.14 The practice should have a protocol for the evaluation of all new cases. 
 
3.15 The practice must be able to identify all patients diagnosed with epilepsy. 
 
     
 
 
 
205 
3.16 All patients diagnosed as suffering from epilepsy and/or their carers should be 
provided with factual information in the form of leaflets, booklets, etc., with further 
contact details where appropriate (eg, British Epilepsy Association, the National 
Society for Epilepsy or the Epilepsy Task Force).  The information should be 
sufficient to enable the patient and/or carer to participate in discussion about their 
care. 
 
3.17 All advice to patients and/or carers must be documented in the patient's notes.  
All patients must have an EEG and/or a CT scan, as agreed with the secondary 
provider(s). 
 
3.18 No diagnosis of epilepsy should be made without a witness and after only one 
fit. 
 
3.19 There must be annual audit carried out by the practice on the assessment and 
diagnosis and management of patients with epilepsy.  (The time to first appointment 
should be compared with the hospital agreement). 
 
3.20 The practice must have written protocol for managing patients diagnosed as 
having epilepsy.  The protocol must include the management of patients retained 
within the practice.  Where patients are not controlled there should be consideration of 
referral for specialist advice. 
 
3.21 The protocol should include documenting the minimum data set (Table 5) and 
when to refer (Table 6) and factors to include in a referral letter (Table 9). 
 
3.22 The protocol should include time scales for reviewing those patients (at least 
annually), and updating the disease register.  A named individual should be 
responsible for these reviews. 
 
3.23 The protocol should include managing of emergencies - those patients with 
status epilepticus - and there should be evidence that emergency first aid had been 
discussed with the patient and/or relative/carer. 
 
3.24 This protocol should be agreed with the neurologist or appropriate specialist. 
 
3.25 The practice must have a policy for re-referral to a neurologist in the case of 
new symptoms/signs, poor control or end of disease.  (Drugs may be withdrawn after 
2 years fit free in absences and 4 years in other types so long as there are no 
neurological signs, there is no mental retardation and less than 30 fits have occurred.  
An estimation of the individual risk should be calculated and discussed, (Liverpool 
data) ). 
 
3.26 The doctor's emergency bag should contain in-date diazepam in its various 
forms. 
3.27 Where the doctor suspects that a patient is experiencing pseudofits, then this 
patient should be referred to a psychiatrist if a neuropsychiatrist is not available. 
 
Outcome or Proxy Outcome Standards for Epilepsy 
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3.28 70 per cent of patients should be seizure free two years from initial diagnosis 
by 1.4.99, this means in the previous 6 months and by 1.4.00  in the previous 12 
months  (If this is not achieved, then the practice must be able to demonstrate why this 
is so.) 
 
3.29 The review of patients must be annually audited to facilitate optimal care to 
reduce seizure frequency in all patients. 
 
3.30 There must be evidence of discussion amongst the primary health care team 
around any critical events. 
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4  Involvement of Author in the updating of QOF 
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5 Email from Kent and Medway Public Health Observatory regarding the 
calculation of trend in mortality rates in England  
 
From: Barlow Julian (EASTERN AND COASTAL KENT PCT)  
Sent: 04 October 2012 11:15 
To: Rogers Greg (EASTERN AND COASTAL KENT PCT) 
Subject: RE: Mortality rate trends for epilepsy 
 
Hello Greg - 
  
I've standardised these deaths for you and added invisible linear trend lines on the 
charts to give R2 for these series. 
  
There does indeed appear to be a downwards trend, more noticeable among males 
than females, with gender rates converging over the period. 
  
There are old and new Excel versions attached. Use the .xlsx version if you can. 
  
I've also included the yearly data sheets in the file, where the arithmetic happens, but 
I've concealed these, so you'll have to unhide these if you want to work with the 
underlying data. 
  
I hope this is OK, good luck with the PhD. 
  
Best wishes, Julian 
  
Julian Barlow 
Senior Public Health Information Analyst 
NHS Kent & Medway 
Templar House, Tannery Lane, Ashford, TN23 1PL 
Tel: 01233 618366 (direct) 
email: julian.barlow@eastcoastkent.nhs.uk julian.barlow@nhs.net 
 
NHS Kent and Medway represents the following primary care trusts (PCTs): 
NHS West Kent, NHS Eastern and Coastal Kent and NHS Medway 
  
  
 
From: Rogers Greg (EASTERN AND COASTAL KENT PCT) 
Sent: 04 October 2012 09:04 
To: Barlow Julian (EASTERN AND COASTAL KENT PCT) 
Subject: RE: Mortality rate trends for epilepsy 
Dear Julian 
  
That would be really great if you would! The area of England and Wales has more 
external variable factors [different commissioning structures etc] and so ideally just 
looking at England figures would be preferable however the overall structure is fairly 
similar as you know. 
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Again, thank you very much for your help, with best wishes, 
  
Greg 
  
  
  
 
From: Barlow Julian (EASTERN AND COASTAL KENT PCT)  
Sent: 03 October 2012 14:57 
To: Rogers Greg (EASTERN AND COASTAL KENT PCT) 
Subject: RE: Mortality rate trends for epilepsy 
  
Hello Greg – 
  
This shouldn’t be very difficult, although I’ll have to get the population data in 
sex/quinary age bands for each year, and that’s the time-consuming bit. 
  
If I get a break in proceedings then hopefully I’ll get something to you by the end of 
the week. 
  
In which area are you most interested? England, or England and Wales? 
  
Best wishes, Julian 
  
Julian Barlow 
Public Health Information Specialist 
NHS Kent and Medway 
 
Templar House 
Tannery Lane 
Ashford 
TN23 1PL 
 
Tel:   01233618366 
Email:   Julian.Barlow@eastcoastkent.nhs.uk 
Email:   julian.barlow@nhs.net 
 
NHS Kent and Medway represents the following primary care trusts (PCTs): 
NHS West Kent, NHS Eastern and Coastal Kent and NHS Medway. 
  
  
  
From: Rogers Greg (EASTERN AND COASTAL KENT PCT)  
Sent: 03 October 2012 14:24 
To: Barlow Julian (EASTERN AND COASTAL KENT PCT) 
Subject: Mortality rate trends for epilepsy 
  
Dear Julian 
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Hi. Thank you for talking to me on the phone and as we discussed I have attached the 
file from the ONS ‘Avoidable Mortality in England and Wales, 2010’ and under the 
bottom page tab for England and Wales there is a list of causes of avoidable death one 
of which is epilepsy separated by age bands and year.  
  
I took this data and added up each year total and divided it by the population count for 
that year. This appeared to demonstrate that the unstandardised mortality rates for 
epilepsy appear to be falling and this seems to have coincided with QOF. If this is the 
case it would be very useful information and would be something I would share with 
the RCGP/Epilepsy Bereaved etc 
  
If you could have a look at the data and ideally standardise them etc it would be really 
helpful and indeed I would owe you a big favour as it will help add weight to my 
PhD! 
  
With many thanks, Greg 
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6 Data produced by the author representing non standardised mortality from 
epilepsy 
 
This data was gather from the document Avoidable Mortality in England and Wales, 
2010 produced by the Office for National Statistics which is available but is not 
summarised being collated in cintiles of 5 years for each year between 2001 and 2010. 
It covers the populations of England and Wales as well as separate reports for 
England and Wales. The document is 213 pages long and is not printed in this thesis 
due to it’s size. 
 
 
 
Pop. Eng and Wales50,748.00 50,875.60 50,985.90 51,116.20 51,272.00 51,410.40 51,559.60 51,720.10 51,933.50 52,140.20 52,042.00
Obs Death from Epilepsy 824 825 853 908 885 942 994 918 1010
Death Rate per 100,000 1.62 1.61 1.66 1.76 1.72 1.82 1.91 1.76 1.94
Gross Death Rates
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
1.57 1.42 1.53 1.44 1.52 1.47 1.39 1.44 1.38 1.32
1.15
1.2
1.25
1.3
1.35
1.4
1.45
1.5
1.55
1.6
1 2 3 4 5 6 7 8 9 10
Series1
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The data further analysed by the author using SPSS statistical software 
 
 
ANOVAa 
Model Sum of 
Squares 
df Mean Square F Sig. 
1 
Regression .031 1 .031 11.186 .010b 
Residual .022 8 .003     
Total .053 9       
a. Dependent Variable: Death rate per 100,000 in England and Wales 
b. Predictors: (Constant), Year of Study 
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7 Mortality Data sent to the author from the Kent and Medway Public Health 
Observatory 
 
Directly age-standardised mortality for epilepsy aged under 75, 2001-2010, England   
           
 Year / directly age-standardised mortality per 100,000 residents aged under 75 
Population 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
Male 1.96 1.91 1.97 1.88 2.02 1.89 1.72 1.89 1.76 1.63 
Female 1.32 1.07 1.22 1.12 1.18 1.17 1.11 1.09 1.09 1.06 
Both sexes 1.64 1.48 1.59 1.50 1.60 1.52 1.41 1.49 1.42 1.34 
Source: Office for National Statistics, KMPHO       
           
 
 
Numbers of deaths from epilepsy, 2001-2010, England      
           
 Year / numbers of deaths aged under 75 
Population 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
Male 459 449 469 449 489 461 424 468 440 411 
Female 317 253 296 274 288 287 275 268 280 269 
Both sexes 776 702 765 723 777 748 699 736 720 680 
Source: Office for National Statistics, KMPHO       
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8 PRICCE-2 Raw Data 
 
Number reviewed  
2002 
Col1 Name ALL EPILEPSY 
% WITH FULL 
EPILEPSY 
FULL 
EPILEPSY - 
REVIEWED 
% FULL 
EPILEPSY - 
REVIEWED 
2002 Ashford  PCG 363.00 0.39% 354.00 97.52% 
2002 Canterbury  PCG 205.00 0.13% 195.00 95.12% 
2002 
East Kent Coastal  
PCG 107.00 0.14% 102.00 95.33% 
2002 Shepway  PCG 311.00 0.42% 304.00 97.75% 
  986.00 1.08% 955.00 385.72% 
   Av = 0.27%  Av = 96.43% 
      
      
      
East Kent population in 2002 = 570,100 [ONS population statistics 2002 by Local 
Authority]   
Number seen in PRICCE 
= 437,232 
 
 
 
 
 
 
 
 
Number reviewed 
2003     
Col1 Name ALL EPILEPSY 
% WITH FULL 
EPILEPSY 
FULL 
EPILEPSY - 
REVIEWED 
% FULL 
EPILEPSY - 
REVIEWED 
  
2003 Ashford  PCG 445.00 0.44% 433.00 97.30%   
2003 Canterbury  PCG 783.00 0.49% 741.00 94.64%   
2003 
East Kent Coastal  
PCG 986.00 0.54% 936.00 94.93%   
2003 Shepway  PCG 391.00 0.46% 381.00 97.44%   
  2,605.00 1.93% 2,491.00 384.31%   
   av= 0.482%  Av = 96.08%   
        
        
        
        
 
 
       
 
Number Reviewed  
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2004 
Col1 Name ALL EPILEPSY 
% WITH FULL 
EPILEPSY 
FULL 
EPILEPSY - 
REVIEWED 
% FULL 
EPILEPSY - 
REVIEWED 
2004 Ashford  PCT 477.00 0.45% 465.00 97.48% 
2004 
Canterbury and 
Coastal  PCT 948.00 0.55% 894.00 94.30% 
2004 
East Kent Coastal  
PCT 1,136.00 0.61% 1,080.00 95.07% 
2004 Shepway  PCT 408.00 0.43% 382.00 93.63% 
  2,969.00 2.04% 2,821.00 380.49% 
   Av = 0.51%  Av = 95% 
      
      
       
      
Seizure Freedom  
2002 
Col1 Name 
FULL EPILEPSY - 
SEIZURE FREE 
% OF FULL EPILEPSY - 
FIT FREE 
2002 Ashford  PCG 267.00 73.55% 
2002 Canterbury  PCG 140.00 68.29% 
2002 
East Kent Coastal  
PCG 78.00 72.90% 
2002 Shepway  PCG 246.00 79.10% 
  731.00 293.84% 
   Av seizure free 73.46 
    
    
East Kent population in 2002 = 570,100 [ONS population statistics 2002 by Local Authority] 
Number seen in PRICCE = 
437,232   
 
Seizure Freedom  
2003 
Col1 Name 
FULL 
EPILEPSY - 
SEIZURE 
FREE 
% OF FULL 
EPILEPSY - FIT 
FREE 
  
2003 Ashford  PCG 352.00 79.10%   
2003 Canterbury  PCG 615.00 78.54%   
2003 
East Kent 
Coastal  PCG 630.00 63.89%   
2003 Shepway  PCG 285.00 72.89%   
  1,882.00 294.43%   
   Av sz free 73.61   
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Seizure 
Freedom 2004 
      
Col1 Name 
FULL 
EPILEPSY - 
SEIZURE 
FREE 
% OF FULL EPILEPSY - 
FIT FREE 
2004 
Ashford  
PCT 387.00 81.13% 
2004 
Canterbury 
and Coastal  
PCT 692.00 73.00% 
2004 
East Kent 
Coastal  
PCT 719.00 63.29% 
2004 
Shepway  
PCT 276.00 67.65% 
  2,074.00 285.07% 
   Av sz free 71.25 
    
    
    
   
   
   
 
Vigabatrin review 2002 
 
Col1 Name 
FULL EPILEPSY - 
VIGABATRIN 
FULL EPILEPSY - 
VIG, VISUAL 6 
MONTHS 
% OF ON VIG - 
VIGABATRIN, 
VISUAL 6 MONTHS 
2002 Ashford  PCG 1.00 1.00 100.00% 
2002 Canterbury  PCG 2.00 1.00 50.00% 
2002 East Kent Coastal  PCG 0.00    
2002 Shepway  PCG 2.00 1.00 50.00% 
   5.00 3.00 200.00% 
    Average 66.7% 
     
     
      
East Kent population in 2002 = 570,100 [ONS population statistics 2002 by Local Authority]  
Number seen in PRICCE = 
437,232    
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Vigabatrin review 2003 
 
Col1 Name 
FULL 
EPILEPSY - 
VIGABATRIN 
FULL 
EPILEPSY - 
VIG, VISUAL 6 
MONTHS 
% OF ON VIG - 
VIGABATRIN, 
VISUAL 6 
MONTHS 
  
2003 Ashford  PCG 4.00 4.00 100.00%   
2003 Canterbury  PCG 8.00 4.00 50.00%   
2003 
East Kent Coastal  
PCG 3.00 1.00 33.33%   
2003 Shepway  PCG 3.00 1.00 33.33%   
  18.00 10.00 216.67%   
    Av = 54.16   
       
       
       
       
       
       
PRICCE-2 review 2003      
 
Vigabatrin review 2004 
 
Col1 Name 
FULL 
EPILEPSY - 
VIGABATRIN 
FULL 
EPILEPSY - 
VIG, VISUAL 6 
MONTHS 
% OF ON VIG - 
VIGABATRIN, 
VISUAL 6 
MONTHS 
2004 Ashford  PCT 4.00 3.00 75.00% 
2004 
Canterbury and 
Coastal  PCT 7.00 4.00 57.14% 
2004 
East Kent Coastal  
PCT 6.00 4.00 66.67% 
2004 Shepway  PCT 4.00 1.00 25.00% 
  21.00 12.00 223.81% 
    Av = 55.95 
     
     
     
PRICCE-2 2004    
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Number of women reviewed in 2002 
 
Col1 Name 
FULL 
EPIL
EPSY 
- 
PRE
GNA
NT IN 
YEA
R 
PRE
GNA
NT - 
ON 
FOLI
C 
% OF 
PREGN
ANT IN 
YEAR - 
ON 
FOLIC 
PRE
GNA
NT - 
REFE
RRE
D 
% OF 
PREG
NANT 
IN 
YEAR - 
REFER
RED 
PREG
NANT 
IN 
YEAR - 
ON 
VITAMI
N K 
% OF 
PREG
NANT 
IN 
YEAR 
- ON 
VITA
MIN K 
2002 Ashford  PCG 7.00 5.00 85.71% 6.00 85.71% 4.00 57.14% 
2002 Canterbury  PCG 2.00 2.00 100.00% 2.00 100.00% 1.00 50.00% 
2002 East Kent Coastal  PCG 1.00 1.00 100.00% 1.00 100.00% 0.00 0.00% 
2002 Shepway  PCG 1.00 0.00 0.00% 0.00 0.00% 0.00 0.00% 
  11.00 8.00 
285.71
% 9.00 
285.71
% 5.00 
107.1
4% 
    
Av on 
folic = 
71.43  
av 
refered 
- 71.43  
Av on 
vit k = 
26.79 
         
         
East Kent population in 2002 = 
570,100 [ONS population statistics 
2002 by Local Authority]      
Number seen in 
PRICCE = 437,232        
 
Number of women reviewed 2003 
 
Col1 
Nam
e 
FULL 
EPILEP
SY - 
PREGN
ANT IN 
YEAR 
PREGN
ANT - 
ON 
FOLIC 
% OF 
PREGN
ANT IN 
YEAR - 
ON 
FOLIC 
PREGN
ANT - 
REFER
RED 
% OF 
PREGN
ANT IN 
YEAR - 
REFER
RED 
PREGN
ANT IN 
YEAR - 
ON 
VITAMI
N K 
% OF 
PREGN
ANT IN 
YEAR - 
ON 
VITAMI
N K 
2003 
Ashfor
d  
PCG 5.00 4.00 100.00% 5.00 100.00% 3.00 60.00% 
2003 
Canter
bury  
PCG 3.00 2.00 66.67% 2.00 66.67% 1.00 33.33% 
2003 
East 
Kent 
Coasta
l  PCG 11.00 7.00 100.00% 11.00 100.00% 4.00 36.36% 
2003 
Shepw
ay  
PCG 2.00 0.00 0.00% 0.00 0.00% 0.00 0.00% 
  21.00 13.00 
266.67
% 18.00 266.67% 8.00 
129.70
% 
    Av on folic= 66.67 
Av ref = 
66.67  
Av = 
32.43 
         
         
Pricce 
2003         
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Number of women reviewed in PRICCE 2004 
 
Col1 
Nam
e 
FULL 
EPILEP
SY - 
PREGN
ANT IN 
YEAR 
PREGN
ANT - 
ON 
FOLIC 
% OF 
PREGN
ANT IN 
YEAR - 
ON 
FOLIC 
PREGN
ANT - 
REFER
RED 
% OF 
PREGN
ANT IN 
YEAR - 
REFER
RED 
PREGN
ANT IN 
YEAR - 
ON 
VITAMI
N K 
% OF 
PREGN
ANT IN 
YEAR - 
ON 
VITAMI
N K 
2004 
Ashfor
d  PCT 2.00 2.00 100.00% 2.00 100.00% 2.00 100.00% 
2004 
Canter
bury 
and 
Coasta
l  PCT 8.00 5.00 75.00% 6.00 75.00% 2.00 25.00% 
2004 
East 
Kent 
Coasta
l  PCT 4.00 3.00 50.00% 2.00 50.00% 1.00 25.00% 
2004 
Shepw
ay  
PCT 2.00 2.00 100.00% 2.00 100.00% 2.00 100.00% 
  16.00 12.00 
325.00
% 12.00 
325.00
% 7.00 
250.00
% 
    
av= 
81.25  
av = 
81.25  
Av = 
62.5 
         
         
Pricce 
2004         
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9 Exception reporting for QOF: Epilepsy 
 
2005/6 Taken from publication ‘National Quality and Outcomes Framework 
Exception Reporting Statistics for England.’122 
 
2005/06 
 
6. Exception Reporting 2005/06 
 
6.1 Exception Reporting by Indicator Group 
Table 1 shows effective exception rates for the 11 diseases of the clinical 
domain, and for cervical screening. The exception rates shown are based on 
the sum of exceptions and the sum of denominators for all indicators within 
these indicator groups. 
Indicator Group 
Total 
Number of 
Exceptions 
Sum of 
Denominators 
Effective 
Exception 
Rate 
Asthma 671,192 8,404,521 7.40% 
Cancer 33,693 346,204 8.87% 
Cervical Screening 586,577 12,170,708 4.60% 
CHD 1,144,002 14,358,540 7.38% 
COPD 279,737 3,700,999 7.03% 
Diabetes 1,704,062 26,672,840 6.01% 
Epilepsy 76,907 877,973 8.05% 
Hypertension 484,122 19,193,570 2.46% 
Hypothyroidism 7,343 1,245,224 0.59% 
LVD 24,173 271,982 8.16% 
Mental Health 25,171 442,085 5.39% 
Stroke 430,973 5,295,563 7.53% 
 
All Indicator Groups 5,467,952 92,980,209 5.55% 
Table 1: Exception rates by indicator group, 2005/06 
 
Table 1 shows that the overall effective exception rate for England, across all 
indicator groups, was 5.55%. (Note that the numbers of exceptions and the 
sum of the denominators refer to patient records associated with indicators, 
not individual patients. Individual patients can occur in more than one 
indicator group, and can occur more than once in any specific indicator group 
when associated with more than one indicator.) 
 
 
2007/8 
This data is available but not included in this thesis as it is in a format which lists 
every surgery England and is 447pages long 
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2008/9 
 
 
 
    
     
     
     
     
     
     
       
       
Quality and Outcomes Framework (QOF) Exception Reporting for April 2008-March 2009, England 
Exception Rates by Indicator, 2008/09. All available practices in England.    
       
Exception rate =  number of exceptions / (number of exceptions + sum of denominators) * 100 
       
Indicator 
Total Number 
of 
Exceptions 
Sum of 
Denominators 
2008/09  
Exception 
Rate    
EPILEP06 12,461 313,755 3.82%    
EPILEP07 11,728 314,477 3.60%    
EPILEP08 52,604 273,545 16.13%    
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2009/10 
 
 
 
 
     
     
     
     
     
     
     
       
       
Quality and Outcomes Framework (QOF) Exception Reporting for April 2009-March 2010, England 
Exception Rates by Indicator, 2009/10. All available practices in England.    
       
Exception rate =  number of exceptions / (number of exceptions + sum of denominators) * 100 
       
Indicator 
Total Number 
of Exceptions 
Sum of 
Denominators 
2009/10  
Exception 
Rate    
EPILEP06 13,015 318,597 3.92%    
EPILEP07 12,560 319,048 3.79%    
EPILEP08 52,231 279,480 15.75%    
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2010/2011 
 
 
 
 
    
     
     
     
     
     
     
       
       
Quality and Outcomes Framework (QOF) Exception Reporting for April 2010-March 2011, England 
Exception Rates by Indicator (Clinical Domain), 2010/11. All available practices in England.  
       
Exception rate =  number of exceptions / (number of exceptions + sum of denominators) * 100 
       
Indicator 
Total Number 
of Exceptions 
2010/11 
Sum of 
Denominators 
2010/11 
Exception 
Rate 2010/11    
EPILEP06 13,549 322,244 4.0%    
EPILEP07 13,174 322,594 3.9%    
EPILEP08 54,400 281,373 16.2%    
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10 Email from East Kent Primary Care Trust supplying figures on the number 
of admissions for epilepsy over the past decade 
 
From: Alison Scantlebury [mailto:Alison.Scantlebury@eastcoastkent.nhs.uk]  
Sent: 06 July 2012 13:02 
To: Rogers Greg (EASTERN AND COASTAL KENT PCT) 
Cc: Felix Robinson 
Subject: RE: Information Management - Epilepsy 
 
Hi Greg 
 
Thanks for your email.  
 
I am unable to go back as far as 1995 for EKHUFT activity but I can supply from 
April 2000 onwards.   I have spoken to the public health observatory this morning 
regarding the mortality data and they have supplied me with data back to January 
2002 at local authority level. 
 
Please find 2 files attached.  The first contains the inpatient activity at EKHUFT for 
epilepsy related activity (where epilepsy is the primary diagnosis) for East Kent PCT 
patients for April 2000 – May 2012.  The second contains the mortality information 
(the file has two tabs – one showing the East Kent local authority areas and the other 
showing the Kent & Medway PCTs).  Public Health have advised that any numbers of 
5 or less should not be quoted outside of the NHS due to the confidential nature. 
 
Please let me know if you have any questions or if you would like the inpatient 
information broken down in more detail (i.e. at locality or practice level). 
 
Regards 
Alison 
 
Alison Scantlebury 
Client Manager - Business Intelligence 
NHS Kent and Medway 
 
Templar House 
Tannery Lane 
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Ashford 
TN23 1PL 
 
Tel:   01233658447 
Fax:  01233618380 
Email:   Alison.Scantlebury@eastcoastkent.nhs.uk 
Email:   alison.scantlebury@nhs.net 
 
NHS Kent and Medway represents the following primary care trusts (PCTs): 
NHS West Kent, NHS Eastern and Coastal Kent and NHS Medway. 
 
From: Rogers Greg (EASTERN AND COASTAL KENT PCT) 
[mailto:greg.rogers@nhs.net]  
Sent: 05 July 2012 13:01 
To: Alison Scantlebury 
Subject: FW: Information Management - Epilepsy 
 
---Hopefully I have used your correct email address this time!! 
  
 
From: Rogers Greg (EASTERN AND COASTAL KENT PCT) 
Sent: 05 July 2012 12:14 
To: alison.scantlebury@eastcoastkent.nhs.net 
Cc: Felix.Robinson@eastcoastkent.nhs.uk 
Subject: RE: Information Management - Epilepsy 
Dear Alison 
  
Hi. I do not think we have met each other but by way of introduction I am a GP in 
Margate and the clinical lead GPwSi for Epilepsy in East Kent. As there are only a 
relative few GPs with a specialist interest in epilepsy I have managed to be involved 
with the epilepsy NICE update and also am on the NICe Epilepsy quality standards 
group. Working with them I realise that Primary care has been pretty slow in 
producing scientific papers on epiliepsy care and I am sure we have a significant role 
in improving the care of people with epilepsy as it is really such a common condition 
[approx 1% of pop.] 
  
I would be really grateful for you help in obtaining East kent hospital activity relating 
to Epilepsy for 1995 - to the present. I am finishing my PhD at UCL on health care 
service delivery and redesign for epilepsy in primary care and this is looking at the 
impact made on epilepsy care as a result of focused programs of care for epilepsy 
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including PRICCE and PRICCE II in the late 1990's which as you know was the fore 
runner of QOF, the impact of QOF, the impact then of the Epilepsy LES I and II, and 
also the impact of the GPwSI service for Epilepsy since 2004. 
  
The value of these services has only poorly been explored for epilepsy and the impact 
on use of secondary and tertiary care has not been studied in depth for epilepsy. I am 
hoping also to match this up with the health economics of both the Primary care 
service contracts and the GPwSI role. 
  
In addition to this would be really helpful to gain access  to epilepsy mortality data on 
a smaller geographical basis that is freely available on the SEPHO website i.e. at 
district level as some of the schemes were not uniformily adopted and also the PCO 
boundries have changed during this time. If you could help me with this too it would 
be really great? 
  
I will be more than happy to do whatever I can to help in this process and would be 
really grateful for any help you can offer. East Kent has been very pro active in 
epilepsy care and it would be grate to share any lessons learnt with the rest of the 
health community. 
  
With many thanks , 
  
Greg 
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11 Data received from Eastern and Coastal Kent PCT showing number of 
admissions for epilepsy from 2000 - 2013 
 
Admitted 
          
User name: 
Alison 
Scantlebury 
         
Report date: 
06/07/2012 
12:30:28 
        
          
PCT (registered) 
Eastern and Coastal 
Kent PCT 
       
          
Criteria Selection Summary 
          
          
Basket: Diagnoses - All Chapter: Nervous System Provider: East Kent 
Hospitals University NHS Foundation T... Diagnosis Group: Epilepsy, 
convulsions Subgroup: All 
 
Admission Type: All Admission Method Group: 
All Sex: All Deprivation: All Age Range: All 
    
Activity Mode: All Year of Tariff: Data Year Market Forces Factor: 
Appropriate to Tariff Year Analyse By (Secondary): ACS condition 
  
Spells: 12442 Day Cases: 279 (37.3%) First / 
Last: Apr-00 / May-12 LoS: - / - LoS 
(superspell): -/- 
    
          
          
Trend 
(Financial 
Year) 
S
pe
lls 
Inp
atie
nts 
Day 
Cas
es 
DOS
A 
Rate 
% * 
Total 
Bed 
Days 
Pre-op 
Bed 
Days 
Post-
op Bed 
Days 
Excess 
bed 
days 
PB
DS 
** 
 2000/01          
Convulsion
s and 
epilepsy 
79
6 
759 37 66.70
% 
2,947 24 161 - 1,8
36 
 2001/02          
Convulsion
s and 
epilepsy 
95
0 
907 43 56.10
% 
3,822 107 270 - 2,5
50 
 2002/03          
Convulsion
s and 
epilepsy 
87
9 
867 12 52.40
% 
3,264 76 88 - 2,0
67 
 2003/04          
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Convulsion
s and 
epilepsy 
1,
02
6 
1,01
5 
11 57.70
% 
3,409 118 174 - 2,1
05 
 2004/05          
Convulsion
s and 
epilepsy 
93
3 
926 7 44.40
% 
3,533 53 80 - 2,4
38 
 2005/06          
Convulsion
s and 
epilepsy 
1,
04
1 
1,03
0 
11 55.60
% 
4,000 31 84 865 2,8
64 
 2006/07          
Convulsion
s and 
epilepsy 
98
6 
975 11 61.10
% 
3,045 63 236 711 2,0
18 
 2007/08          
Convulsion
s and 
epilepsy 
1,
08
8 
1,06
8 
20 58.40
% 
2,986 145 844 628 2,0
49 
 2008/09          
Convulsion
s and 
epilepsy 
1,
01
0 
998 12 61.50
% 
2,665 187 1,060 546 1,8
55 
 2009/10          
Convulsion
s and 
epilepsy 
1,
07
5 
1,05
0 
25 57.90
% 
2,653 245 1,328 614 1,6
96 
 2010/11          
Convulsion
s and 
epilepsy 
1,
14
3 
1,10
7 
36 71.60
% 
3,401 286 1,910 768 2,2
94 
 2011/12          
Convulsion
s and 
epilepsy 
1,
30
6 
1,26
2 
44 74.10
% 
3,282 263 1,867 674 2,0
30 
 2012/13 
(Apr & 
May only) 
         
Convulsion
s and 
epilepsy 
16
5 
155 10 75.80
% 
361 21 164 - 201 
 
         
* Day of 
Surgery 
admission 
rate 
         
** Potential Bed Days Saved (the number of bed days that would 
have been saved if no patients stayed longer than the national 
average) 
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12 Admission data for East Kent provided by Eastern and Medway PCT using 
‘Dr Foster Intelligence’ software. 
 
 
 
 
 
User name: Alison Scantlebury
Report date: 06/07/2012 12:30:28
PCT (registered) Eastern and Coastal Kent PCT
Basket: Diagnoses - All Chapter: Nervous System Provider: East Kent Hospitals University NHS Foundation T... Diagnosis Group: Epilepsy, convulsions Subgroup: All
Admission Type: All Admission Method Group: All Sex: All Deprivation: All Age Range: All
Activity Mode: All Year of Tariff: Data Year Market Forces Factor: Appropriate to Tariff Year Analyse By (Secondary): ACS condition
Spells: 12442 Day Cases: 279 (37.3%) First / Last: Apr-00 / May-12 LoS: - / - LoS (superspell): -/-
Trend (Financ ial Year) Spells Inpat ients Day Cases DOSA Rate % * Total Bed Days Pre-op Bed Days Post-op Bed Days Excess bed days PBDS **
 2000/01
Convulsions and epilepsy 796 759 37 66.70% 2,947 24 161 - 1,836
 2001/02
Convulsions and epilepsy 950 907 43 56.10% 3,822 107 270 - 2,550
 2002/03
Convulsions and epilepsy 879 867 12 52.40% 3,264 76 88 - 2,067
 2003/04
Convulsions and epilepsy 1,026 1,015 11 57.70% 3,409 118 174 - 2,105
 2004/05
Convulsions and epilepsy 933 926 7 44.40% 3,533 53 80 - 2,438
 2005/06
Convulsions and epilepsy 1,041 1,030 11 55.60% 4,000 31 84 865 2,864
 2006/07
Convulsions and epilepsy 986 975 11 61.10% 3,045 63 236 711 2,018
 2007/08
Convulsions and epilepsy 1,088 1,068 20 58.40% 2,986 145 844 628 2,049
 2008/09
Convulsions and epilepsy 1,010 998 12 61.50% 2,665 187 1,060 546 1,855
 2009/10
Convulsions and epilepsy 1,075 1,050 25 57.90% 2,653 245 1,328 614 1,696
 2010/11
Convulsions and epilepsy 1,143 1,107 36 71.60% 3,401 286 1,910 768 2,294
 2011/12
Convulsions and epilepsy 1,306 1,262 44 74.10% 3,282 263 1,867 674 2,030
 2012/13 (Apr & May only)
Convulsions and epilepsy 165 155 10 75.80% 361 21 164 - 201
* Day of Surgery admission rate
** Potential Bed Days Saved (the number of bed days that would have been saved if no patients stayed longer than the national average)
Admitted
Criteria Select ion Summary
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13 QOF Achievement tables 
QOF Achievement for 2004/2005 
Disease Summaries    
Quality and Outcomes Framework (QOF) for April 2004 – March 2005, England 
Achievement by disease,  by Strategic Health Authority with national summary 
     
SHA 
Code Strategic Health Authority Name 
No. of  
Practices 
Epilepsy 
Total 
Points 
Achieved 
Epilepsy 
Total 
Points 
Achieved 
/Available 
% 
Q01 Norfolk, Suffolk and Cambridgeshire 298 4,377.4 91.8% 
Q02 Bedfordshire and Hertfordshire 228 3,342.2 91.6% 
Q03 Essex 288 3,971.4 86.2% 
Q04 North West London 434 6,144.7 88.5% 
Q05 North Central London 288 3,971.4 86.2% 
Q06 North East London 367 4,818.0 82.0% 
Q07 South East London 287 3,746.0 81.6% 
Q08 South West London 232 3,188.5 85.9% 
Q09 Northumberland, Tyne & Wear 239 3,341.2 87.4% 
Q10 County Durham and Tees Valley 176 2,382.7 84.6% 
Q11 North and East Yorkshire and Northern Lincolnshire 253 3,556.7 87.9% 
Q12 West Yorkshire 359 4,606.1 80.2% 
Q13 Cumbria and Lancashire 358 5,052.1 88.2% 
Q14 Greater Manchester 548 7,166.4 81.7% 
Q15 Cheshire & Merseyside 428 5,626.9 82.2% 
Q16 Thames Valley 286 4,288.7 93.7% 
Q17 Hampshire and Isle Of Wight 231 3,491.1 94.5% 
Q18 Kent and Medway 294 3,979.5 84.6% 
Q19 Surrey and Sussex 366 5,337.1 91.1% 
Q20 Avon, Gloucestershire and Wiltshire 318 4,675.2 91.9% 
Q21 South West Peninsula 248 3,650.2 92.0% 
Q22 Dorset and Somerset 177 2,754.6 97.3% 
Q23 South Yorkshire 224 2,825.8 78.8% 
Q24 Trent 413 5,781.8 87.5% 
Q25 Leicestershire, Northamptonshire and Rutland 229 3,267.7 89.2% 
Q26 Shropshire and Staffordshire 262 3,679.3 87.8% 
Q27 Birmingham and the Black Country 515 6,795.8 82.5% 
Q28 West Midlands South 230 3,349.6 91.0% 
England England 8576 119,168.3 86.8% 
     
Data source: QMAS database – 2004/05 data as at end of June 2005    
SHA codes are used for administrative purposes in local and national databases 
Copyright © Health and Social Care Information Centre 2005   
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QOF Achievement 2005 – 2006 
 
 
SHA 
Code Strategic Health Authority Name 
Number of 
Practices 
Epilepsy 
Total 
Points 
Achieved 
Epilepsy 
Total Points 
Achieved 
/Available % 
Q01 Norfolk, Suffolk and Cambridgeshire 292 4,561.9 97.6% 
Q02 Bedfordshire and Hertfordshire 223 3,413.9 95.7% 
Q03 Essex 282 4,226.7 93.7% 
Q04 North West London 432 6,411.1 92.8% 
Q05 North Central London 273 4,002.7 91.6% 
Q06 North East London 350 5,048.5 90.2% 
Q07 South East London 285 4,090.1 89.7% 
Q08 South West London 232 3,496.0 94.2% 
Q09 Northumberland, Tyne & Wear 233 3,485.6 93.5% 
Q10 County Durham and Tees Valley 172 2,562.0 93.1% 
Q11 North and East Yorkshire and Northern Lincolnshire 250 3,787.6 94.7% 
Q12 West Yorkshire 348 5,033.3 90.4% 
Q13 Cumbria and Lancashire 344 5,147.0 93.5% 
Q14 Greater Manchester 536 7,794.2 90.9% 
Q15 Cheshire & Merseyside 417 6,085.6 91.2% 
Q16 Thames Valley 282 4,409.4 97.7% 
Q17 Hampshire and Isle Of Wight 230 3,616.5 98.3% 
Q18 Kent and Medway 284 4,242.1 93.4% 
Q19 Surrey and Sussex 361 5,543.5 96.0% 
Q20 Avon, Gloucestershire and Wiltshire 315 4,871.4 96.7% 
Q21 South West Peninsula 249 3,866.3 97.0% 
Q22 Dorset and Somerset 178 2,827.9 99.3% 
Q23 South Yorkshire 222 3,164.0 89.1% 
Q24 Trent 407 6,092.3 93.6% 
Q25 Leicestershire, Northamptonshire and Rutland 227 3,378.1 93.0% 
Q26 Shropshire and Staffordshire 258 3,910.7 94.7% 
Q27 Birmingham and the Black Country 498 7,434.5 93.3% 
Q28 West Midlands South 229 3,554.4 97.0% 
England  8409 126,057.3 93.7% 
Data source: QMAS database – 2005/06 data as at end of June 2006   
Copyright © 2006, The Information Centre, Prescribing Support Unit. All rights reserved.  
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QOF Achievement 2006 to 2007  
 
The high uptake was maintained in 2006/2007 however the Epilepsy 8 standard is lower as 
previously practices had been unclear whether to only include convulsive seizures however the 
supporting literature now makes it clear that all seizure types are to be included. 
 
 
Epilepsy      
Quality and Outcomes Framework (QOF) for April 2006 to March 2007, England   
Achievement by indicator within this clinical 
area    
Total number of practices = 
8,372     
      
 (a) (b) © (d)  
Indicator 
Points 
available 
Total points 
achieved 
Total points achieved / 
Available % 
Underlying 
achievement  
Epilepsy 5 1 
                       
8,366.0  99.9% ---  
Epilepsy 6 4 
                     
32,840.9  98.1% 95.6%  
Epilepsy 7 4 
                     
32,753.3  97.8% 95.2%  
Epilepsy 8 6 
                     
43,872.3  87.3% 73.0%  
Epilepsy 
Total 15 
                   
117,832.6  93.8% ---  
      
(a) Points available to each practice for this 
indicator    
(b) Sum of points achieved by all practices for this 
indicator    
© Sum of points achieved by all practices / (available points for this indicator * total number of practices) 
expressed as a percentage 
(d) Underlying achievement = ( sum of indicator numerators / sum of indicator denominators ) * 100  
      
Data source: QMAS database – 2006/07 data as at end of June 2007.   
Copyright © 2007. The Information Centre for health and social care, Prescribing Support Unit. All rights 
reserved. 
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QOF Achievement 2007 – 2008 
 Basic register and epilepsy surveillance is continued but again seizure freedom for 70% of the 
population is not reached by approximately a quarter of the country. 
Clinical Domain     
Epilepsy      
Quality and Outcomes Framework (QOF) for April 2007 – March 2008, England   
Achievement by indicator within this clinical area    
Total number of practices = 
8,294     
      
 (a) (b) © (d)  
Indicator 
Points 
available 
Total points 
achieved 
Total points achieved / 
Available % 
Underlying 
achievement  
EPILEP05 1 8,288.0 99.9% -  
EPILEP06 4 32,658.7 98.4% 95.6%  
EPILEP07 4 32,595.6 98.3% 95.2%  
EPILEP08 6 43,813.5 88.0% 73.2%  
EPILEPSY 
TOTAL 15 117,355.8 94.3%   
      
(a) Points available to each practice for this indicator    
(b) Sum of points achieved by all practices for this 
indicator    
© Sum of points achieved by all practices / (available points for this indicator * total number of practices) 
expressed as a percentage 
(d) Underlying achievement = ( sum of indicator numerators / sum of indicator 
denominators ) * 100   
      
Data source: QMAS database – 2007/08 data as at end of June 2008   
SHA and PCT codes are used for administrative purposes in local and national databases  
For PMS practices participating in the national QOF, achieved points shown are prior to PMS points 
deductions. 
This work remains the sole and exclusive property of the Health and Social Care Information Centre and 
may only be reproduced where  
there is explicit reference to the ownership of the Health and Social Care Information Centre.  
This work may be re-used by NHS and government organisations without 
permission.   
This work is subject to the Re-Use of Public Sector Information Regulations and permission for 
commercial use must be obtained from the copyright holder. 
Copyright © 2008, The Health and Social Care Information Centre, Prescribing Support Unit. All rights 
reserved. 
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QOF Achievement 2009 – 2010 
This year saw a greater emphasis on exception reporting and exception reporting rates between 
practices was used as a tool to identify some who were too quick to exemption report people 
with epilepsy who were more of a challenge to help lead to seizure freedom. 
 
 
Epilepsy      
Quality and Outcomes Framework (QOF) for April 2009 – March 2010, England 
Total number of practices = 8,305      
      
 (a) (b) © (d) (e) 
Indicator 
Points 
available 
Total 
points 
achieved 
Total 
points 
achieved / 
Available 
% 
Underlying 
achievement 
Exception 
rate 
Epilepsy05 1 8,275 99.6% - - 
Epilepsy06 4 32,651.4 98.3% 95.3% 3.92% 
Epilepsy07 4 32,609.1 98.2% 95.0% 3.79% 
Epilepsy08 6 44,394.1 89.1% 74.4% 15.75% 
Epilepsy Total 15 117,929.6 94.7% - 7.82% 
      
(a) Points available to each practice for this indicator   
(b) Sum of points achieved by all practices for this indicator   
© Sum of points achieved by all practices / (available points for this indicator * total number of practices) expressed as a percentage 
(d) Underlying achievement = ( sum of indicator numerators / sum of indicator denominators ) * 100 
(e) Exception rate = number of exceptions / (number of exceptions + sum of denominators) * 100 
      
Data source: QMAS database – 2009/10 data as at end of July 
2010      
For PMS practices participating in the national QOF, achieved 
points shown are prior to PMS points deductions.      
This work remains the sole and exclusive property of the Health 
and Social Care Information Centre and may only be 
reproduced where       
there is explicit reference to the ownership of the Health and 
Social Care Information Centre.      
This work may be re-used by NHS and government 
organisations without permission. 
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QOF Achievement 2010 – 2011 
The uptake of QOF for epilepsy remains high at around 95.6% of practices working with 
people with epilepsy for QOF however the achievement of seizure freedom remains fairly static 
at 73.9% 
 
 
Epileps
y 
             
Quality and Outcomes Framework (QOF) for April 2010 – 
March 2011, England 
       
Achievement by indicator within this 
group, England 
         
               
  Nu
mb
er 
of 
Pra
ctic
es 
EPI
LEP
05 
Su
m 
of 
Poi
nts 
EPIL
EP06 
Sum 
of 
Point
s 
EPILE
P06 
Sum 
of 
Numer
ators 
EPILE
P06 
Sum 
of 
Deno
minat
ors 
EPIL
EP06 
Unde
rlyin
g 
achie
veme
nt 
EPI
LEP
07 
Su
m 
of 
Poi
nts 
EPIL
EP07 
Sum 
of 
Num
erato
rs 
EPILE
P07 
Sum 
of 
Deno
minat
ors 
EPIL
EP07 
Unde
rlyin
g 
achie
veme
nt 
EPI
LEP
08 
Su
m 
of 
Poi
nts 
EPIL
EP08 
Sum 
of 
Num
erato
rs 
EPILE
P08 
Sum 
of 
Deno
minat
ors 
EPIL
EP08 
Unde
rlyin
g 
achie
veme
nt 
En
gla
nd 
8,2
45 
8,22
9 
32,54
2.5 
308,53
7 
322,9
03 
95.6
% 
32,4
82.0 
307,
717 
323,2
51 
95.2
% 
44,2
69.8 
208,
267 
281,9
60 
73.9
% 
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14 Admissions as a direct result of epilepsy for East Kent 
 
 
 
PCT (registered) Eastern and Coastal 
Kent PCT       
          
Criteria Selection Summary 
          
          
Basket: Diagnoses - All Chapter: Nervous System Provider: East Kent Hospitals University NHS Foundation 
T... Diagnosis Group: Epilepsy, convulsions Subgroup: All 
Admission Type: All Admission Method Group: All Sex: All Deprivation: All Age Range: 
All   
Activity Mode: All Year of Tariff: Data Year Market Forces Factor: Appropriate to Tariff Year Analyse By 
(Secondary): ACS condition 
Spells: 12442 Day Cases: 279 (37.3%) First / Last: Apr-00 / May-12 LoS: - / - LoS 
(superspell): -/-   
          
          
Trend 
(Financial 
Year) 
Sp
ells 
Inpati
ents 
Day 
Cases 
DOSA 
Rate % * 
Total 
Bed 
Days 
Pre-op 
Bed Days 
Post-op 
Bed Days 
Excess 
bed days 
PBD
S ** 
 2000/01          
Convulsions 
and epilepsy 
79
6 759 37 66.70% 2,947 24 161 - 
1,83
6 
 2001/02          
Convulsions 
and epilepsy 
95
0 907 43 56.10% 3,822 107 270 - 
2,55
0 
 2002/03          
Convulsions 
and epilepsy 
87
9 867 12 52.40% 3,264 76 88 - 
2,06
7 
 2003/04          
Convulsions 
and epilepsy 
1,0
26 1,015 11 57.70% 3,409 118 174 - 
2,10
5 
 2004/05          
Convulsions 
and epilepsy 
93
3 926 7 44.40% 3,533 53 80 - 
2,43
8 
 2005/06          
Convulsions 
and epilepsy 
1,0
41 1,030 11 55.60% 4,000 31 84 865 
2,86
4 
 2006/07          
Convulsions 
and epilepsy 
98
6 975 11 61.10% 3,045 63 236 711 
2,01
8 
 2007/08          
Convulsions 
and epilepsy 
1,0
88 1,068 20 58.40% 2,986 145 844 628 
2,04
9 
     
 
   242 
 2008/09          
Convulsions 
and epilepsy 
1,0
10 998 12 61.50% 2,665 187 1,060 546 
1,85
5 
 2009/10          
Convulsions 
and epilepsy 
1,0
75 1,050 25 57.90% 2,653 245 1,328 614 
1,69
6 
 2010/11          
Convulsions 
and epilepsy 
1,1
43 1,107 36 71.60% 3,401 286 1,910 768 
2,29
4 
 2011/12          
Convulsions 
and epilepsy 
1,3
06 1,262 44 74.10% 3,282 263 1,867 674 
2,03
0 
 2012/13 (Apr & 
May only)          
Convulsions 
and epilepsy 
16
5 155 10 75.80% 361 21 164 - 201 
          
* Day of Surgery admission 
rate        
** Potential Bed Days Saved (the number of bed days that would have been saved if no patients stayed longer 
than the national average) 
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15 Locally Enhanced Service documentation to practices 
 
 
 
East Kent Coastal Teaching Primary Care Trust 
 
Local Enhanced Service for Epilepsy 
 
Service Level Agreement 
 
 
Contents 
 
1. Finance Details 
2. Signature Sheet 
3. Service Aims 
4. Criteria 
 
 
 
Finance Details 
 
In 2006/2007 each practice contracted to provide this service would receive the following 
‘QOF’ points: 
 
Questionnaire to all patients 
with epilepsy 
 
3 
Women with Epilepsy 4 
Driving 1 
Social 3 
Links to secondary care 4 
Total: 15 
 
Therefore an average practice would receive 15 x £124.60 = £1869 for full achievement. 
 
This LES is time-limited to 12 months from 1 April 2006. 
 
 
 
 
 
 
15.1.1.1.1.1 Note 
 
This contract may become invalid if the practice opts to close its list 
 
 
PAYMENT WILL ONLY BE MADE UPON RECEIPT OF PRACTICE SIGNATURE 
SHEET 
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Signature Sheet 
 
 
This document constitutes the agreement between the practice and the PCT in 
regards to this local enhanced service. 
 
 
Please name the doctor who will lead for epilepsy in your practice and tick to confirm 
that the basic training described below has been received. 
 
Name of GP Training attended 
(please tick)  
 
 
 
 
 
Signature on behalf of the Practice: 
 
Signature Name Date 
 
 
 
 
  
 
 
 
 
 
Signature on behalf of the PCT: 
 
Signature  Name Date 
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Background 
This local enhanced service is a step to improving the care of epileptic patients in the 
PCT area.   
Further developments are planned which involve the development of greater expertise 
and further services.   Updates to the practice register performed under this LES lay the 
foundations for future developments. 
The objectives set out in this agreement should be achievable by practises which have 
attended the mandatory basic training that is outlined below. 
Service Aims 
 
The aim of this local enhanced service is to: 
 Have a named doctor for each GP practice who will take the lead for epilepsy. 
 Enhance links with secondary care. 
 Begin the process of improving quality and appropriate use of resources. 
 Be of benefit to people with epilepsy. 
Mandatory basic training 
The GP who will be the practice lead for epilepsy must have attended the basic training 
that is provided as a prerequisite to providing this enhanced service. This is brief detail 
only, and should take only 1.5 hours. For those who wish to take epilepsy care further, 
these issues will be dealt with in greater depth later. 
The training covers: 
 Introductory video session: seizures,  
 Epidemiology of Epilepsy  
 Basic functional anatomy of the central nervous system     
 Overview of Epileptic Syndromes    
 Medical Treatment of Epilepsy  
 Some imaging techniques used to investigate epilepsy 
 Female Issues relating to epilepsy 
 Social Aspects of Epilepsy – Quality of life in epilepsy 
 Marriage Epilepsy and the family  
 Sudden unexpected death in epilepsy 
 Employment 
 Drivers'  licenses 
Criteria 
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This Local Enhanced Scheme has the following criteria: 
Development of templates 
Practice register 
Female issues 
Driving 
Links with secondary care 
Criterion One: Development of templates  
The practice should develop (or maintain if they already exist) templates for annual 
review of all patients [both paediatric and adult] with epilepsy.  
Criterion Two: Practice register  
The practice’s register must be kept up-to-date to show: 
 Medication, age and sex of patient (assume if patient on register these are 
minimum details retained) 
 Driving status  [target 90%] 
 Social Factors  [target 80% in year 1 and 90% in year 2] 
 Education issues for paediatric patients 
 Employment status (for links to social services) 
 Social circumstance e.g. lives alone, with family, etc. (as predictor of social 
morbidity 
 Safety issues e.g. bathing, cooking, etc. See Epilepsy Action’s leaflet on 
safety 
 Stigma (feelings about own condition, attitudes from others)                                                                                                                                  
 Patients who are currently under hospital care – Including the name of the 
consultant[s] they are under 
 List the patients whose medication is not being actively managed  
Criterion Three: Women with Epilepsy 
This section relates to all females aged 14 – 55 
Practices must: 
 Be conversant with the list of Anti Epileptic Drugs (AEDs) that interact with the 
Oral Contraceptive Pill (OCP) – as tabulated in the NICE guideline for epilepsy. 
[Target 100%] 
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 Ensure women are on appropriate contraception if required i.e. not on anti-
convulsant medication that interacts with ICP, etc.[Target 100%]  
 Offer folic acid (5mg) to women likely to become pregnant to help prevent neural 
tube defects and offer epilepsy action leaflet 
 Arrange pre-conceptual advice and provide Epilepsy Action Leaflet 
 Record method of contraception 
Criterion Four: Links with secondary care 
Practices must: 
● All known patients that have been seen [within the LES year] in A&E, as a result 
of a seizure need to be reviewed within 6 weeks and the trigger for the seizure 
assessed. If this is complex they should be referred to an appropriate service. 
[Targets Year 1 40%: Year 2 50%; Year 3 60%] 
● Ensure that changes to medication etc. suggested by secondary care at 
outpatient appointment are discussed and, on agreement, started with the 
patient. This could be in conjunction with a GPwSI in Epilepsy. 
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16 Patient Questionnaire used for the Locally Enhanced Service for Epilepsy 
Patient Questionnaire 
You are being asked to complete this questionnaire so that your GP may ensure that all 
relevant information is added to your records: If you need help completing this 
questionnaire please contact……………………………………... 
About your epilepsy 
1. Name:………………………………………………………   Age………………….. 
2. Male /Female 
3. When did you last see your GP in relation to your epilepsy?......................... 
4. Have you had any fits/seizures in the last 12 months?                Yes      No 
If yes please tell us the frequency of your fits/seizures (tick the one that best 
describes you) 
1 – 12 per year:     2 – 4 per month:      1 - 7 per week:      Every day 
5.   Have you attended Accident & Emergency (A&E) as a result of a fit/seizure within 
the last 12 months? 
  If yes have you been seen by your GP since then to review your epilepsy?  
           Yes      No 
6.   What medication do you currently take for your epilepsy? 
  
Medication Dose How many times 
a day 
   
   
   
  
7 Do you drive?        Yes      No 
8 Are you in paid employment?      Yes      No 
9 If not would you wish to be in paid employment?   Yes      No 
10 Do you live alone?       Yes      No 
11 Do you have someone you consider a carer?    Yes      No 
If yes please provide their name and contact number……………………………  
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…………………………………………………………………………………………. 
12 Have you been made aware of the safety issues with regards to epilepsy?      
Yes   No                                                                                                       
If no, would you like to receive more information regarding safety issues? 
13 Would you like to speak with someone with regard to your epilepsy? 
If yes; would you like medical advice?    Yes   No 
 From your GP?      Yes   No 
 From another GP who specialises in epilepsy?  Yes   No 
 From a specialist nurse?     Yes   No 
 Would you like emotional advice?    Yes   No 
14 Are you currently being seen by a hospital consultant for your epilepsy? 
Yes    No  
If yes; please provide consultant name ……………………………………. 
 Which hospital were you seen at?.................................................. 
 When did you last see the consultant?............................................ 
This question only applies to the care of children under 16  
15 Are you happy with the provision of help from your school with regard to your 
epilepsy? 
Yes     No 
The following questions only apply to females aged 14 – 55 
16   Are you taking a contraceptive pill?     Yes    No 
 If no: please state what method of contraception you are using……………  
               …………………………………………………………………………………… 
17    Have you received advice if pregnancy is a real possibility for you? Yes    No 
18    And did this include advice about taking a higher dose of folic acid? Yes    No 
 
 
Thank you for taking the time to complete this information. Please return your 
completed questionnaire to………………………………………………………………  
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17 Epilepsy Local Enhanced Service Monitoring Sheet     
      
Practice List Size @ 31.3.06  
Number of patients with Epilepsy  
Prevalence as % of practice registered population  
Practice Register  
Patients with driving status recorded  
Social Factors numbers of patients with recorded status of:  Education issues 
Employment status 
Social circumstance e.g. lives alone, with family, etc 
Safety issues e.g. bathing, cooking, etc. 
Stigma (feelings about own condition, attitudes from others) 
 
Number of patients currently under secondary care consultant  
And number with consultant name recorded 
 
Women with Epilepsy  
Run report from GP software system of all women aged 14 – 55 with epilepsy, showing all medications and 
recorded method of contraception 
 
      Links with Secondary Care  
Number of patients with epilepsy attending A&E in year  
Number of these reviewed within 6 weeks  
Number of onward referrals  
Of these number referred to GPwSI  
      Access to patient Information Leaflets  - 
       please provide evidence of ordering of leaflets through Epilepsy Action 
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18 Data obtained for Epilepsy Locally Enhanced Service from Practice A 
 
Monitoring Sheet for 2005-2006 
 
 Epilepsy 
   
 Practice list size 12891 
 Patients with Epilepsy:   107 
  #DIV/0! 
 Prevalence:   0.83 
   
Practice Register  
 Patients with medication, age and sex recorded: 107 
 Patients with driving status recorded: 57 
 Patients with Social Factors recorded: 57 
   
   
   
Female issues  
 Femail patients with epilepsy: 52 
 Of these, the number of child bearing age: 29 
 Child bearing age and offered folic acid: 2 
 Child bearing age and offered pre-conceptual advice: 0 
 
Child bearing age where any interaction between their anti-convulsive 
and contraceptive method has been checked 1 
   
   
Secondary care  
 Patients who are currently under hospital care: 34 
 Of these patients whose medication is being actively managed: 107 
 
 
 
 
 
Monitoring Sheet for 2006-2007 
 
 Epilepsy 
   
 Practice list size 13442 
 Patients with Epilepsy:   100 
  #DIV/0! 
 Prevalence:   0.74 
   
Practice Register  
 Patients with medication, age and sex recorded: 100 
 Patients with driving status recorded: 44 
 Patients with Social Factors recorded: 54 
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Female issues  
 Femail patients with epilepsy: 48 
 Of these, the number of child bearing age: 23 
 Child bearing age and offered folic acid: 7 
 Child bearing age and offered pre-conceptual advice: 1 
 
Child bearing age where any interaction between their anti-convulsive 
and contraceptive method has been checked 6 
   
   
Secondary care  
 Patients who are currently under hospital care: 20 
 Of these patients whose medication is being actively managed: ? 
 
 
Monitoring Sheet for 2007-2008 was returned blank 
 
 Epilepsy 
   
 Practice list size   
 Patients with Epilepsy:     
  #DIV/0! 
 Prevalence:   0.00 
   
Practice Register  
 Patients with medication, age and sex recorded:   
 Patients with driving status recorded:   
 Patients with Social Factors recorded:   
   
   
   
Female issues  
 Female patients with epilepsy:   
 Of these, the number of child bearing age:   
 Child bearing age and offered folic acid:   
 Child bearing age and offered pre-conceptual advice:   
 
Child bearing age where any interaction between their anti-convulsive 
and contraceptive method has been checked   
   
   
Secondary care  
 Patients who are currently under hospital care:   
 Of these patients whose medication is being actively managed:   
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19 Data obtained for Epilepsy Locally Enhanced Service from Practice B 
 
Monitoring Sheet 2006-2007 
 
 Epilepsy 
   
 Practice list size 13786 
 Patients with Epilepsy:   126 
  #DIV/0! 
 Prevalence:   0.91 
   
Practice Register  
 Patients with medication, age and sex recorded: 126 
 Patients with driving status recorded: 76 
 Patients with Social Factors recorded: 101 
   
   
   
Female issues  
 Femail patients with epilepsy: 61 
 Of these, the number of child bearing age: 25 
 Child bearing age and offered folic acid: 3 
 Child bearing age and offered pre-conceptual advice: 4 
 
Child bearing age where any interaction between their anti-convulsive 
and contraceptive method has been checked 4 
   
   
Secondary care  
 Patients who are currently under hospital care: 37 
 Of these patients whose medication is being actively managed: 37 
 
 
Monitoring sheet 2007-2008 
 
 
 Epilepsy 
   
 Practice list size 13985 
 Patients with Epilepsy:   124 
  #DIV/0! 
 Prevalence:   0.89 
   
Practice Register  
 Patients with medication, age and sex recorded: 124 
 Patients with driving status recorded: 88 
 Patients with Social Factors recorded: 96 
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Female issues  
 Female patients with epilepsy: 58 
 Of these, the number of child bearing age: 26 
 Child bearing age and offered folic acid: 3 
 Child bearing age and offered pre-conceptual advice: 6 
 
Child bearing age where any interaction between their anti-convulsive 
and contraceptive method has been checked 11 
   
   
Secondary care  
 Patients who are currently under hospital care: 11 
 Of these patients whose medication is being actively managed: 11 
 
 
 
 
Monitoring sheet 2008-2009 
 
 
 Epilepsy 
   
 Practice list size 14172 
 Patients with Epilepsy:   114 
  #DIV/0! 
 Prevalence:   0.80 
   
Practice Register  
 Patients with medication, age and sex recorded: 114 
 Patients with driving status recorded: 90 
 Patients with Social Factors recorded: 106 
   
   
   
Female issues  
 Female patients with epilepsy: 50 
 Of these, the number of child bearing age: 24 
 Child bearing age and offered folic acid: 2 
 Child bearing age and offered pre-conceptual advice: 7 
 
Child bearing age where any interaction between their anti-convulsive 
and contraceptive method has been checked 15 
   
   
Secondary care  
 Patients who are currently under hospital care: 19 
 Of these patients whose medication is being actively managed: 19 
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20 Approval to use pooled data from the Epilepsy Locally Enhanced Service in this 
study 
 
From: Dodds Peter (MAIDSTONE AND TUNBRIDGE WELLS NHS TRUST) 
Sent: 08 June 2012 15:53 
To: Chris Greener; Rogers Greg (EASTERN AND COASTAL KENT PCT) 
Subject: RE: Permission to use the summary sheet from the Epilepsy LES 
Dear Chris and Greg, 
I have confirmed my answer with a colleague: if the data is pooled data from which individual patients 
cannot be identified or indeed individual sets of data cannot be distinguished (or “unpooled”), there is no 
requirement for ethical or governance approval. It is always worth noting that you should refer to the 
Data Protection Act for any issues with personal data, but I suspect it will not come into play here. If you 
have any plans to examine the data in more detail, you should check again before proceeding. 
Best regards, 
Peter 
  
__________________________________________ 
Dr Peter F. Dodds 
RM&G Coordinator 
  
RM&G Consortium for Kent and Medway 
No. 6 The Courtyard 
Campus Way 
Gillingham Business Park 
Gillingham 
Kent, ME8 0NZ 
  
Temporary phone: 01622 227361 
Fax: 01634 262564 
e-mail:  pdodds2@nhs.net 
  
Please note new contact details. The telephone number is temporary. 
  
The RM&G Consortium for Kent & Medway provides services to NHS Kent and Medway, Kent 
Community Health NHS Trust, Medway Community Healthcare CIC, Kent & Medway NHS & 
Social Care Partnership Trust and South East Coast Ambulance NHS Trust  
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21 Locally Enhanced Service – Read Codes 
 
Epilepsy LES Mark 2 
 
 
Driving Status (I cannot find a read code that states does not drive, so maybe the questionnaire 
should be worded slightly differently) 
 
Patient advised about driving .8CAJ 
Patient advised not to drive .8CA8 
Motor Car driver .OI37 
Car Owner .13C7 
Has access to a car .13C8 
Has other personal transport .13C9 
Depends on public transport .13CB 
Driving license .6673 
 
 
Social Care 
I feel there are too many subsections of social care contributing to one overall target of 80%. 
This is open to practices doing as much or as little as they wish. Do all questions need to be 
addressed to fulfil the target, or only 1? 
 
Provision of education needs .800 (+ appropriate) 
Epilepsy impairs education .667J 
Epilepsy restricts employment .667G 
Epilepsy prevents employment .667H 
In employment .13JV 
Employment milestones .13J (+ appropriate) 
Housing dependency scale .13F (+ appropriate) 
Home safety advice .67IB 
Epilepsy associated problems .6674 (? Could use for stigma question) 
 
 
Secondary Care 
 
Seen in neurology clinic .9N1R 
  
 
Patients whose treatment who is not being actively managed 
How on earth do we find these other than a clinician wading through every patients’ notes?! 
 
Epilepsy treatment changed .6678 
Epilepsy treatment started .6679 
Epilepsy treatment stopped .667A 
 
Emergency Treatment 
 
Emergency epilepsy treatment since last appointment .667W 
 
 
Leaflets 
     
 
   257 
 
Epilepsy leaflet given .8CE7 
Epilepsy society member .13Y9 
 
 
Contraception (I wouldn’t be able to produce the sort of report you are asking for in the 
LES!!) 
 
Contraception .61 (+ appropriate) 
Pre conception advice .67IJ 
Folic acid advice – pre pregnancy .6760 
Over the counter folic acid therapy .8BP2 
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22 Epilepsy Locally Enhanced Service – Patient Questionnaire 
About your epilepsy      Surgery Number……………… 
 
Please tick the appropriate answers.                          
 
Name............................................................................................ 
 
Age: ......... Sex   ................ 
 
When did you last see your GP in relation to your epilepsy? ................................... 
 
Have you had any fits in the last 12 months?  Yes  No 
 
If yes do you have:- (tick the one that best describes the frequency of your fits) 
 
1-12 fits a year  
2-4 fits a month  
1-7 fits a week  
Daily fits  
 
What medication do you currently take for your epilepsy? 
 
Medication Dose How many times a day 
   
   
   
 
Do you drive?     Yes  No 
 
Are you in paid employment?    Yes  No 
 
Would you wish to be in employment?  Yes  No 
 
Do you live alone?    Yes  No 
 
Do you someone you consider a carer? Yes  No 
 
If yes, please provide their details 
 
Name ………………………………………     
     
Tel No…………………………………………… 
 
Are you aware of the safety issues with regards to epilepsy? Yes  No 
(e.g. bathing, cooking etc.)      
 
How would you like to receive more information regarding safety issues? 
 
…………………………………………………………………………….. 
…………………………………………………………………………….. 
 
Would you like to see someone with regards to your epilepsy? Yes  No 
 
If yes  
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Would you like medical advice?   Yes  No  
 
Would you like emotional advice? Yes  No 
 
Are you currently being seen for your epilepsy by a hospital consultant?  
 
Yes  No 
 
If Yes, which consultant   …………………………………….. 
 
            Which hospital      ……………………………………… 
 
 When did you last see the consultant   …………………………….. 
 
 
Only children under the age of 16 years need answer the question below. 
 
Are you happy with the provision of help from your school in regards to your epilepsy?  
 
Yes  No 
 
Only female patients of child bearing age need to answer the questions below. 
 
Are you taking the contraceptive pill?  Yes  No 
 
 
Have you been given advice about pregnancy? Yes  No 
 
Did the advice include taking folic acid?  Yes  No 
 
Thank you completing this questionnaire this will help us keep our records up to date and 
offer the best possible care to you. 
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23 Targeted Medicines Use Review for Epilepsy 
 
 
 
 
Epilepsy; Targeted Medicine Use Review,  in partnership with Boots 
 
 
Eastern and Coastal Kent PCT 
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 Executive Summary   
 
- This project seeks to improve the effectiveness of “Medicines Use Reviews” by community 
pharmacists  by focussing for one month on people with epilepsy. Using a ‘red flag’ template 
Community Pharmacists will be able to refer to Intermediate Care epilepsy services.  
- The red flags will include unscheduled admission to A&E in the previous 12 months, 
hazardous poor concordance, pre – natal teratogenic risk and uncontrolled seizure.  This 
will only apply to people who are currently not receiving specialist care and aims to reduce 
unscheduled admissions, improve medication adherence and improve the quality of life for 
people with epilepsy in Thanet . 
 
  
Cost Summary:   
 
Total non-
recurrent cost 
(£’000) 
Full year 
recurrent cost 
(£’000) 
Non-recurrent 
cost (2009/10) 
(£’000) 
Recurrent cost 
(2009/10) 
(£’000) 
Total cost 
(2009/10)  
(£’000) 
£2200  
 
   
 
Stages - Planned Completion Dates:   
 
Scope Design Select Implement Operate 
Feb 2011 April 2011 July/August 2011 4 weeks Sept to October 
2011 
 
Localities affected (mark with an ‘X’): 
  
Ashford Canterbury Dash Dover Shepway Swale Medway Thanet 
       X 
  
2. Evidence of Need  
Community Pharmacists are well placed to address this need as they deliver health care 
arguably the closest to people with epilepsy when they dispense the patients anti epilepsy 
drugs[ A.E.D.s] This provides the opportunity to ensure the patient is receiving appropriate care 
and they can identify high risk patients through the epilepsy MUR and where appropriate refer 
to Intermediate Care. 
 
1 If prescriptions appear to be requested too infrequently the NexPhase pharmacy 
dispensing software can alert pharmacists to this possibility and offer the patients a 
Epilepsy Focused MUR.  
2 Epilepsy nationally was found to be the 12th most common Healthcare Resource Group 
[HRG] for a patient to be admitted as an emergency in adults aged 16-74yrs in 2006/7  
and has a 28 day readmission rate of 12.7% which places it 7th highest disease likely to 
be readmitted. This suggests that current services are not effective at detecting such 
high risk patients and this project helps to address that need by identifying this patient 
sub group. 
3 For East Kent even a modest 3% reduction in hospital admissions over 24 months for 
epilepsy would release over £67,013 which would cover the cost of this project if rolled 
out across the PCT. 
4 Medicines Use Reviews are currently not organised to achieve the most effective 
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outcome as they are ad hoc and  tend to be taken up by already well informed and well 
managed patients. The Pharmacist sends a GP notification list each month and there is a 
risk of recommendations being lost in the paperwork. If a clinical problem is identified 
a copy or the MUR is sent to the registered GP but this tends to be in a format that is not 
particularily user friendly and still can passed over.  By allowing Pharmacists to refer 
directly within agreed parameters to Intermediate care the MUR becomes a dynamic 
and more effective tool in the hands of a very skilled and arguably currently under 
utilised pharmacist. 
5 Clinical confidence in the management of epilepsy will be enhanced by a day’s 
educational update in epilepsy for Pharmacists delivered through the Medway School of 
Pharmacy. Information leaflets on living in epilepsy provided by Epilepsy Action will 
be available for Pharmacists to use.   
6 The project looks to narrow the gap of health inequalities by identifying those at 
greatest need who currently for any reason are outside of the usual specialist health care 
provision. 
 
The MUR campaign will run for a Month [Sept to October 2011] and be repeated nine 
months later to review progress in this group and to re-enforce the educational and 
supportive elements delivered. It will be also an opportunity to review medicine 
concordance. Prior to this second campaign an educational half day will run for the 
Pharmacists involved to revise their epilepsy education. 
 
 
Outcomes and Benefits   
 
 
1 This project looks to reduce unscheduled emergency care for this group and to reduce 
the A&E Admission and Re-admissions principally at the QEQM Hospital. 
2 The community pharmacy team are highly trained and dedicated health care 
professionals who currently contribute a great deal to supporting people with epilepsy 
however this project looks to maximise this contribution. If successful it may be a 
model that could be applicable to other long term diseases. 
3 We would expect to see people identified who are at high risk of emergency admission 
and on going seizures. At the end of the project it will be possible to assess if this group 
have benefited by reviewing admission rates, seizure freedom rates, and concordance 
estimations. 
4 Pre-Natal women who have been identified as being at risk  from teratogenic regimes 
will also be referred to a specialist community clinic. 
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4. Delivery 
 
This section outlines (a) the changes we expect to put in place in order to achieve the above 
outcomes and benefits - and (b) the plan and approach we will use in order to deliver these 
changes. 
 
4.1. Expected changes   
 
GPs will need to welcome community pharmacists as partners to feel confident in their ability 
to refer patients who appear to have red flag symptoms [as per template] to Intermediate Care. 
This applies only for people who are currently not under specialist epilepsy services. By 
offering referral rights to pharmacists this is a significant move into bringing pharmacists under 
the Primary Care Team and paves the way, if successful, to closer working and collaboration 
between the two groups.  
 
The communication routes will be simple non IT based initially and will involve a copy of the 
medicines use review and also where applicable a copy of the pharmacists referral letter to 
Intermediate Care. This will highlight the area of concern that the pharmacist has for the person 
with epilepsy.  
 
Another arm of this project is to explore how public – private partnership can be utilised aid to 
improve the healthcare and indeed the public health of the community. Working in partnership 
with Boots will allow a co-ordinated campaign and benefit from Boots expertise in marketing 
the scheme to it’s customers. Bringing care even closer to the patient will inevitably require 
closer collaboration with the ‘high street’ and given Boots excellent relationship with the NHS 
is a very appropriate partner to work with. 
 
The pilot will enlist the help of the Kent and Medway R&D Department and the Institute of 
Neurology in the pilot evaluation. 
 
 
4.2. Plan and approach     
 
Scope Design Select Implement Operate 
Feb 2011 April 2011 July/August 4 weeks Sept/October 
2011 
 
Key dependencies for this project are as follows : 
 
Other project/activity Lead Description of dependency 
Discovering how best 
to explore public – 
private working to 
improve community 
healthcare 
Minakshi Odedra  Boots pharmacy chain willing to advertise the 
epilepsy awareness campaign and use their 
marketing skills to reach the patient target group. 
Secondary Care 
Specialist providers for 
epilepsy 
Greg Rogers Ensure care pathways are clearly identified and 
relationships well maintained to ensure seamless 
care for people with epilepsy 
Epilepsy Specialist 
Nurses 
Greg Rogers and 
Minakshi Odedra 
Ensure care pathways are clearly identified and 
relationships well maintained to ensure seamless 
care for people with epilepsy 
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GPs Greg Rogers and 
Minakshi Odedra 
Ensure care pathways are clearly identified and 
relationships well maintained to ensure seamless 
care for people with epilepsy 
   
   
 
4.3. Expected non-recurrent cost   
 
Key elements of non-recurrent cost expected for this project are as follows: 
 
Cost Item Brief description Cost (£’000) 
Locum Pharmacists 
costs 
Pharmacist locum costs for training 8 Thanet 
Boots pharmacists 
£2,000 
Training facilities Medway School of Pharmacy First Training 
Day 
£200 
 Medway School of Pharmacy follow-up 
Training Half Day 
£150 
   
   
   
   
   
   
   
   
   
Total non-recurrent cost £2350 
Non-recurrent cost (2009/10)  
 
Expected breakdown of non-recurrent cost by Stage: 
 
Scope (£’000) Design (£’000) Select (£’000) Implement (£’000) Operate (£’000) 
£2350    £2350 
 
 
4.4. Expected Staffing 
  
Key roles required to deliver the project  
 
Role Name Overview of role and time commitment 
     
Pharmacists Thanet 
Pharmacies 
Invited to participate in the scheme 
Boot’s Pharmacists 8 Boots 
Pharmacists 
Thanet 
To be available to implement  the epilepsy MURs 
during the 4 weeks trial with expertise on media 
management offered by Boots 
 
GP Lead Greg Rogers To provide the training for the pharmacists and 
clinical oversight of scheme 
Pharmacist Lead Minakshi Odedra To co-ordinate the pilot with Greg Rogers 
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Pharmacy Academic 
Lead 
Trudy Thomas To ensure the pilot is in line with current pharmacy 
development plans for the DH and ensure design is 
both able to deliver the necessary information to 
future commissioning and is deliverable 
   
 
5. Ongoing Operation 
 
This section outlines what it will take to run the services which this project will deliver, on an 
ongoing basis 
 
5.1. Expected recurrent cost   
 
Key elements of recurrent cost expected for this project are as follows: 
NB-  
 Arguably patients identified with red flag symptoms of epilepsy will merit referral to 
specialist care whether the scheme in operation or not and this cost is hard to identify. 
 Medicines use reviews are currently already funded by the PCT  
 
 
  
5.2. Workforce expectations 
  
Key additional workforce expected in order to operate the proposed service(s) are as follows: 
 
Role type Brief description of requirement Expected 
WTEs 
Epilepsy GPwSI To take referrals for red flag patients identified by 
Community Pharmacists 
 
   
   
   
 Not Applicable  
   
   
   
   
   
   
   
 
 
6. Risks 
  
Key risks and proposed mitigating actions are as follows: 
 
Risk and implications Brief description of mitigating actions 
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Un-coordinated campaign Look to Boots expertise in sales and marketing to 
help devise a well constructed plan 
Lack of expertise in Pharmacy team Will provide appropriate training ahead of the 
project in the Medway School of Pharmacy 
Overload the Intermediate Care Team - 
Thanet 
Unlikely to be a problem as there is ample 
capacity at present and GPwSIs from outside of 
Thanet can be drafted in if required to Thanet 
clinics 
Complaints of equality of care from people 
with epilepsy in other localities in East Kent 
 Evaluate the pilot quickly to assess size of the 
problem of unmet need and to estimate feasibility 
for roll out. Findings will be available at 
completion of pilot for wider dissemination   
Daily and weekly pharmacy workload To ensure there is protected time for doing the 
epilepsy MURs 
  
  
  
  
  
  
  
 
Assumptions   
 
Please list any assumptions upon which the estimates, etc. detailed in this document have been 
developed: 
 
1 Unmet need exists for people with uncontrolled epilepsy 
2 Proactive care will require less resource than reactive emergency care for epilepsy 
 
Stakeholder Engagement and Sign-off   
 
Stakeholder engagement undertaken in defining this project is outlined below: 
 
Stakeholder Group Overview of engagement.  Signed-off?** 
(Y/N) & date 
PBC Greg Rogers to discuss with Thanet PBC group and 
Medway Consortia 
 
Epilepsy Action Greg Rogers to liaise with Epilepsy Action in the scoping 
and design of the project as well as the outcome 
 
Community 
Pharmacists in Thanet 
Via the “Local Pharmacy Forum” and via direct invitation  
Pharmacy Academia Meet with Trudy Thomas from the Univ of Kent school of 
pharmacy and ensure the pilot outline concords with 
current guidelines for medicines use review and will be in 
the direction of travel for emerging pharmacy 
developments 
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** - Meaning approved in principle.  A formal pen and ink signature is not required 
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24 Attachment 1 – Project Plan and timeline 
 
  
Project Plan and timeline for Thanet QIPP Project Proposal for Epilepsy; Medicine Use 
Review campaign  
 
April 2011 – Meeting with Cheryl Clennett 
April 2011 – Agree on training day and flyers 
April 2011 - Greg Rogers and Minakshi Odedra to meet with GP Consortia 
April 2011 – Greg Rogers to meet with Prof. Shorvon  
April 2011 – Greg Rogers to meet with Neurologist 
May 2011 – Send out flyers to all Thanet pharmacies 
May 2011 – Response from all pharmacies by end of May 
August 2011 – Full day training at Medway School of Pharmacy 
September 2011 – 4 weeks pilot 
 
March 2012 – Refresher training at Medway School of Pharmacy 
April/May2012 – Re-run pilot for 4 weeks 
May/June 2012 – Disseminate findings with all stakeholders 
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25 Referral form used by Pharmacists to the GPwSI service for epilepsy 
 
Please fill in all sections of the referral form and email to 
bethesda.secretary@nhs.net  
or send to the;  
Epilepsy Centre, 
Bethesda Medical Centre,  
Palm Bay Avenue,  
Margate  
Kent.  
CT9 3NR 
Tel 01843 209342  
Fax 01843 209301 
  
 
PATIENT  DETAILS 
Patient details: 
 
 
Please attach label or enter patient’s Name , 
Address and D.O.B. 
 
 
 
 
Pharmacist; 
 
Pharmacy Address; 
 
 
 
Registered GP: 
 
Patient telephone no: 
 
NHS no: 
 
Date: 
 
 
 
Referral Guidance: 
  
1 All referrals must be 16yrs and over with established epilepsy. 
2 Referrals will be triaged by GPwSI clinical lead 
3 Patients are currently not under specialist epilepsy care 
 
 
Reason for follow up in Primary Care Scheme: 
 
1. Emergency admission to A&E or treatment by Paramedic Ambulance Service within 
the past 12months 
2. On-going seizures / worsening seizures.  
3. Pre-natal hazard identified in women receiving medication which is potentially 
teratogenic. 
4. Hazardous poor concordance of medication [taken as being estimated as less than 80%] 
  
 
 
 
 Patient Questionnaire Pre and Post Epilepsy Targeted MUR 
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26 Pre-MUR questions 
Please tick one box for each question 
1. How do you rate your understanding of the causes of epilepsy? 
    
Excellent I can tell you in detail why and how epilepsy occurs 
 
  
    
Good I have a reasonable idea of why and how my epilepsy occurs 
 
  
    
Satisfactory I have a rough idea of why and how my epilepsy occurs 
 
  
    
Poor I don’t really understand why and how my epilepsy occurs 
 
  
 
2. How confident are you that you know how to lessen the chance of having a seizure? 
    
Very 
Confident 
I can tell you in detail how I could lessen my chances of having a seizure   
    
Confident I have a reasonable idea of how I could lessen my chances of having a seizure   
    
Not very 
confident 
I have some idea of how I could lessen my chances of having a seizure   
    
Very 
unconfident 
I don’t know how I could lessen my chances of having a seizure   
 
3. Before today, have you thought about consulting your pharmacist for advice about your epilepsy? 
    
Frequently I consult my pharmacist regularly about my epilepsy 
 
  
    
Now and 
again 
I have occasionally consulted my pharmacist about my epilepsy   
    
Rarely I haven’t really thought about consulting the pharmacist about my epilepsy   
    
Never I have never thought of consulting my pharmacist about my epilepsy   
 
After-MUR questions 
Please tick one box for each question 
1. How do you rate your understanding of the causes of epilepsy? 
    
Excellent I can tell you in detail why and how epilepsy occurs 
 
  
    
Good I have a reasonable idea of why and how my epilepsy occurs 
 
  
    
Satisfactory I have a rough idea of why and how my epilepsy occurs 
 
  
    
Poor I don’t really understand why and how my epilepsy occurs 
 
  
 
2. How confident are you that you know how to lessen the chance of having a seizure? 
    
Very 
Confident 
I can tell you in detail how I could lessen my chances of having a seizure   
    
Confident I have a reasonable idea of how I could lessen my chances of having a seizure   
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Not very 
confident 
I have some idea of how I could lessen my chances of having a seizure   
    
Very 
unconfident 
I don’t know how I could lessen my chances of having a seizure   
 
3. After today, how likely are you to consult your pharmacist for advice about your epilepsy? 
    
 Very likely 
 
  
    
 Quite likely 
 
  
    
 Unlikely 
 
  
    
 Very unlikely 
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27 Information sent to Pharmacists taking part 
 
 
 
 
 
 
 
 
Medicines Use Reviews for People with Epilepsy: 
Pilot Project 
 
 
 
Pilot Information and Resource Pack for Pharmacists 
Dear Pharmacist 
Thank you once again for taking part in the training for this pilot project and for agreeing to 
undertake MURs for people with epilepsy. 
This pack describes the next steps in the project and provides some resources so you can start 
carrying our MURs for people with epilepsy. 
This pack includes 12 resources. We include 20 copies of all resources marked * These will 
also be sent electronically to the email address you supplied to us at the end of the training day. 
If you require more hard copies please contact Tracy Joseph at the School of Pharmacy on 
t.joseph@kent.ac.uk 
Resource 1: A list of some commonly used drugs used in epilepsy to assist computer search 
Resource 2: Sample letter –You need to adapt these letters by printing onto your own headed 
notepaper and adding your own details. You can either send these out to patients who you 
identify through the search or give them to patients when they are in the pharmacy. Please feel 
free to use your own letter. However you must give patients who you wish to include in the 
pilot a patient participant information sheet. We are not supplying hard copies of this letter but 
it will be sent electronically to the email address you supplied at the end of the training day. 
Resource 3* and 4*: Copy of patient participant information sheet (Resource 3).  All patients 
taking part in the pilot must have an information sheet and complete the consent form and pre-
MUR questions (resource 4). 
A word about patient consent. We cannot use any patient data for this project (even if it is 
anonymous)  without patient permission. Patients who do not consent for their data to be shared 
must still be offered an MUR in exactly the same way, however we can’t include them in the 
project. 
Patient pre-MUR questions appear on the reverse of the consent form. You will recognise the 
questions as similar to the ones that you completed yourself before your training. We are using 
these simple questions (and a similar after-MUR set) to try to assess the ‘added value’ of the 
MUR.   
However as you will see later we have also incorporated then into the MUR and we think it will 
be useful for you to see the patient’s answers before your start the MUR.  If patients do not 
want to complete them, just record this on the form.  
These can also be sent to you electronically as pdfs if you wish to print out your own copies 
Resources 5 and 6: Sample MUR form and suggested ‘script’. As you know I was anxious at 
the training day that the evaluation of this service would not involve extra paperwork for 
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yourselves. We think that we have found a way to include the extra pilot only ‘check for 
referral’ questions into the MUR and this way the data will get captured on the MUR form as 
you go along. After the training day Greg and I worked though an epilepsy MUR and tried to 
see where the questions would come ‘naturally’ and so where the information would go on the 
form. The result is this sample form and suggested script. This is only a suggestion! You will 
no doubt develop your own words when delivering this service. As long as the pilot referral 
questions are recorded on the MUR form, then you only need to send us that form for 
evaluation. If a patient is referred to Greg, you will complete the referral form (resource 8) and 
we will have a copy of that (via Greg). However many patients will not be referred and the fact 
that you have asked the questions and have a reason for not referring needs to be captured.  
Resource 7: How to do Greg’s assessment of adherence. We need you to do this each time you 
do an MUR and record it on the MUR form.  
Resource 8*: Referral form. We have made some amendments to this since the training session, 
so please use this most recent version.  
Resource 9: Algorithm for referral 
Resource 10*: After-MUR question sheet. Please ask patients who have undertaken an MUR to 
complete this as soon as they have finished the consultation. You should attach it to the consent 
form/pre-MUR question sheet 
Resource 11 and 12: Participant information sheet and consent for you. Remember I threatened 
you with some qualitative analysis to capture your views on this pilot project. We are planning 
to run a focus group after you have done your MURs. Details about what this entails, the date, 
time etc are included here. If you are interested in taking part, then please read the Pharmacist 
Participant information sheet and complete the Pharmacist consent form and return it to Trudy 
at the University in the pre-paid envelope. 
If you have any questions, comments, suggestions, worries or just want to chat, please get in 
touch with either Trudy or Greg – details below. 
We hope you are really excited about taking part in this project. The eyes of the pharmacy and 
epilepsy world are on us (so no pressure there). We really hope that you enjoy trying out your 
new skills and knowledge and we look forward to hearing how it went after the event.  
Good luck 
 
Trudy and Greg 
Trudy Thomas  
t.thomas@kent.ac.uk 
01634 883176 
 
Greg Rogers 
Email greg.rogers@nhs.net 
Phone 01843 209342 
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What to do next 
Familiarisation 
 Read through this resource pack and familiarise yourself with everything that is here. 
Complete the Pharmacist consent to take part in focus group form and return to Trudy 
if you would like to be involved in this aspect of the project 
 
Identify Patients for MUR 
 Carry out a search on your pharmacy computer to identify patients over the age of 16 
with epilepsy. Resource 1 may be helpful here 
NB if you notice that there are a number of patients with the same address, consider 
that this may be a learning disability care home. We recommend that you do not send 
letters to each patient, but contact the home manager directly and discuss carrying out 
MURs for this group of patients.  
 Adapt patient invite letter (resource 2) adding your pharmacy address and other 
details 
 Send letter to identified patients 
 
Practice MUR 
We suggest you do a ‘mock MUR’ to practice the flow you want to adopt to best carry out the 
MUR and incorporate the referral questions 
 
Epilepsy MURs (for real) 
These can be carried out from  15th September 2011 to 15th October 2011.  
For each MUR 
 Establish whether the patient is happy to take part in the pilot project by collecting 
their signed consent form and completed pre-MUR questions – if they do not want to 
take part, the MUR can go ahead as usual 
 For patients that do consent, add the extra information required by this project eg 
consultant details, adherence check (see resources 5 and 6)  
 Complete MUR referral form if referral needed 
 At end of MUR ask patient to complete the after-MUR questions 
 Attach pre-MUR questions and After-MUR questions for that patient together using a 
staple. Place into large envelop provided to be returned to Trudy at end of project 
 
Paperwork after a pilot project MUR (where patient consent given) 
 Give patient a copy of their MUR as normal 
 If referring to Greg – send copy of MUR form and referral to Greg at address indicated 
on referral form 
 If not referring  - send copy of MUR form to patient’s GP (only if deemed necessary). If 
you are referring to Greg this isn’t necessary as Greg’s secretary will contact the 
patient’s GP.  
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 Print off anonomysed copy of the completed MUR form and store in large envelope provided. 
This should be returned to Trudy at end of project period. 
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28 Resource 1 – List of drugs commonly used in Epilepsy 
This list may be useful in helping you to search your computer records to identify adult 
patients with epilepsy. It is not exhaustive. Please be mindful that many of these drugs are used 
for other conditions. We have added a caveat to our sample letter, saying we recognise that 
patients may not be taking these medicines for epilepsy, but offering those people an MUR 
anyway. (Time to brush up on your knowledge of neuropathic pain too perhaps?) 
Carbamazepine (Tegretrol/Tegretol Retard) 
Clobazam (Frisium) 
Clonazepam (Rivitril) 
Gabapentin 
Keppra 
Lamictal 
Lamotrigine 
Levetiracetam (Keppra) 
Neurontin 
Oxcabazepine (Trileptal) 
Phenytoin (Epanutin) 
Phenobarbital 
Topiramate (Topamax) 
Valproate (sodium) (Epilim) 
Vigabatrin (Sabril) 
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29 Resource 2 – Sample letter for patients 
Pharmacy headed notepaper or address 
 
Date 
Dear xxxxxx 
I am writing to invite you for a medicine use review (MUR). The MUR is an NHS service and 
is free of charge.  An MUR is a consultation in the pharmacy which lasts about 15 minutes and 
gives you the opportunity to chat to a pharmacist (chemist) about how you can get the best out 
of your medicines. You can ask any questions you want and discuss in confidence any 
medicine related worries or issues.  
You have been asked specifically at this time because you take medicines which can be used by 
people with the condition epilepsy. However we realise that these medicines can be used for 
lots of different conditions, including chronic pain and you may not have epilepsy. If you do 
not take medicines for epilepsy, but would like to talk to the pharmacist about these or any 
other medicines you take please feel free to contact the pharmacy and book an appointment for 
an MUR. 
For people who do take these medicines for epilepsy, we are offering MURs linked to a pilot 
project in Thanet. The project which starts in September and runs for one month enables the 
community pharmacist not only carry out an MUR, but if necessary, refer the person with 
epilepsy directly to a doctor who specialises in this condition. This project is being run in 
conjunction with the charity Epilepsy Action and has come about because research has shown 
that many people with epilepsy would benefit from talking to someone about their medicines. 
Many people may be having seizures unnecessarily.  
The enclosed leaflet tells you about the epilepsy project. If you decide to take part in this 
project you will be asked to answer 3 straightforward questions before you come for the MUR 
and 3 related questions after the MUR. The before-MUR questions are included with this letter. 
If you agree to take part this will also mean that information on the form filled in at your MUR 
can be analysed by a team from the Medway School of Pharmacy (University of Kent) and the 
Thanet Consortia (the health body for Thanet). The form will be anonymous; only you and the 
pharmacist will see your name and address. 
If you do not want to fill in the questions and/or share the anonymous information of the form, 
that isn’t a problem, you can still have an MUR with the pharmacist. Just let the pharmacist 
know that you do not want to be part of the project. 
What happens next? 
If you would like to book an MUR please ring XXXXX (Pharmacy name) on XXXXXXX 
(pharmacy number).  
If you are happy to take part in the pilot project, please bring your completed 3 questions and 
the attached consent form with you. (The pharmacist will have spares if you forget or change 
your mind). 
We hope that you will be interested on having an MUR and helping the Thanet Consortia to 
help people with epilepsy in Thanet. 
Yours sincerely  
 
 
 
Pharmacist 
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30 Resource 3 
Participant information Sheet – to be given to all people who may undertake an MUR 
Information for patients 
 
 
Medicines Use Reviews (MURs) for People with Epilepsy: 
A Pilot Project 
 
 
 
Your pharmacist has asked you to visit the pharmacy for a medicines use review (MUR). The 
MUR is an NHS service and is free of charge.  You have been asked specifically at this time 
because you take medicines which can be used by people with the condition epilepsy. Please read 
this leaflet carefully. It will hopefully answer some of your questions. If there is anything that 
isn’t clear in this leaflet, or if you would like more information, or would like to talk to someone 
about the project please feel free to contact us. Our details are on page 3 of this leaflet. 
 
Why is this project being carried out? 
Epilepsy is the most commonly occurring serious neurological condition in the UK. It affects 
around 380,000 people in England and Wales. The good news is that with the right treatment 
around 70% of people with epilepsy could be seizure free. The not so good news is that despite 
the development of many new and effective medicines for epilepsy, many people have continue 
to have seizures and a poor quality of life. Thanet has a higher than average incidence of epilepsy. 
In recent years however there have been a number of local initiatives to try to help people with 
epilepsy, including the training of general practitioners (GPs) who have a special interest in 
epilepsy. The new health organisation for Thanet (the Thanet Consortia wants to improve further 
the care of people with epilepsy and has now trained some pharmacists (chemists) in this 
condition too. 
 
What is this project about? 
In this pilot project these specially trained pharmacists will carry out medicines use reviews 
(MURs) with people with epilepsy who get their prescriptions dispensed at that pharmacy. An 
MUR is a pharmacy based consultation available free of charge of the NHS. It lasts about 15 
minutes and is designed to help people get the best out of their medicines. In an MUR you can 
ask any questions you want and discuss, in confidence, any medicine related worries or issues. 
At the moment anyone who takes regular medicines can have an MUR at their local pharmacy. 
In this project, the pharmacists will be particularly focussing on people who take medicines for 
epilepsy. The pilot project will run for one month, starting in September 2011. During this month, 
the specially trained pharmacists will be able to refer people directly to the Thanet GP with a 
special interest in epilepsy, if this is appropriate. After the project has finished, the results will 
be used to develop local services to help people with epilepsy. 
 
 
 
What do I have to do? 
If you would like to talk to your pharmacist about your medicines, simply ring the pharmacy to 
book an appointment. If you are happy to take part in the pilot project, then you need to consent 
to take part. This means confirming that you have read and understood the contents of this leaflet 
and that you are happy for a copy of your MUR (without your name and address on it) to be 
shared with the Thanet Consortia and a small project team at Medway School of Pharmacy who 
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will analyse the project results on behalf of the Consortia. You confirm your consent by 
completing the enclosed consent form and answering the 3 questions on the reverse of the sheet. 
You need to take this form to the pharmacy with you when you go for your MUR. The pharmacist 
will have spare copies. 
 
Do I have to take part in the pilot project? 
It is entirely up to you. You are free to change your mind at any time, without giving a reason. 
This would not affect the standard of care that you receive. If you don’t want to take part, you 
can still have an MUR with the pharmacist if you would like. 
 
Who to Contact about this project 
You can get information from; your pharmacist whose details are listed in the covering letter 
with this leaflet  
Thanet Consortia - name 
The team at the School of Pharmacy is headed up by Trudy Thomas. She can be contacted 
via 01634 883150 you can write to her at t.thomas@kent.ac.uk 
 
If you would like to talk to someone impartial about taking part in research like this, you can 
contact the epilepsy charity, Epilepsy Action on XXXXXXXXX 
Of course you can always speak to your GP, nurse or consultant. 
 
What happens if I get referred to the Primary Care Epilepsy Service? 
If you are not already under the care of a specialist and the pharmacist thinks it is appropriate, he 
or she will complete a referral form and refer you to an accredited GP with a Special Interest in 
Epilepsy. This GP’s secretary will offer you an appointment. These consultations will normally 
take place at the Bethesda Medical Centre in Cliftonville. Your own GP will also be notified. 
 
What happens after the project ends? 
The Medway School of Pharmacy team will review the results and write up their findings and 
make recommendations to the Consortia. You can be sent copies of any aspect of the research 
that you are interested in. No part of the research that is written up will have any personally 
identifiable information included.  
 
Are there any risks/disadvantages in taking part? 
No 
 
What are the advantages of taking part? 
Understanding more about your epilepsy and the medicines you take can help you manage the 
condition better.  
 
What if there is a problem? 
Any complaint about any aspect of the project can be made to the Medway School of Pharmacy 
or the NHS.  
 
Medway School of Pharmacy 
University of Kent 
Anson Building 
Central Avenue, Chatham Maritime. 
Kent ME4 4TB 
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Resource 4 – Consent form with Pre-MUR questions 
Resource 5 – Sample MUR form 
Resource 6 – Helpful words to use in your MUR and how to record the Thanet referral 
questions on the MUR form 
Hello Ms Twist 
My name is X and I am the pharmacist here at Y Pharmacy 
You have been invited to the pharmacy today so that we can have a chat about your medicines. 
Can I just check that you have had a leaflet about the pilot project being run in Thanet in 
association with the charity Epilepsy Action. Hopefully the leaflet explained the session today. 
Is there anything you would like to ask me about anything that you read? I’d also like to ask 
whether you are happy to have the information that I gather today used (without your personal 
details on) to see how useful the project has been. 
Be prepared to explain again if necessary. 
Assuming patient agrees 
You are? That’s great. Can I just collect your completed consent form. Now on the back of that 
form there were some questions which we will come to in a minute. 
We have got about 15 minutes together today for this medicines use review (MUR). Obviously  
the focus is going to be the medicines you take for epilepsy, but we may need to look at some 
of the other medicines you take as well if they are relevant to your epilepsy. Is there anything 
else specifically to do with any of the other medicines that you would like to discuss today? 
Include in MUR if they do 
Now the first thing I am going to do is confirm your details 
Checks name/address and DOB 
Now I want to ask you a little bit about your epilepsy. How long have you had epilepsy?  Do 
you know what type of epilepsy you have? 
RECORD ON MUR FORM – in comment section (make note if not known) 
Now one of the pre-MUR questions asked you about the causes of epilepsy? How did you rate 
your understanding? 
Use answer to guide where conversation goes next? 
a] If they know what type of epilepsy they have e.g. temporal lobe epilepsy or frontal lobe 
epilepsy  you can go on to discuss their seizures using the diagram of the brain in Seizures 
Explained. If they know they have generalised epilepsy this also is included toward the end of 
the booklet. The dialogue could progress something like, “I wonder do you know where your 
temporal lobes are? Don’t worry - a lot of people don’t. I have this great leaflet here (Seizures 
Explained) – RECORD GIVEN ON MUR FORM) which shows you just where the temporal 
lobes are. Sometimes the bit of the brain with the faulty wiring can be as small as a full stop on 
a page. This booklet also explains the sorts of things that people with your type of seizure can 
experience – does any of this sound familiar?” (shows appropriate page of Seizures Explained 
book) 
b] If they do not know what sort of epilepsy they have and I would imagine most will not, then 
explain how part of the brain is more prone that it should be to send out nerve signals. The 
medication acts to settle this down and make it behave more normally. In a sense it is  ‘faulty 
brain wiring’,  
Now the questions also asked about preventing seizures. Do you know what sorts of things 
trigger a seizure for you? 
Right so you have obviously worked out quite a few things that do. There are a few more in this 
leaflet too. Sometimes if you are having quite a few seizures it is worth keeping a diary. How 
about you – do you have regular seizures? For example when was the last time you had one? 
Did you have to go to A&E or was a paramedic called? Have you ever been taken to casualty or 
had a paramedic called? When was the last time? How would you say your seizures are now 
compared to say a year ago? Less frequent, about the same, or more frequent RECORD 
ANSWER – CONSIDER REFERRAL and explain this 
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Who do you see about your epilepsy? Do you see a consultant at the hospital? RECORD 
ANSWER IN SECTION OF MUR FORM UNDER GP DETAILS – see algorithm 
Let’s now look at your medicines. Can you tell me which ones you take for epilepsy from your 
list? So let’s start with the first one, Tegretol EC. Can I ask how often you take those each day? 
When in the day exactly do you take them?  
Goes through each of epilepsy medicines in turn 
Now some epilepsy medicines are not great to take if you are pregnant. We ask all ladies 
whether there is any possibility of them being pregnant or if they are contemplating becoming 
so in say the next 5 years. RECORD ANSWER UNDER AGE ON MUR FORM – CONSIDER 
REFERRAL IF PREGANT OR PLANNING – Consider giving appropriate Epilepsy Action 
leaflet as well. Can I just confirm whether you use a method of contraception because 
sometimes people get the pill from somewhere other than their doctor and we don’t always 
have it recorded. 
Check adherence with all AEDs using the Greg Roger’s adherence – ometer – see resource 7 
Calculate  adherence and act as shown  
<80% - If they are under specialist care already REFER to usual consultant (this will have to be 
via GP). If they are not under any specialist epilepsy care offer them a refer to Greg and the 
intermediate care epilepsy service, using the referral form 
80-90% - INVESTIGATE/ADVISE. Ok that’s not bad, but you are still missing quite a few – 
can we have a think about why that might be, because missing these medicines could mean a 
seizure and seizures can be dangerous, so we like to reduce the number people are having to 
none if possible! – GIVE A LEAFLET ON SAFETY IN EPILEPSY IF NOT GIVEN 
ALREADY 
90% PRAISE + ENCOURAGE. That’s not bad – is there anything we could do to make it even 
better? 
98-100% PRAISE ++ 
RECORD ADHERENCE ON MUR FORM in comments section. It may well appear in action 
section too 
One of the things we always ask at these reviews is about other medicines that you take from 
anywhere else? Hospital, dentist, clinic? Do you buy any medicines over the counter? This 
includes eye drops, inhalers, creams and ointments. What about herbal or homeopathic 
medicines or anything of the internet? I also need to ask if you smoke? Do you drink alcohol 
and if so much and I have to ask about recreational drugs? RECORD AS APPROPRIATE ON 
MUR FORM 
Now we have got about 2 minutes left of our time: is there anything you would like to ask me 
about the medicines we have talked about or anything else to do with your medicines or your 
health? 
Just to summarise – goes over main points – confirms referral to GPwSI (if appropriate) and 
how MUR forms are to be used (1 to patient, 1 to Greg with referral – who will notify patient’s 
GP and anonymised data to University for analysis 
Finally can I just ask you to complete 3 questions before you leave – gives after MUR form 
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31 Resource 7 – How to do Greg’s Adherence Check for medication taken for epilepsy 
Possible words: Now we all know that people often miss a tablet if they have been taking them 
for a long time. If we consider all your regular epilepsy medicines together.......Let’s think 
about the doses you take in the morning – you have three to take in the morning don’t you? On 
a good week how many of those tablets do you take?  Gives score out of a possible 21 (in this 
case). Put score in table below. So what about on a bad week in the morning? – So you pretty 
much always take those. That’s good.  
Let’s move to the lunchtime doses. You only take 1 tablet at lunchtime. Right so even on a 
good week you miss occasionally? What about the bad week ?– So sometimes they all get 
missed at lunchtime?  
Evening doses – again you take 3 tablets at night – good week? – all of them – bad week? So 
perhaps one evening missed. Right let me calculate your percentages using my trusty 
calculator...... 
 
 Good week Bad week total prescribed/week 
Am 21 21 21 
Lunchtime 5 0 7 
PM 21 18 21 
Total taken 47/49 39/49 49 
percentage 96% 80%  
 
Shows patient 
So on a good week you are really hitting the target, but on a bad week that put you in the ‘not 
so good/could be better’ category. Let’s look at those lunchtime doses again........ 
Pharmacist explores 
NB This patient would not be referred to Greg on adherence alone. 
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32 Letter from Department of Health 
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33 Training with Pharmacists before MURs 
Proposed Outline of MURs in epilepsy day 
 
10-10.30 –  scene setting      
 GR/TT/MO 
10.30 – 11.30 – Classification of epilepsy     GR 
11.30 – 11.45 – Break 
11.45 – 1.30  Session 2 – drugs used in epilepsy?    GR 
1.30 – 2.00  Lunch 
2.00 – 2.15 Referring in the East Kent scheme    GR 
2.15 – 4.00 Role plays – doing MURs for people with epilepsy  TT/GR 
3 case studies (see below) 
4.00 – 4.15 Top tips and next steps     
 TT/GR 
 
 
 
 
 
 
Case studies 
 
1. Doing an MUR for someone with an epilepsy drug – where there is high dose 
drowsiness 
a. TT See attached document 
2. Referring – a male patient who has been experiencing a sore tongue – has been 
nagged into going in by his girlfriend. Has a recent admission to A&E after 
partying and taking ‘E’ was referred but DNA 
a. GR to work up 
3. Someone on 3 AEDs and rescue (Frisium) – some suggestion of a 
perimenopausal seizure at one point 
a. GR to work up 
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34  Response from the Patient Questionnaires – Pre and Post Targeted Epilepsy 
MUR 
           
  
 
 
Key  4 = highly positive, 3 = positive, 2 = negative, 1= highly negative NQ = No 
Questionnaire 
 
  
  
 1 2 3 4 5 6 7 8 9 
1
0 
1
1 
1
2 
1
3 
1
4 
15 16 17 
TOT
AL 
Avera
ge 
Question 
1 
                                    
Pre 
MUR 
2 3 4 1 3 
N
Q 
1 3 4 3 1 2 2 4 1 
N
Q 
N
Q 
34 2.62 
Post 
Mur 
2 4 4 2 3 
N
Q 
2 3 4 3 3 2 2 4 1 
N
Q 
N
Q 
39 3 
                    
                    
Question  
2 
                    
Pre Mur 4 1 4 3 3 
N
Q 
1 3 4 4 1 1 3 2 2 
N
Q 
N
Q 
36 2.77 
Post 
MUR 
4 3 4 3 4 
N
Q 
1 3 4 4 3 2 3 3 
N
Q 
N
Q 
N
Q 
41 3.41 
                    
Question 
3 
                   
Pre 
MUR 
3 1 1 1 
N
Q 
N
Q 
1 1 1 1 1 1 1 1 1 
N
Q 
N
Q 
15 1.25 
Post 
MUR 
4 4 1 4 4 
N
Q 
4 1 3 1 2 3 4 4 
N
Q 
N
Q 
N
Q 
39 3.25 
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